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Abstract 
 
Background and Objective: Diabetes is a global problem and high postprandial blood 
glucose is one of the risk factors for developing type 2 diabetes. In vitro studies have 
shown that polyphenols have inhibitory effects on carbohydrate-digesting enzymes and 
glucose transporters which could lead to reduced postprandial glucose in vivo. This study 
investigated the effects of a mixture of polyphenols (for maximum effect) capable of 
inhibiting the different stages of carbohydrate digestion on glycaemic response. 
Additionally, a single source of polyphenols in two different matrices was also examined.  
Methods: In vitro inhibition assays were used to determine the inhibition potential of 
polyphenols from the polyphenol and fibre-rich food (PFRF) consisting of freeze-dried 
apple, blackberry, blackcurrant, strawberry and green tea as well as from a single source 
(pomegranate). Three randomised, crossover studies were conducted on healthy 
volunteers (n=16 for each study) to determine the effects of polyphenols on glycaemic 
response in vivo using PFRF, pomegranate capsules and juice as sources of polyphenols.  
Results: Polyphenols found in PFRF dose-dependently inhibited α-amylase and α-
glucosidase in vitro and gave rise to a decrease in postprandial glucose area under the 
curve by (IAUC) =-27.4±7.5 % (mean ± SD) p<0.001 and IAUC=-49.0±15.3 %, 
p<0.001) for the single and double dose respectively. Insulin IAUC was also attenuated 
by -46.9±13.4% (mean ± SD; p<0.01) for the double dose. Pomegranate polyphenols in 
juice dose-dependently inhibited α-amylase and α-glucosidase in vitro and gave rise to a 
decrease (-33.1±18.1 %, p <0.01) in postprandial glucose IAUC but did not show any 
effect when administered in the form of capsules. 
ii 
 
   
Conclusions: Certain polyphenol-rich foods have the potential to be used in the risk 
prevention and management of type 2 diabetes since they inhibit carbohydrate digestive 
enzymes in vitro and reduce postprandial glycaemic response in healthy volunteers, but 
only in certain food matrices. 
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Chapter 1 .  Introduction and Literature 
review 
1.1 Introduction 
Diabetes is a global problem with estimates indicating that by the year 2030, 439 million 
adults worldwide will have diabetes with a 69 and 20 % increase in  prevalence in 
developing and developed countries between the years 2010 and 2030 (Shaw et al., 
2010). In addition to diabetes, other related conditions include pre-diabetes (impaired 
glucose tolerance (IGT) and impaired fasting glucose (IFG)) as well as metabolic 
syndrome (obesity, hypertension and insulin resistance). Pre-diabetes and metabolic 
syndrome increases the risk of developing cardiovascular disease and diabetes mellitus 
(Coutinho et al., 1999).  
Diet plays an important role in chronic diseases such as cardiovascular disease, type 2 
diabetes, hypertension and obesity (Wolfe et al., 2003). For type 2 diabetes, scientific 
evidence suggests that hyperglycaemia caused by frequent rise of blood glucose in 
humans has a major role to play in the development of the disease as it leads to the 
exhaustion of the β-cells of the pancreas and hinders the production of insulin to 
overcome the high blood glucose (WHO, 2016). This results in high blood glucose levels 
above the healthy range and develops into pre-diabetes and eventually type 2 diabetes. 
In the diet, carbohydrates are the major source of blood glucose. (Hanhineva et al., 2010). 
Dietary carbohydrate is important to maintain glycaemic homeostasis and is the major 
source of energy in the diets of most people. The control of blood glucose is a hormonal 
process and is very important for human physiology. Hormonal processes involve the 
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release of insulin from the β-cells of the pancreatic cells which stimulates the uptake of 
glucose after a meal, to other tissues either for utilisation (glycolysis) or to be stored in 
the liver as glycogen (glycogenesis). When blood glucose falls below normal, glucagon 
is secreted from the pancreatic α-cells and it promotes liver glucose production by 
inducing the generation of glucose from non-carbohydrate substrates such as amino 
acids, lactate and glycerol (gluconeogenesis) and the generation of glucose from 
glycogen (glycogenolysis) (Macdonald, 2014).  When the glucose homeostatic hormonal 
control fails, it entails high blood glucose levels (postprandial hyperglycaemia) because 
insulin plays a major role in signalling the uptake of glucose from the blood .This can 
lead to metabolic syndrome which includes obesity, impaired glucose tolerance (IGT), 
hypertension and dyslipidaemia. Disturbance of glucose homeostasis can also lead to 
other symptoms such as inflammation and oxidative stress at the whole body level, 
disturbances of the functionality in several organs as well as diabetes and cardiovascular 
disease (Hanhineva et al., 2010). Blood glucose concentration is one of the important 
criteria used to diagnose diabetes in addition to other signs and symptoms. According to 
the American Diabetes Association, ranges for normal or healthy, pre-diabetic and 
diabetic are fasting plasma glucose (FPG) levels of 3.9 to 5.6 mmol/L, 5.7 to 6.9 and ≥ 7 
mmol/L respectively whereas the World Health Organisation provides a higher cut off 
of 6.1 mmol/L for the normal range of FPG. For screening purposes for the current study, 
an average of 5.9 will be used as the cut off for healthy range. 
As a dietary intervention, the glycaemic index (GI) was originally proposed with the aim 
of managing diabetes. However, recent studies have shown that the GI has potential in 
the prevention of type 2 diabetes as well as in the treatment of metabolic syndrome. High 
GI diets are associated with a number of abnormalities like increased metabolic 
syndrome and insulin resistance (McKeown et al., 2004, Scaglioni et al., 2004) and hence 
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increases the risk of developing type 2 diabetes (Steven et al., 2002, Hodge et al., 2004,). 
On the contrary, low GI diets have shown to have the beneficial effects of improving  
insulin sensitivity (Frost et al., 1996) but it was not certain whether this was as a result 
of improved insulin sensitivity, improved insulin secretion or due to reduced rate of 
glucose absorption. Therefore, low glycaemic index diets or any intervention that can 
lower the glycaemic index of foods can play a major role in the prevention and 
management of type 2 diabetes and contribute in lessening the burden of the diabetes 
prevalence of which type 2 diabetes accounts for >90 % of diabetes cases (Kahn, 1998). 
Research using animal models, as well as a limited number of human studies, have shown 
that polyphenols and polyphenol-rich foods or beverages have the potential to affect 
postprandial glycaemic responses and fasting glycaemia as well as improve acute insulin 
secretion and sensitivity (Hanhineva et al., 2010). Other possible mechanisms include 
pancreatic β-cells stimulation to secrete insulin as well as activation of insulin receptors, 
modulation of the release of glucose from the liver as well as of intracellular signalling 
pathways and gene expressions (Hanhineva et al., 2010). A recent review (Williamson, 
2013) concluded that it is very possible that the effects of polyphenols in the diet will 
affect glycaemic index of foods as well as postprandial glucose responses in humans and 
highlighted that inhibition of starches/disaccharides metabolising enzymes as well as 
transporters are potential mechanisms by which this can be achieved. Therefore, the 
greatest effect would be observed when more than one of the suggested pathways was 
inhibited (Williamson, 2013).  
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1.2 Polyphenols  
Polyphenols are one of the major groups of phytochemicals. Phytochemicals are natural 
biochemical compounds found in plant-derived foods like tea, coffee, fruits and 
vegetables. Other groups of phytochemicals include  carotenoids (found in carrots, yam 
and apricots) and allyl sulphides (found in garlic and onions) (Wolfe et al., 2003). It is 
assumed that plants produce phytochemicals for defence purposes whereas emerging 
evidence suggests that phytochemicals can also protect humans against diseases (Slavin 
and Lloyd, 2012). Fruits and vegetables contain many compounds that are responsible 
for the protective health effects and they include; fibre, carotenoids and the vitamins E 
and C (Wolfe et al., 2003, Liu, 2013). Polyphenols are non-nutritive plant chemicals that 
are produced by plants as secondary metabolites whose chemical structure has more than 
one aromatic ring and at least one hydroxyl group. They are widely distributed in various 
plant-based foods in varying amounts (Perez-Jimenez et al., 2010) and types and they 
are further divided into different groups based on their structures. Depending on the 
source of polyphenols, some can be consumed unprocessed like in fruits and some 
vegetables whereas mostly polyphenols are consumed in the processed forms in plant-
based food products which include tea, wine, fruit juices, canned fruits and jams. 
Approximately 1 g/day is the estimated intake of dietary polyphenols (Scalbert and 
Williamson, 2000). Polyphenols are divided into phenolic acids, flavonoids, stilbenes, 
lignans and tannins with flavonoids being an essential sub-group of polyphenols which 
have received the most attention in research. Flavonoids have a basic structure of a three 
ringed molecule having the carbon 6-carbon 3-carbon 6 (C6-C3-C6) general structural 
backbone (fig 1-1). 
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Figure 1-1: Basic structure of flavonoids 
The two C6 units (ring A and ring B) are of phenolic nature whereas the chromane ring 
(ring C) may differ and may have different hydroxylation patterns. The variations in the 
chromane ring give rise to flavonoids being divided into different sub-groups which are 
flavanols, flavones, isoflavones, flavanones, flavonols and anthocyanidins (fig 1-2). 
Although the basic structures of flavonoids are aglycones, they mostly exist as glycosides 
in plants. Their biological activities depend on the glycosylation patterns as well as the 
structural differences (Tsao, 2010). 
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Figure 1-2: Flavonoids sub-classes and their structures. 
 
Flavanols      Flavanones  
 
Flavones      Flavonols    
  
Isoflavones                                                                    Anthocyanidins 
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1.2.1 Polyphenol bioavailability 
Knowledge about the bioavailability of polyphenols in vivo is important in order to 
understand whether the polyphenols are absorbed, metabolised and reach their target sites 
in amounts that are required for them to exert beneficial effects. Polyphenols are 
absorbed and metabolised in the human body (Scalbert and Williamson, 2000, Williams 
et al., 2004) and this varies greatly between individuals and depends on a number of 
factors such as differences in microbial populations as well as the influences of other 
dietary components present together with the polyphenols. Even though most 
polyphenols are absorbed, the bioavailability of different classes depends on the food 
source, type of polyphenol and especially due to the nature of the sugar attached 
(Hollman et al., 1999, Williamson and Manach, 2005). Studies have shown that 
polyphenols are much lower in the human body and rarely exceed nM concentrations in 
plasma after normal dietary intake and that after consumption of 10-100 mg of a single 
phenolic compound, the maximum plasma concentration rarely exceeds 1 µM without 
accounting for any metabolites that may be formed (Scalbert and Williamson, 2000, Del 
Rio et al., 2010).  
For polyphenols that have been reported to be poorly absorbed from the small intestine 
such as proanthocyanidins, anthocyanins and galloylated tea catechins, it is suggested 
that their action is thus restricted to the intestine (Manach et al., 2004, Manach et al., 
2005). This agrees with the in vitro studies that have shown that anthocyanins and 
galloylated catechins have the potential to inhibit energy metabolism as they would be 
in high amounts in the intestine where they can inhibit digestion enzymes and glucose 
transporters. For the purpose of this research, polyphenol concentrations that have been 
shown to inhibit carbohydrate digestion and absorption as shown in table1-1, are 
achievable in the intestinal lumen (Scalbert and Williamson, 2000) which justifies one 
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of their mechanism of action (inhibition of digestive enzymes and glucose transporters). 
A recent review also points out that the gut lumen is the prime likely target for polyphenol 
effects on carbohydrates metabolism as it contains the highest concentration of 
polyphenols post-prandially (Williamson, 2013). 
1.3 Carbohydrate digestion and absorption 
Dietary carbohydrates are macronutrients that have a range of physical and chemical 
properties. They are important in the human diet as they are the principal substrate of 
energy metabolism, blood glucose and insulin among other functions (Cummings and 
Stephen, 2007). Dietary carbohydrates are classified according to the degree of 
polymerization or number of monomeric units (single sugars). They are classified as 
mono, di, oligo and polysaccharides (fig 1-3). The simplest is glucose and 
polysaccharides are the most complex with more than 10 glucose units and they include 
amylose, amylopectin, modified starches, cellulose and hemicelluloses. 
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Figure 1-3: Chemical structures of some monosaccharides, disaccharides and 
polysaccharides amylose and amylopectin. 
Monosaccharides  
 
α –D-Glucose       Fructose                      Galactose 
 
Disaccharides  
Sucrose       Maltose    Lactose 
Polysaccharides 
 
Amylose – More than 10 glucose molecules in a straight line 
 
 
Amylopectin – more than 10 glucose molecules but branched  
CH2 
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In the diet, polysaccharides which are most represented by starch play a major role as the 
source of energy supply in the human diet. Starch is made up of amylose and amylopectin 
polymers of glucose linked by α-1, 4 glycosidic bonds together with alpha-1, 6-
glycosidic bonds which form branch points mainly in amylopectin. It has to be broken 
down during digestion to produce glucose which is the main carbohydrate that is usually 
absorbed through the intestinal wall. Starch in foods is classified into rapidly digestible 
starch (RDS), slowly digestible starch (SDS) and resistant starch (RS). RDS is the starch 
that is digested to glucose rapidly (approximately 20 min) and SDS is digested into 
glucose much slower (approximately 2 h). The total of RDS and SDS makes up what is 
known as available carbohydrate and is defined as the starch that is digested to give 
glucose plus any glucose already present in the food. This is achieved by a series of 
enzymes with the upper gastrointestinal tract being the main site of digestion (Hanhineva 
et al., 2010). Salivary and pancreatic α-amylases catalyse the endo-hydrolysis of α-1, 4 
glycosidic bonds giving mainly maltose, maltotriose and related α-1, 6-oligomers which 
contain 1, 6-linked glucose units from amylopectin. The final step in the digestion of 
carbohydrates takes place in the small intestinal brush boarder where α-glucosidases 
catalyse the hydrolysis of a single glucose residue from disaccharides and 
oligosaccharides by acting on the terminal α-1, 4 bonds in addition to the cleavage of α-
1, 2 bonds found in sucrose and α-1, 6 bonds in iso-maltose (fig 1-3) (Quezada-Calvillo 
et al., 2008).  
When glucose is produced in the gut lumen, it enters the blood stream through absorption 
through the gut wall. Active transport is responsible for the absorption of glucose via the 
sodium-dependent glucose transporter 1 (SGLT1) and by facilitated sodium-independent 
glucose transporter 2 (GLUT2). This is achieved by conformation changes that allow 
glucose to bind to the transporters. When two sodium ions binds to SGLT1 on the luminal 
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side of the intestinal brush boarder membrane, the conformation of SGLT1 changes and 
allows glucose to bind to it. Another conformational change occurs which then allows 
glucose and sodium ions to enter the enterocyte. GLUT2 found in the basolateral 
membrane releases glucose from the enterocyte into the circulation (Hanhineva et al., 
2010). This results in an increase in blood glucose concentration which stimulates insulin 
release. Insulin is a hormone produced by the pancreas and is secreted by the β-cells of 
the pancreas which is part of the digestive system and is located behind the stomach, next 
to the duodenum. The exocrine cells of the pancreas release digestive enzymes in the gut 
and the islets of Langerhans release hormones like insulin and glucagon when required 
in glucose regulation. The primary function of insulin is to regulate blood glucose to 
avoid hyperglycaemia (too high) or hypoglycaemia (too low). The presence of insulin in 
the blood then stimulates the uptake of glucose to other tissues either to be utilised for 
inhibition of lipolysis in adipose tissue or stored in the liver as glycogen (glycogenesis) 
and in this way bringing the concentration of glucose back to normal within 1-3 h. 
Similarly, when blood glucose levels fall below normal, insulin release is inhibited and 
glucagon is secreted from the pancreatic α-cells and it promotes liver glucose production 
by breaking down glycogen to glucose (glycogenolysis) and the production of glucose 
from other sources other than carbohydrates (gluconeogenesis) raising the glucose level 
to normal and hence maintaining glucose homeostasis (Hanhineva et al., 2010, 
Williamson, 2013, Macdonald, 2014). Insulin is very important because its absence or 
the inability of the body to respond to it can both lead to hyperglycaemia and diabetes 
(Mueller and Jungbauer, 2009). Fasting insulin concentration > 62.5 pM is regarded to 
identify  pre-diabetes as reported by Johnson et al. (2010). In insulin-dependent diabetes 
mellitus (IDDM) there is a severe reduction of insulin concentrations whereas in non-
insulin dependent diabetes mellitus (NIDDM), insulin levels are raised. In the absence 
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of hindrances from other food components, carbohydrate digestion in the gut occurs quite 
rapidly although this may vary depending on the source and physical state of the starch. 
The carbohydrates that provide glucose for metabolism after digestion are said to be 
glycaemic carbohydrates and those which do not are non-glycaemic carbohydrates. Most 
unprocessed foods contain both glycaemic and non-glycaemic carbohydrate (Cummings 
and Stephen, 2007). Ingestion of digestible carbohydrates leads to a sharp rise of 
postprandial blood glucose and these foods are classified as ‘high glycaemic index’ 
foods. 
1.3.1 Concept of Glycaemic index 
Glycaemic index was originally defined as “The indexing of the glycaemic response to 
a fixed amount of available carbohydrates from a test food to the same amount of 
available carbohydrates from a standard food consumed by the same subject (glucose or 
white bread) (Jenkins et al., 1981). A practical definition by (FAO/WHO, 1998) says that 
glycaemic index is the increase in the area under the blood response curve of a 50 g 
carbohydrate portion of a test food over 2 hours. This is then expressed as the percentage 
of the response of the test food, to the response of a standard food of the same amount 
consumed by the same person. The glycaemic index of glucose is set at 100 and other 
foods are presented relative to this.  
Classification of carbohydrates based on mono, oligo and polysaccharides is not 
sufficient to determine how they affect blood glucose (glycaemic response). Different 
carbohydrates have different glycaemic indices and can therefore be classified into high 
and low glycaemic index foods depending on their postprandial glucose as well as insulin 
response (Jenkins et al., 2002). Carbohydrates that are digested and absorbed slowly, are 
said to be low GI foods and those that are digested and absorbed rapidly are said to be 
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high GI foods and it is this high digestion and absorption rate that may elevate blood 
glucose levels which induces many imbalances that may affect health and disease (Bornet 
et al., 2007). Investigations have shown that consumption of low GI foods or having 
components in the diet that can lower the GI of foods, can lower the risk of certain 
chronic diseases such as cardiovascular diseases and diabetes (Aston, 2006, Barclay et 
al., 2008). Similarly, consumption of high glycaemic index foods plays a role in the 
development of chronic diseases like type 2 diabetes, obesity and cardiovascular disease 
(Ludwig, 2002).  
1.3.2 Carbohydrates metabolism and disease  
The control of blood glucose is a hormonal process and it is very important to human 
physiology.  When this control fails, it can lead to metabolic syndrome which is a major 
contributing factor to the development of diabetes and increasing the risk of 
cardiovascular disease. Metabolic syndrome consists of a number of conditions  such as 
obesity, hypertension and insulin resistance whereas high postprandial blood glucose and 
high fasting blood glucose are contributing factors (Hanhineva et al., 2010). 
The World Health Organisation has reported that about 422 million people suffer from 
diabetes worldwide and that by the year 2030, diabetes will be the 7th leading cause of 
death. The WHO also reports that in 2012, about 1.5 million people died directly due to 
diabetes and 2.2 million deaths were due to high blood glucose related complications 
(WHO, 2016). Diabetes can be classified into type 1 (formerly known as insulin-
dependent) and type 2 (formerly known as non-insulin dependent) diabetes. Type 1 
diabetes is due to the absence of insulin production and thus requires daily injection of 
insulin to control it. Type 2 diabetes is largely due to diet, overweight and lack of physical 
activity characterised by high blood glucose levels (hyperglycaemia) followed by failure 
14 
 
   
of the pancreas to release enough insulin to overcome high blood glucose levels (fig 1-
4).  
 
Figure 1-4: Proposed mechanism showing how high glycaemic load in the diet may lead 
to hyperglycaemia and consequently health risk adapted from (Aston, 2006). 
 
Therefore, as much as carbohydrates are required in the human body as a major source 
of energy, too much in the diet can have adverse health effects especially high compared 
to low glycaemic index foods. Therefore, having anything in the diet that can slow down 
the digestion or absorption of carbohydrates can help reduce health risks (Barclay et al., 
2008). Two potential solutions are that of consumption of low glycaemic index foods or 
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having ingredients in the diet that can reduce the glycaemic index of foods as well as 
postprandial blood glucose levels. The presence of inhibiting components in the diet that 
can reduce postprandial glucose can also be a solution to reducing the risk.  Polyphenols 
have the potential to inhibit the rise in blood glucose by hindering carbohydrate digestion 
and rapid absorption of glucose (Hanhineva et al., 2010, Williamson, 2013). 
1.3.3 Polyphenols and carbohydrate digestion 
The study of polyphenols has become very popular in the recent years due to the health 
benefits that are attributed to them. Epidemiological studies have attributed their 
presence in food to health effects which include protection against cardiovascular 
diseases and diabetes and have shown that regular consumption of fruits and vegetables 
give a positive effect to human health (Clifford, 2004, Scalbert et al., 2005, Crozier et 
al., 2009, Slavin and Lloyd, 2012). Scientific studies in vivo and in vitro have also shown 
that polyphenols have potential health benefits. Specific to this research, there is growing 
evidence that polyphenols have the potential to influence glucose metabolism 
(Hanhineva et al., 2010, Williamson, 2013, Morand and Sies, 2016) and hence can help 
in the prevention and management of type 2 diabetes. This research focuses on the 
potential of polyphenols in the prevention and management of type 2 diabetes through 
the inhibition of carbohydrate digesting enzymes and glucose transporters which may 
reduce postprandial blood glucose after a carbohydrate-rich meal (Williamson, 2013). 
More is discussed in chapters 5 and 6 on the health effects of polyphenols. 
A number of in vitro studies have shown that polyphenols inhibit carbohydrate digestive 
enzymes (α-amylase and α-glucosidase) (Hanhineva et al., 2010). They also inhibit 
glucose transporters SGLT1 and GLUT2 in vitro using the intestinal brush border 
membrane vesicles and caco-2 cells. (Welsch et al., 1989, Johnston et al., 2005). This 
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property of polyphenols is important as it can affect carbohydrate digestion and 
absorption leading to a reduced postprandial blood glucose which is a risk factor for type 
2 diabetes (fig 1-4). If each stage of the biochemical pathway of carbohydrate digestion 
and absorption is inhibited (fig 1-5), reduced postprandial glucose would be expected as 
this is the same mechanism used by acarbose, a drug in the treatment of type 2 diabetes. 
Polyphenols have a very high potential to inhibit carbohydrate digestion and absorption 
in humans. In vitro studies (table 1-1) have shown that polyphenols are able to inhibit all 
the steps in carbohydrate digestion and absorption. If this is the case in humans, 
polyphenols can thus help reduce the rises of blood glucose levels after a meal which is 
particularly important to diabetic people as well as those with metabolic syndrome and 
the general public as a whole in reducing the risk of cardiovascular diseases and type 2 
diabetes. The glycaemic index of foods will thus be reduced when consumed together 
with polyphenols which may bring about desirable conditions that may help prevent the 
risk of developing cardiovascular diseases and type 2 diabetes (Ludwig, 2002).  
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Figure 1-5: A summary showing the stages of carbohydrate digestion and glucose 
absorption with polysaccharides used as an example to show how polyphenols have the 
potential to affect postprandial plasma glucose by having the potential to inhibit both 
digestive enzymes and glucose transporters. 
Starch is hydrolysed 
to disaccharides and 
oligosaccharides 
Carbohydrates in the diet: 
starch (polysaccharides) Polyphenols 
Biochemical 
process 
Digestion in the mouth 
(salivary α-amylase) 
Digestion in the upper 
small intestine 
(duodenum). 
(pancreatic α-amylase) 
Digestion in the small 
intestine. (α-glucosidase) 
Glucose is transported into the 
blood (Glucose transporters) 
Large intestine 
Carbohydrates that were not hydrolysed nor transported into the blood are 
degraded by microorganisms and excreted.  
Starch is chewed and 
mixed with salivary 
α-amylase and other 
salivary juices 
Disaccharides and 
oligosaccharides are 
hydrolysed to 
monosaccharides 
Certain 
polyphenols 
inhibit α-
amylase 
Certain 
polyphenols 
inhibit 
α-amylase 
Certain 
polyphenols 
inhibit 
α-glucosidase 
Certain polyphenols inhibit 
glucose transporters 
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1.4 Research rationale 
This research utilised available data from the literature on in vitro studies on the 
inhibition potential of different polyphenols on carbohydrate digesting enzymes (α-
amylase and α-glucosidase) and glucose transporters sodium-dependant glucose 
transporter 1 (SGLT1) and glucose transporter 2 (GLUT2). From the data obtained, the 
half-maximal inhibitory concentration (IC50) of the polyphenols for the enzymes and 
transporters were tabulated and converted to micromolar (µM) units (table 1-1). The 
criterion used was to select the polyphenols with the lowest IC50 value as well as only 
consider the ones that are mostly found in fruits and non-alcoholic beverages to help with 
design of the meal. Fruits and beverages were preferred because when selecting foods 
which have high amounts of polyphenols using the Phenol Explorer (web-based database 
on the polyphenol content of foods), it is important to estimate the amount of polyphenols 
in a serving rather than the total amount of polyphenols by Perez-Jimenez et al., 2010. 
For example herbs and spices, even though they rank first in the total polyphenol 
contents, usually the amount consumed is very low. Using the ranking based on total 
polyphenols per serving by Perez-Jimenez et al., 2010, changes the ranking from spices 
being first to fruits (berries) and non-alcoholic beverages (coffee and tea) ranking high. 
After identifying the polyphenols with the lowest IC50 values, Phenol Explorer was used 
to come up with the fruits and non-alcoholic beverages that contained the highest 
amounts of the named polyphenols (table 1-2).  
Therefore, polyphenols with the lowest IC50 value mostly found in fruits and non-
alcoholic beverages were selected as they would provide more polyphenols in a serving 
(cup/glass of beverage and/or portion of fruit).  
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Polyphenol Mammalian α-amylase 
inhibition (IC50) 
Mammalian α-glucosidase 
inhibition (IC50) 
Inhibition of glucose absorption from 
intestine  
Anthocyanins    
Cyanidin-3-O-galactoside 
 
>1000 μM (Adisakwattana et 
al., 2009) 
>1000 µM (Akkarachiyasit et 
al., 2010) 
Sucrase 500 μM, Maltase >3000 
μM (Adisakwattana et al., 2009) 
 
Cyanidin-3-O-rutinoside 
 
24.4 μM (Akkarachiyasit et al., 
2011) 
Sucrase  250.2 μM, Maltase 
2323 μM (Adisakwattana et al., 
2011) 
 
Cyanidin-3-O-
sambubioside 
960 μM (Iwai et al., 2006) Sucrase 3260 μM, Maltase 3850 
μM (Iwai et al., 2006) 
 
Cyanidin-3-O-glucoside 
 
300 μM (Iwai et al., 2006) 
 
Sucrase 970 μM, Maltase >3000 
μM (Adisakwattana et al., 2009) 
 
Cyanidin-3-O-rhamnoside 
 
  Inhibited moderately(Hanamura et al., 
2006) 
Pelargonidin-3-O-
glucoside 
  802 μM (Manzano and Williamson, 
2010) 
Pelargonidin-3-O-
rhamnoside 
  Inhibited highly (Hanamura et al., 2006) 
Isoflavones     
Daidzein   >500µM (Tadera et al., 2006)  
Flavanones    
Naringenin    8 -50 μM (Park, 1999) 
 
Table 1-1: Summary of polyphenols that are good inhibitors of α-amylase, α-glucosidase and glucose transport. All IC50 values have been 
converted to µM which may be different units from the source. 
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Polyphenol Mammalian α-amylase 
inhibition (IC50) 
Mammalian α-glucosidase 
inhibition (IC50) 
Inhibition of glucose absorption from 
intestine  
Catechins    
Catechin 
 
 Sucrase 2490 μM, Maltase 1350 
μM (Ishikawa et al., 2007) 
 
Epicatechin 
 
 
 
 Sucrase 2030 μM, Maltase 1750 
μM (Ishikawa et al., 2007) 
Sucrase 1080 μM, Maltase 770 
μM (Matsui et al., 2007) 
Sucrase 1000 μM, Maltase 290 
μM (Kamiyama et al., 2010) 
 
Catechin gallate 
 
 Sucrase 86 μM, Maltase 62 μM 
(Kamiyama et al., 2010) 
Sucrase 610 μM, Maltase 150 
μM (Ishikawa et al., 2007) 
 
Epicatechin gallate 
 
 Sucrase 172 μM, Maltase 53 μM 
(Matsui et al., 2007) 
Sucrase 140 μM, Maltase 40 μM 
(Kamiyama et al., 2010) 
100 μM (35 %) (Johnston et al., 2005) 
1000 μM SGLT1, μM GLUTs 
(1&3)(Kobayashi et al., 2000) 
1000 μM (Kobayashi et al., 2000) 
Strongly 0.45 mM inhibition constant 
(Hossain et al., 2002) 
 
Table 1-1 (continued): Summary of polyphenols that are good inhibitors of α-amylase, α-glucosidase and glucose transport. All IC50 values 
have been converted to µM which may be different units from the source. 
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Polyphenol Mammalian α-amylase 
inhibition (IC50) 
Mammalian α-glucosidase 
inhibition (IC50) 
Inhibition of glucose absorption from 
intestine  
Catechins continued    
Epigallocatechin 
 
 Sucrase 921 μM, Maltase 1260 
μM (Matsui et al., 2007) 
Sucrase 480 μM, Maltase 120 
μM (Kamiyama et al., 2010) 
100 μM (40 %) (Johnston et al., 2005) 
 
 
Epigallocatechin gallate 400 μM (Tadera et al., 2006) 
220 μM (Koh et al., 2010) 
20 μM (34%) (Forester et al., 
2012) 
Sucrase 169 μM, Maltase 40 μM 
(Matsui et al., 2007) 
Sucrase 130 μM, Maltase 16 μM 
(Kamiyama et al., 2010) 
Sucrase  100 μM (Honda and 
Hara, 1993) 
100 μM (63 %) (Johnston et al., 2005) 
1000 μM (Kobayashi et al., 2000). 
Strongly 0.45 mM inhibition constant 
(Hossain et al., 2002) 
Phenolic acids    
Caffeic acid 
 
380 μM (Narita and Inouye, 
2009) 
Sucrase 2180 μM, Maltase 8280 
μM (Ishikawa et al., 2007) 
 
 
Chlorogenic acid 
(5-Caffeoyl quinic acid) 
70 μM (Narita and Inouye, 
2009) 
Sucrase 2180 μM, Maltase 2990 
μM (Ishikawa et al., 2007) 
sucrase 1400 μM (Iwai et al., 
2006) 
2570 μM (Manzano and Williamson, 
2010) 
Quinic acid 25300 μM (Narita and Inouye, 
2009) 
  
 
Table 1-1 (continued): Summary of polyphenols that are good inhibitors of α-amylase, α-glucosidase and glucose transport. All IC50 values 
have been converted to µM which may be different units from the source. 
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Polyphenol Mammalian α-amylase 
inhibition (IC50) 
Mammalian α-glucosidase 
inhibition (IC50) 
Inhibition of glucose absorption from 
intestine  
Flavonols    
Quercetin  
 
500 μM (Tadera et al., 2006) Sucrase 1460 μM (Ishikawa et 
al., 2007). Maltase 710 μM 
(Ishikawa et al., 2007) 
13 μM (Kwon et al., 2007) 
Quercetin-3-O-glucoside   64 μM (Kwon et al., 2007) 
800 μM (Cermak et al., 2004) 
640 μM (Kottra and Daniel, 2007) 
Quercetin-4’-O-glucoside   37 μM (Kottra and Daniel, 2007) 
103 μM (Kwon et al., 2007) 
Quercetin-3-O-rhamnoside 
 
  31 μM (Manzano and Williamson, 2010) 
Phloridzin   146 μM (Manzano and Williamson, 
2010) 
 
Myricetin  
 
380 μM (Tadera et al., 2006)  
 
8 -50 μM (Park, 1999) 
17 μM (Kwon et al., 2007) 
Flavones     
Apigenin    8 – 50 μM (Park, 1999) 
Luteolin  360 μM (Tadera et al., 2006)   
 
Table 1-1 (continued): Summary of polyphenols that are good inhibitors of α-amylase, α-glucosidase and glucose transport. All IC50 values 
have been converted to µM which may be different units from the source. 
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Name of 
polyphenol  
Good fruit/ non-
alcoholic 
beverage source 
 
 
 
Average total 
polyphenols in 
source (mg/100g 
FW) (Phenol 
Explorer) 
Content in source 
(mg/100g FW or 
mg/100ml) 
(Phenol Explorer) 
 
Cyanidin-3-O-
rutinoside 
 
Blackcurrant 
Sweet Cherry 
Fresh plums 
Blackberry  
821 
173 
410 
569 
160.8 
143.3 
33.9 
8.9 
Cyanidin-3-O-
glucoside 
 
Black elderberry 
Blackberry 
Sweet cherry  
Red raspberry 
1950 
569 
173 
148 
794.1 
138.7 
18.7 
13.3 
Epicatechin 
gallate 
 
Green tea infusion 
Black tea infusion  
Oolong tea 
infusion  
62 
1045 
- 
7.5 
7.3 
4.9 
Epigallocatechin 
gallate 
Green tea infusion  
Oolong tea 
infusion  
Black tea infusion  
62 
- 
 
105 
27.2 
17.9 
 
9.1 
Quercetin-3-O-
glucoside 
Black 
chokenberry 
Red raspberry 
Blackcurrant 
Highbush-
blueberry 
 
1752 
148 
821 
223 
 
 
41.9 
3.6 
2.6 
1.5 
Quercetin-3-O-
rhamnoside 
 
Lingonberry 
American-
cranberry 
Apple dessert -
whole 
Apple dessert 
pure juice  
Apple cider pure 
juice  
652 
315 
 
202 
 
34 
 
143 
12.2 
6.2 
 
1.3 
 
0.7 
 
0.2 
Phloridzin Apple puree 
Apple dessert-
whole  
Apple cider-
peeled 
Apple dessert 
pure juice 
Apple cider pure 
juice 
- 
202 
 
251 
 
34 
 
143 
5.6 
2.8 
 
2.5 
 
2.4 
 
1.5 
Table 1-2: Identification of good sources of polyphenols that have good inhibitory effects 
(lowest IC50 value) towards α-amylase, α-glucosidase and glucose transporter. 
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From table 1-1, the best inhibitors for α-amylase are cyanidin-3-O-rutinosode, EGCG 
and cyanidin-3-O-glucoside which are present in highest amounts in blackcurrant, green 
tea and blackberry respectively (table 1-2). For α-glucosidase, EGCG was identified as 
the best inhibitor with green tea as the best source. Phloridzin, quercetin-3-O-glucoside, 
quercetin-3-O-rhamnoside and pelargonidin-3-O-glucoside were identified as the good 
inhibitors of glucose transport and are found in highest amounts in apple, blackcurrant, 
and strawberry respectively (tables 1-2 and 1-3). EGCG and EGC are also good inhibitors 
of glucose transport (table 1-1) and hence green tea would also contribute to the overall 
glucose transport inhibition. The information was used to propose the composition of a 
polyphenol and fibre-rich food (PFRF) mixture containing polyphenols that showed the 
highest inhibition towards carbohydrate digestion (carbohydrase inhibition) and 
absorption (glucose transport). Moreover, the consideration of just using one beverage 
in the test meal meant that even if coffee has good α-amylase inhibitory potential due to 
the presence 5-caffeoyl quinic acid, green tea was preferred because although it has the 
highest inhibition towards α-glucosidase, it also has inhibitory potential to both α-
amylase and glucose transport (table 1-1 and table 1-2). Hence the composition of the 
PFRF mixture comprised of green tea, blackberry, blackcurrant, strawberry and apple 
(table 1-3). From the ranking table based on total polyphenols per serving, the PFRF 
mixture ranking was (3, 9, 10, 17, 18 and 19) for blackcurrant strawberry, blackberry, 
green tea, pure apple juice and apple fruit respectively (Perez-Jimenez et al., 2010).  
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Table 1-3: Summary of best polyphenol inhibitors of carbohydrate digestion and glucose 
absorption selected from literature by comparing their IC50 values and their good food 
sources as obtained from Phenol Explorer database (Neveu et al., 2010). 
 
Inhibition 
target 
Good polyphenol 
inhibitor in vitro  
 
IC50 value 
(reference) 
Best food 
source 
(http://www.
phenol-
explorer.eu/) 
α-amylase Cyanidin-3-O-
rutinoside  
 
Epigallocatechin 
gallate  
Cyanidin-3-O-
glucoside  
24.4 µM 
(Akkarachiyasit et 
al., 2011) 
220 µM (Koh et al., 
2010) 
300 µM (Iwai et al., 
2006) 
Blackcurrant  
 
Green tea 
 
Blackberry 
α-Glucosidase EGCG  Sucrase 130 μM, 
Maltase 16 μM 
(Kamiyama et al., 
2010) 
Sucrase 169 μM, 
Maltase 40 μM 
(Matsui et al., 
2007) 
Sucrase  100 µM 
(Honda and Hara, 
1993) 
Green tea 
Glucose 
transport 
Phloridzin  
 
 
Quercetin-3-O- 
glucoside  
Quercetin-3-O- 
rhamnoside  
Pelargonidin-3-O-
glucoside  
146 µM (Manzano 
and Williamson, 
2010) 
64 µM (Kwon et 
al., 2007) 
31 μM (Manzano 
and Williamson, 
2010) 
802 μM (Manzano 
and Williamson, 
2010) 
Apple 
 
 
Blackcurrant  
Apple 
 
 
Strawberry 
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1.4.1 Polyphenols and type 2 diabetes  
The potential of polyphenols in the prevention and management of type 2 diabetes 
through the control of postprandial blood glucose in the PFRF mixture was reassessed in 
vitro using enzyme inhibition assays (chapter 4) before using the PFRF mixture in an 
intervention study (chapter 5) to test its effects on glycaemic response in vivo. The PFRF 
mixture was also analysed for the presence of polyphenols using the Folin assay and 
characterised for specific polyphenols using high pressure liquid chromatography 
(HPLC) as discussed in detail in chapters 2 and 3. This was necessary to ensure that the 
polyphenols of interest were in concentrations at least 3 times higher than the IC50 values 
to account for intestinal dilutions (Williamson, 2013). The PFRF mixture was also 
analysed for the presence of sugars which was an important control aspect for both the 
in vitro assays and the human intervention study as they could interfere with the assay 
and add to the amount of sugars present in the test meals respectively.  This is the first 
research that intentionally utilised a combination of different polyphenol sources that are 
able to inhibit different stages of carbohydrate metabolism to determine the combined 
effect in vivo.  
Thereafter, a single source of polyphenols in different food matrixes (juice and capsules) 
was used to determine the effects of polyphenols on glycaemic response in vivo as a step 
forward in the development of functional foods (chapter 6). Similarly, the source of 
polyphenols was reassessed in vitro for enzyme inhibition and was also characterised for 
the presence and amounts of specific polyphenols. Sugars were also determined to be 
taken into account for the design of the assays and human intervention study. This is also 
the first study to compare the effects of polyphenols on glycaemic response in vivo when 
using different food matrices of the same polyphenol source. Both studies used white 
bread as the source of starch and control meal to which the glycaemic response was 
27 
 
   
compared to when consumed on its own compared to consuming the bread with the 
polyphenols in addition to water and balancing sugars if needed. This is described in 
detail in chapters 5 and 6. 
1.4.1.1 Blackcurrant and blackberry polyphenols 
The major polyphenols found in blackcurrant and blackberries are the flavonoids called 
anthocyanidins. The most common anthocyanidin aglycones are pelargonidin, cyanidin, 
delphinidin, peonidin, petunidin and malvidin. The named aglycones form conjugates 
with sugars and organic acids forming anthocyanins.  Anthocyanins are water-soluble 
and they impart blue, purple or red colours to plant tissues making berries the richest 
sources of anthocyanins. Consumption of anthocyanin-enriched foods is associated with 
a reduced risk of chronic diseases such as diabetes (Akkarachiyasit et al., 2010). The 
berries are ranked highly in the list of the richest sources of polyphenols with 
blackcurrant being ranked number 3 and blackberry number 10 (Perez-Jimenez et al., 
2010). For people who consume berries routinely, anthocyanins are major polyphenol 
sources in excess of 1 g per serving. Anthocyanins are said to be among the least absorbed 
polyphenols and would therefore make the small intestine as their site of action including 
the inhibition of α-amylase and α-glucosidase as they are found in high concentrations 
in the intestine (Manach et al., 2004, Manach et al., 2005). However, microbial 
metabolites of anthocyanins might also have an effect. 
Cyanidin and its glycosides are reported to have promising potential health benefits to 
humans especially in reducing the risk of obesity, metabolic syndrome and type 2 
diabetes (Akkarachiyasit et al., 2010). In vitro studies (Akkarachiyasit et al., 2011, Iwai 
et al., 2006) have shown that cyanidin-3-O-rutinoside and cyanidin-3-O-glucoside are 
good inhibitors of α-amylase.  Cyanidin-3-O-sambubioside was also reported to have 
inhibitory properties though with a slightly higher IC50 value (table 1).  Cyanidin-3-O-
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rhamnoside inhibited glucose transport moderately whereas pelargonidin-3-O-glucoside 
highly inhibited glucose transport (Hanamura et al., 2006, Manzano and Williamson, 
2010).  
Figure 1-6: Chemical structure of cyanidin and its glycosides 
 
Inhibition of carbohydrate digesting enzymes as well as glucose transporters has the 
potential to suppress postprandial hyperglycaemia and hence may play a very important 
role in reducing the risk of metabolic syndrome, insulin resistance, and subsequently 
diabetes type 2. Therefore the inclusion of blackberry, black currant and strawberry in 
the PFRF mixture will provide polyphenols to inhibit carbohydrate digestion and 
absorption. 
1.4.1.2 Green tea polyphenols 
Tea is one of the most consumed beverages in the world ranked second to water in 
popularity globally (Yang et al., 2009). Tea is produced from the leaves of Camellia 
sinensis and depending on the level of fermentation, four types are usually produced. 
White and green teas are both unfermented whereas oolong tea is semi-fermented and 
black tea is fermented. When tea is fermented, it induces enzymes to oxidise catechins 
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giving the characteristic black or orange-red colour of tea due to the formation of two 
major pigments known as theaflavins and thearubigins. (Horzic et al., 2009). 
Epidermiological studies have shown that consumption of tea is linked to health benefits 
and polyphenols found in them may play a role. The presence of the flavonoids catechins 
and theaflavins have been attributed to the great potential that tea has in reducing the risk 
of preventing various chronic diseases such as cardiovascular disease, obesity and 
diabetes (Higdon and Frei, 2003). In green tea, the beneficial effects observed are 
attributed to the presence of flavonoids. The five main flavonols found in green tea are 
catechin derivatives and include (+)-catechin, (-)-epicatechin, (-)-epigallocatechin, (-)-
epicatechin gallate and (-)-epigallocatechin gallate (fig 1-7).  
 
Figure 1-7: Chemical structures of green tea flavanols 
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Oral administration of 1.5, 3.0 and 4.5 g decaffeinated green tea solids to human 
volunteers gave maximal plasma concentrations (Cmax) of 326, 550, and 190 ng/L for 
ECGC, EGC and EC at 1.4 - 2.4 h after ingestion of the tea preparations. About 14 and 
31 % of EGC and EC was detected in plasma whereas <1 % EGCG was bioavailable in 
rats. It is presumed that EGCG converts to EGC in the small intestine hence the highest 
concentration of EGCG is found in the small intestine before it converts to EGC which 
was excreted in the urine together with EC (Yang and Landau, 2000). From the average 
data obtained from seven studies on green tea consumption, EC was highly absorbed and 
EGCG was the least absorbed (Williamson et al., 2011). Catechins are however potent 
enough to act in the gut and concentrations have been reported to be high and reach 
millimolar levels (Williamson, 2013). The consumption of green tea has been linked to 
the reduction of the risk of diabetes (Vinson and Zhang, 2005) and studies have shown 
the potential of green tea in reducing blood glucose levels. An in vitro study showed that 
different types of tea have different inhibitory potential on the two main carbohydrate 
digestion enzymes α-amylase and α-glucosidase (Koh et al., 2010). Among the catechins, 
the galloylated catechins EGCG and ECG have stronger inhibitory effects against 
mammalian α-glucosidase and moderate inhibition on human salivary α-amylase in vitro 
(Koh et al., 2010). A relatively low effective dose of EGCG acutely reduced postprandial 
blood glucose levels in mice when co-administered with common corn starch which 
gives a compelling case for human studies (Forester et al., 2012). This shows that green 
tea has the potential to inhibit the breakdown of starch in vivo and hence reduce the 
glycaemic index/load of the starch. Tea catechins inhibited glucose transport using caco-
2 cells by 63, 40 and 35 % using 100 µM, EGCG, EGC and ECG as inhibitors 
respectively (Johnston et al., 2005).  
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Therefore, it is evident that green tea has the potential to affect postprandial blood 
glucose by acting as an inhibitor of carbohydrate digestion and absorption due to the 
inhibitory properties of its catechins on the digestive enzymes α-amylase and α-
glucosidase as well as glucose transporters. This justifies its inclusion in the polyphenol-
rich mixture for the human intervention study, specifically to act as the inhibitor for α-
glucosidase for its inhibition (IC50 value <50 for maltase and <200 µM for sucrase) 
towards α-glucosidase in vitro (table 1-1). 
1.4.1.3 Apple polyphenols  
Apples are widely consumed worldwide and historically it has always being associated 
with health benefits as can be seen from the famous saying which says ‘an apple a day 
keeps the doctor away’ (Boyer and Liu, 2004). Research has since attributed the presence 
of polyphenols as a contributing factor to the health benefits of fruits and vegetables in 
addition to vitamins and fibre. A number of epidemiological studies have linked the 
consumption of apples to a reduced risk of cancer, cardiovascular disease, asthma, 
obesity and diabetes (Boyer and Liu, 2004). Apples are a good source of polyphenols 
and were ranked 18 (pure apple juice) and 19 (apple fruit) in the richest dietary sources 
of polyphenols per serving by Perez-Jimenez et al., 2010. 
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Figure 1-8: Chemical structures of apple polyphenols which have inhibitory effects on 
glucose absorption. 
A review by Boyer and Liu (2004), reviews a number of studies that looked at the 
associations of consumption of apples to a number of chronic diseases including type 2 
diabetes and results showed favourable effects in humans. Among the polyphenols found 
in apples, quercetin and its conjugates (Boyer and Liu, 2004) are reported to offer more 
protection against the chronic diseases including type 2 diabetes, with quercetin-3-O-
rhamnoside and quercetin-3-O-glucoside having inhibitory properties against glucose 
transporters GLUT2 and SGLT1 (Ader et al., 2001, Cermak et al., 2004).  In addition, 
phloretin and its glucosidic form phloridzin (phloretin-2’-O-glucoside) (fig-1-5) also 
inhibit glucose transporters GLUT2 and SGLT1 respectively (Minami et al., 1993, 
Gromova, 2006). Phloridzin is said to be a stronger inhibitor of glucose transport and 
may thus be beneficial for reducing the risk of obesity, type 2 diabetes and cardiovascular 
disease (Johnston et al., 2002, Manzano and Williamson, 2010). 
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1.4.1.4 Pomegranate polyphenols 
Pomegranate is one of the oldest edible fruits and it is consumed fresh or processed into 
fresh juice, jams flavours and colourants. The different parts of the pomegranate tree 
have been used since ancient times in folk medicine for various diseases (Vidal et al., 
2003).  The presence of polyphenols is said to play a major role in the health properties 
and they include anthocyanins (which impart the red colour), phenolic acids (mainly 
ellagic and gallic acids), tannins (mainly punicalin and punicalagin) as well as flavonoids 
such as quercetin, phloridzin and catechins. The anti-diabetic activity (property to control 
blood glucose levels) of pomegranate is generally attributed to the presence of the tannins 
(punicalin, pendunculagin and punicalagin) (Medjakovic and Jungbauer, 2013). The 
tannins have high molecular weights and their chemical structures (fig 1-9) indicate the 
presence of hydroxyl groups which may play a major role in its anti-diabetic mechanisms 
which will be discussed in chapter 7. Other pomegranate polyphenols that also show anti-
diabetic properties include: ellagic acid found in the flower, which increases insulin 
sensitivity (Huang et al., 2005), phenolic acids in seeds which decreased weight gain and 
improved insulin sensitivity and hence reduced the risk of type 2 diabetes in rats 
(McFarlin et al., 2009, Banihani et al., 2013). Details of their anti-diabetic properties are 
discussed in chapter 6. 
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Figure 1-9: Chemical structures of pomegranate tannins punicalin and punicalagin as 
well as ellagic acid which will be investigated for inhibitory effects on carbohydrate 
digestive enzymes. 
 
 
Punicalin 
Ellagic acid 
Punicalagin 
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1.5 Hypothesis 
By having a mixture of polyphenols in a meal that inhibit all the different stages of 
carbohydrate digestion and absorption (fig 1-5), a maximum effect of polyphenols on 
glycaemic response would be expected as all inhibitions would give a combined effect. 
Intervention studies will be carried out to determine the effects of polyphenols on 
glycaemic response in vivo. 
1.6 Main Objective 
To determine the effect of polyphenols on glycaemic response in healthy volunteers 
when consumed together with white bread (high glycaemic index food). 
1.6.1 Specific objectives  
 To determine the effects of polyphenols in the polyphenol and fibre-rich 
food (PFRF) mixture on glucose and insulin response in healthy volunteers. 
 To determine the effects of different doses of polyphenols in the PFRF 
mixture on postprandial plasma glucose and insulin responses of healthy 
volunteers. 
 To determine the effects of polyphenols from a single food source and 
compare the effects on postprandial glucose when different food matrices 
are used. 
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Chapter 2 . Materials and methods 
optimisation 
2.1 Materials 
Below is a list of equipment and materials used in this research. 
2.1.1 Equipment  
1. PHERAstar FS micro-plate reader (BMGlabtech, Ortenberg, Germany).  
2. 96-well plate compatible for ultraviolet (UV) (Greiner Bio-one, Stonehouse, 
UK).  
3. Accuchek Glucometer, Aviva Lancets and Strips (Roche Diabetes care Limited, 
Burgess Hill, West Sussex, UK). 
4. 96-well plate for non UV range (Nunc A/S., Roskilde, Denmark). 
5. Micro-plate sealing film (Z369659-100EA, Sigma-Aldrich, St Louis, MO, USA). 
6. An Agilent 1200 SL system (Agilent Technologies, Dorset, UK). 
7. Zorbax Eclipse plus C18 (1.8 µm, 100 x 2.1 mm) and Agilent-Zorbax eclipse 
XDB-C18 (1.8 µm, 50 x 4.6 mm) columns (Agilent Technologies, Dorset, UK). 
8. Millipore water purifying system (Millipore, Hertfordshire, UK). 
9. Genevac (EZ-2 plus model) (Fisher Scientific Ltd, Leicestershire, UK). 
10. Eppendorf centrifuge (5810R) (Fisher Scientific Ltd, Leicestershire, UK). 
11. Water bath (GLS Aqua 12 plus, Grant Instruments, Cambridge, UK). 
12. Prevail Carbohydrate ES 5 μm column (GRACE, Lokeren, Belgium). 
13. The Oasis Max SPE Cartridges (Waters Corporation Ltd, Milford, MA, USA). 
14. UFLCXR Shimadzu system (Shimadzu, Kyoto 604-8511, Japan). 
37 
 
   
15. VISIPREP Manifold for solid phase extraction (Supelco Analytical, Sigma-Aldrich, St 
Louis, MO, USA). 
16. Oasis MAX cartridge 1 mL (30 mg) and 3 mL (60 mg) (Waters Co-operation Ltd., 
Mildford, Mass, U.S.A).  
2.1.2 Reagents  
1. Glucose Hexokinase (G 3293) reagent (Sigma-Aldrich, St Louis, MO, USA). 
2. Mercodia human insulin ELISA kit and Mercodia Diabetes Antigen Control (10-1164-
01)  (Mercodia AB, Uppsala,Sweden). 
3. Formic acid, 3,5-Dinitrosalicylic acid, acetic acid, benzoic acid and trifluoroacetic acid 
(Sigma-Aldrich, St Louis, MO, USA). 
4. Human salivary α-amylase type IX-A, powdered acetone protein extract from rat 
intestine, pancreatin, amyloglucosidase and invertase (Sigma-Aldrich, St Louis, MO, 
USA). 
5. Folin-Ciocalteu Reagent (Merck, Steinheim, Germany). 
6. Sodium carbonate, sodium phosphate dibasic, sodium phosphate monobasic sodium 
potassium tartrate, 3,5-dinitrosalicylic acid, disodium hydrogen phosphate (Na2HPO4 
anhydrous), sodium dihydrogen phosphate (NaH2PO4 anhydrous), sodium chloride 
(NaCl), sodium acetate trihydrate, calcium chloride, acetonitrile and sodium hydroxide 
(NaOH) (Sigma-Aldrich, St Louis, MO, USA). 
7. Methanol, DMSO and ethanol, (Sigma-Aldrich, St Louis, MO, USA). 
8. Glucose, sucrose, fructose, maltose, iso-maltose, amylose, amylopectin and guar (Sigma-
Aldrich, St Louis, MO, USA). 
 
 
 
38 
 
   
2.1.3 Polyphenols 
1. Gallic acid (Alfa Aesar, Lancashire, UK) 
2. Epigallocatechin, epigallocatechin, epicatechin gallate, epicatechin, cyanidin-3-O-
rutinoside, cyanidin-3-O-glucoside, phloridzin, pelargonidin-3-O-glucoside, hesperetin, 
taxifolin, myricetin and quercetin-3-O-rhamnoside (Extra-synthase, Genay, France).  
3. Ellagic acid, punicalagin, an isomeric mixture of punicalagin A and B, and punicalin, a 
mixture of A and B (Phytolab, Vestenbergsgreuth, Germany).  
2.1.4 Food/supplements samples 
1. Glucose, and fructose for human consumption (Holland and Barrett, Leeds, UK).  
2. Warburton bread and sucrose (Morrison’s and Tesco, Leeds, UK) 
3. Green tea powder (Nestle, Research Centre, Lausanne, Switzerland). 
4. Pomegranate juice (Healthy Supplies, Lancing, UK) 
5. Freeze dried blackcurrant, blackberry and strawberry (Healthy Supplies, Lancing, UK) 
6. Freeze dried apple peel (AppleBoost, USA) 
7. Pomegranate supplements (CSIC-CEBAS, Spain) 
8. Pomegranate extract (CSIC-CEBAS, Spain) 
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2.2 Hexokinase assay for the determination of blood glucose  
2.2.1 Introduction 
There are different methods that can be used to measure blood glucose. The common 
methods include glucose oxidase, automatic analysers, glucometers and hexokinase 
(HK). Due to the nature of the analysis (comparison of reference and test glucose 
response), any recognized and well standardised method of measuring glucose can be 
used. However it should have a coefficient of variation (CV) of analytical variation of 
<3 % and should give at least 98 % recovery from a glucose spike as is the 
recommendation for clinical trials (Widjaja et al., 1999) . The hexokinase assay was 
modified and optimised (Encarnacao, 2015) and will be used as it meets the requirements 
of CV of analytical variation of <3 % and at least 98 % recovery from a glucose spike. 
2.2.2 Principle of the method 
In enzyme kinetics, the rate of an enzyme reaction changes with substrate concentration. 
Determination of amount of product formed can thus be used to measure the substrate 
initially present. The glucose HK assay from Sigma (product code GAHK-20) utilises a 
second enzyme which converts the product into a measurable substance as shown below. 
1) Glucose     +      ATP       Hexokinase                   Glucose-6-phosphate + ADP 
2) G6P  +  NAD+                 G-6-PDH                      6-phosphogluconate + NADH 
In the first reaction, glucose reacts with ATP in the presence of hexokinase enzyme and 
is phosphorylated to form glucose-6-phosphate (G-6-P). In the second reaction, G-6-P 
oxidation is catalysed by the enzyme glucose-6-phosphate dehydrogenase (G-6-PDH) in 
the presence of NAD+ to give the oxidised form 6-phosphogluconate and an equimolar 
amount of NAD+, is reduced to NADH. NADH is measured by a spectrophotometer at 
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340 nm and is used to obtain the concentration of glucose in the original sample, since 
the increase in absorbance at 340 nm is directly proportional to the glucose concentration 
in the original sample. 
2.2.3 Equipment and reagents 
The PHERAstar FS micro-plate reader and 96-well plate compatible for ultraviolet (UV) 
reading were used for UV absorbance readings. The glucose hexokinase reagent  
contained 1.5 mM of NAD+, 1.0 mM ATP and 1.0 unit m/L hexokinase. A unit 
phosphorylates 1.0 µmol of D-glucose per min at 25 °C and pH 7.6 with phosphorylation 
rate constant of 0.12 mM at 30 °C and pH 7.5. It also contains 1.0 unit m/L of glucose-
6-phosphate dehydrogenase with 1 unit defined to convert 1.0 µmol of glucose-6-
phosphate to 6-phosphogluconate per min at 25 °C and pH 7.4 in the presence of NADH. 
D-glucose was used for glucose standard curves. 
2.2.4 Procedure 
The method was modified and optimised to use a 96 well plate to reduce analysis time 
and plasma volume from 1 mL to 10 μL (Encarnacao, 2015). A stock solution of 1.5 
mg/mL D-glucose solution was prepared and different concentrations required for the 
standard curve were obtained by diluting the stock with millipore water accordingly to 
obtain concentrations of 0.025, 0.25, 0.5, 1.0 and 1.5 mg/mL (0.14, 1.39, 2.7, 5.55 and 
8.33 mM). The sample blank, reagent blank, standard blank, standard and plasma were 
then mixed accordingly with either millipore water or reagent in 96 well plates and 
incubated for 15 min at 0 °C and then placed in the plate reader to read the absorption at 
340 nm. After correcting for all the blanks (sample/standard and reagent blank), a 
standard curve for D-glucose was obtained and the equation used to calculate amount of 
glucose in the plasma.  
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2.2.4 Method optimisation 
2.2.4.1 Glucose standard curves 
To set up the basis to accept or disregard a standard curve for each experiment, three 
experiments were carried out to obtain the equation of D-glucose standard curves as 
shown in figure 2-1. The aim was to come up with a range of Slopes that should always 
be checked for each experiment to ensure that the standard curve equation is within the 
acceptable range. 
 
 Figure 2-1: D-glucose standard curves for three biological triplicates (A, B and C) each 
data point being mean±SD, n=3, to determine an acceptable range of the slopes to be 
used as a guide for each experiment’s glucose standard curve. The average of the D-
glucose standard curves (D) with standard deviation error bars for standard curves (A, B 
and C), n=3. 
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The glucose standard curve slopes from the equations of the three biological triplicates 
gave a mean ±SD of 0.159±0.017 which was used as a reference for each glucose analysis 
experiment of which the slope had to be within this range to be acceptable. All 
experiments carried out had their slopes falling in the acceptable range.  Linearity shows 
the proportionality of the response to the measured analyte and is determined by how 
well a standard curve follows a straight line. A common measure of linearity is the square 
of the correlation coefficient (R2). The coefficient of determination R2 was good for all 
the D-glucose standard curves that were carried out and was above 0.999.  
2.2.4.2 Precision 
Precision shows how well replicate measurements agree with one another and are usually 
expressed as a standard deviation. Instrument precision is the reproducibility obtained 
when the same quantity of one sample is repeatedly introduced in an instrument. To test 
this, three fasting plasma samples were aliquoted and analysed on five different days and 
results were calculated using the appropriate standard curve equations and the following 
results were obtained.  
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Biological 
triplicates 
Glucose concentration (mM/L) 
 
Week 1 Week 2 Week 3 Week 4 Week 5 Average ±SD 
1 4.6 4.5 4.5 4.5 4.5 4.52±0.04 
2 4.5 4.3 4.4 4.4 4.4 4.4±0.07 
3 4.6 4.4 4.5 4.3 4.5 4.5±0.11 
 
Table 2-1: Plasma glucose results of biological triplicates of fasting blood samples which 
were each aliquoted in five tubes and stored in the -80 °C freezer. Each week, one aliquot 
of each of the biological triplicates was analysed for the determination of glucose 
concentration using the hexokinase assay. 
2.2.5 Conclusion  
The method is reliable and reproducible as the aliquots of the same sample analysed on 
different days gave results that were very close with standard deviations of  0.04, 0.07 
and 0.11 giving CV of 0.9, 1.6 and 2.4 % respectively which are all <3 %.  In addition, 
a glucose spike result was 100±2 % which is also in the acceptable range of >98 %. This 
proved that the method and techniques were good and will be used for the analysis of 
blood glucose in the intervention study. 
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2.3 Insulin measurement by ELISA 
2.3.1 Introduction 
There are three types of methods that are used for the determination of insulin content in 
blood. They are in vivo, in vitro and immunological methods. In the in vivo methods, 
serum is injected into animals in which an insulin-like effect is produced. This effect is 
then compared with the response of known standard insulin solutions. The in vitro 
method involves incubating an isolated tissue in serum and one metabolic process 
produced by the tissue is compared to that produced by known insulin standard solutions 
Immunological methods determine the concentration of insulin in the serum by its 
binding to insulin antibody. The latter is the most commonly used method for insulin 
analysis especially the enzyme-linked-immuno-sorbent-assay (ELISA) (Federlin, 2012). 
2.3.2 Principle of the method 
The Mercodia insulin ELISA is based on the direct sandwich technique (solid phase two-
site enzyme immunoassay). It is based on the affinity of an antibody (ABI) coated well 
which is specific to the antigen or molecule of interest on the insulin molecule. The 
sample to be analysed is added into the well and there is a specific binding reaction 
between antibody and molecule of interest. A washing buffer step then follows and it 
removes any unbound molecule. A second antibody linked to an enzyme (peroxidase) is 
then added into the antibody-antigen complex formed in the first step. A substrate 
solution, 3,3’,5,5’-tetramethylbenzidine (TMB), is then added and reacts with the 
enzyme. The reaction is stopped by adding acid and a colour develops, proportional to 
the amount of molecule of interest present in the well. The colour intensity is measured 
spectrophotometrically using a micro-plate reader at 450 nm. The molecule of interest 
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can be quantified by using the standard curve equation obtained using the standard 
solutions enclosed in the kit. 
2.3.3 Equipment and reagents 
The PHERAstar FS micro-plate reader with 450 nm filter was used for absorbance 
reading. The plate shaker was used for incubation step with shaking. The kit contained 
ready-to-use coated plate, calibrators 0, 1, 2, 3, 4 and 5, enzyme conjugate buffer, 
substrate TMB and stop solution. It also contained 11 times concentrated enzyme 
conjugate buffer (11X) and 21 times concentrated wash buffer (21X). 
The plate is coated with mouse monoclonal anti-insulin and calibrators 0, 1, 2, 3, 4 and 
5 are recombinant human insulin with concentrations of 0, 3.2, 10.5, 31.1, 103 and 214 
mU/L respectively. Substrate contains 3,3’,5,5’-tetramethylbenzidine (TMB) which is 
light sensitive and the stop solution contains 0.5 M sulphuric acid. Mercodia Diabetes 
Antigen Control was purchased separately. 
2.3.4 Procedure 
As recommended by the supplier, the ELISA kit was always stored at 4 °C and one batch 
was used for all the plasma samples to avoid batch related differences. The wash buffer 
(21X) was diluted 21 times with millipore water to 1X for use and once diluted could be 
stored for 8 weeks at 2-8 °C. Enzyme conjugate solution (11X) was also diluted to 1X 
fresh each time to use in the assay by diluting it 11 times with enzyme conjugate buffer. 
For each analysis, insulin calibrators 0, 18, 60,180, 600 and 1200 pM were analysed to 
obtain a standard curve for insulin calculations in the plasma. They were taken out of the 
fridge and allowed to equilibrate to room temperature (20 °C). Plasma stored at -80 °C 
was thawed each time before analysis, hand mixed and centrifuged in a 5810R Eppendorf 
centrifuge at a speed of 4000 rpm at 4 °C for 10 min.  
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Using an appropriate pipette, 25 µl each of plasma and calibrators were added to clearly 
labelled wells of the coated plate. To each well 100 µL of enzyme conjugate 1X solution 
was added and the plate was incubated for 1 hr on a plate shaker at room temperature (20 
°C). Incubation allows for the insulin molecules in the plasma to bind to the anti-insulin 
antibody on the plate. After incubation, the contents of the wells were discarded by 
inverting the micro-plate over the sink. The wells were then washed 6 times by adding 
350 µL wash buffer 1X solution to each well and making sure excess liquid is removed 
between washes by tapping firmly several times against adsorbent paper. This washing 
step removes any unbound molecules. A second substrate TMB (200 µL) was added to 
each well and allowed to react with the bound complex by incubating at room 
temperature for 15 min. The reaction was stopped by adding 50 µL stop solution to each 
well. The plate was then placed on the shaker for 5 sec to mix and absorbance was read 
at 450 nm in the plate reader. Results were calculated by using the insulin standard curve 
equation to determine the amount of insulin in the plasma. 
2.3.5 Method optimisation 
The commercially available kit from Mercodia for insulin analysis is already optimised 
by the supplier.  The assay kit guarantees high accuracy and avoids cross reactions with 
similar molecules such as pro-insulin because it uses monoclonal antibodies for both the 
primary and secondary antibodies. To validate this, insulin standard curve analysis with 
biological triplicates was carried out as shown in figure 2-2 to determine reliability of 
the results. 
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Figure 2-2: Insulin standard curves for three biological triplicates (A, B and C), for the 
determination of insulin concentration in plasma (data points are expressed as mean±SD 
n=3). (D) Is the average of the insulin standard curves (A, B and C) with standard 
deviation error bars (n=3).   
The coefficient of determination R2 was good for all the insulin standard curves and was 
all above 0.999. The average of the curves gave very small standard deviations as shown 
by the error bars in figure 2-1 (D).  Mercodia antigen controls (high and low insulin 
concentrations) were always analysed together with samples and calibrators to ensure 
that the sensitivity of the assay was maintained. The coefficients of variation between the 
assays were 7.3 and 8.2 % for the low and high controls respectively. 
48 
 
   
2.3.6 Conclusion 
The Mercodia kit for insulin was shown to be a good method for insulin determination 
as demonstrated by the standard curves and the R2 values confirming good linearity. Inter 
assay repeatability was also confirmed as shown by the coefficients of variation values 
between the assays for the low and high controls. Hence this assay is precise and has 
good linearity and suitable to be used for determining insulin concentration in plasma. 
2.4 Folin assay for the determination of total polyphenols 
2.4.1 Introduction 
There are different methods used to measure the total phenol contents of food with the 
Folin-Ciocalteu method being the most acceptable (Margraf et al., 2015). The Folin assay 
method determines the total polyphenol content in food samples using Folin-Ciocalteu 
reagent and the spectrophotometer. It is preferred as it is inexpensive, soluble in water, 
recrystallized easily from water, readily dried and stable in dry form Singleton et al., 
1999). The Folin-Ciocalteu assay was first used by Singleton and Rossi in 1965 when 
they improved the method from using Folin-Denis reagent which gave precipitation 
problems. The Folin-Ciocalteu formulation gave greater colour, less variation and better 
recovery (Singleton, 1985). The method used in this research is adapted directly from 
Singleton et al. (1999) with modifications by including a control for each sample to 
account for any interference from other reducing agents in the food sample (Yahya, 
2012). 
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2.4.2 Principle of the method 
The assay involves the reduction of Folin-Ciocalteu reagent by phenols to form a blue 
coloured complex which gives maximum absorbance in the spectrophotometer at 765 
nm. The Folin-Ciocalteu reagent measures total phenols and any reducing agents and 
will thus measure the total reducing capacity of a sample. Therefore, to measure the 
amount of total polyphenols, most commonly gallic acid is used as a standard so that all 
phenols are reported in gallic acid equivalents (GAE).  
2.4.3 Reagent and standard preparation 
Folin-Ciocalteu Reagent was prepared by diluting it 10 times with millipore water. 
Sodium carbonate solution was prepared by dissolving 75 g (Mw=75) in 1 L using a 1 L 
volumetric flask and  80 % methanol was prepared by mixing 200 mL of millipore water 
with 800 mL of pure methanol in a 1 L volumetric flask. Gallic acid stock standard 
solution (1 mg/mL) was prepared and used to obtain various concentrations (25, 50, 75, 
100, 125, 150, 175, 200 µg/mL) for the standard curve, by diluting with millipore water.  
2.4.4 Procedure 
The assay was conducted by adding 1 mL of every solution (sample, standard and 
control) into separate 15 mL Falcon tubes followed by the addition of 5 mL of the Folin-
Ciocalteu reagent to each tube. The tubes were capped, mixed on a vortex mixer and 4 
mL of sodium carbonate solution was added within 3-8 min from the addition of Folin-
Ciocalteu reagent. The tubes were capped and mixed quickly and then placed in the 
water-bath at 26 °C and incubated for 2 hr. The control sample had 4 mL sodium 
carbonate replaced with 4 mL millipore water. Absorbance was read using the plate 
reader spectrophotometer at 765 nm wavelength. A gallic acid standard curve was 
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obtained and using its equation, the amount of GAE of the sample and control were 
determined. The total polyphenol content was calculated as: 
 GAE of sample - GAE of the control.  
2.4.5 Method optimisation 
The method was optimised by including a control sample to account for other 
interferences from other reducing agents such as ascorbic acid (Yahya, 2012). The 
coefficient of determination (R2) was good in all the experiments (>0.99). Moreover, the 
value of the Slope was also very similar in all the experiments as shown by the error bars 
in the average standard curve (figure 2-3D). 
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Figure 2-3: Gallic acid standard curves for three biological triplicates (A, B and C) for 
the determination of insulin concentration in plasma (each data point being mean±SD 
n=3). (D) is the average of the gallic acid standard curves (A, B and C) with standard 
deviation error bars (n=3). 
 
2.4.6 Conclusion 
The coefficient of determination for the gallic acid standard curve was good for all 
experiments. Hence the method is reproducible and reliable to use. 
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2.5 High Performance Liquid Chromatography (HPLC) for 
polyphenol identification and quantification 
2.5.1 Introduction 
HPLC is a chromatographic method that separates, identifies and quantifies components 
from a mixture. Unlike the Folin-Ciocalteu assay that gives the total amount of 
polyphenols in a food sample, HPLC is more specific as it will identify as well as quantify 
individual components. Reverse phase HPLC was used.  
2.5.2 Materials and equipment 
An Agilent 1200 SL system equipped with a diode array detector (DAD) was used for 
all HPLC analysis. It comprised of a binary pump, degasser, column oven (35 ˚C) and 
well plate auto-sampler (5 ˚C).  Two columns were used depending on sample; a Zorbax 
Eclipse plus C18 column (1.8 µm, 100 x 2.1 mm) and Agilent- Zorbax eclipse XDB-C18 
(1.8 µm, 50 x 4.6 mm).  They are 600 bar, rapid resolution and high throughput columns. 
Other parameters include 5 µL injection volume, 0.5 mL/min flow rate with needle wash 
in flush point for 3 sec. 
 For all analysis, ultrapure, nuclease free water (≥18.2 MΩ cm at 25 ˚C) from a Millipore 
water purifying system was used. For sample preparation, a Genevac (EZ-2 plus model) 
was used for evaporation. 
2.5.3 Reagents and standards preparation 
1 mg/mL standard solutions were prepared in 50 % ethanol and aliquots of 100 µL (100 
µg) were dried using the Genevac evaporator and stored dry at -20 °C until further use. 
Addition of 1 mL of 50 % ethanol to the tube containing 100 µg of the standard, gave a 
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concentration of 100 µg /mL which was used to obtain concentrations of 10, 30, 50, 70 
and 90 µg /mL. The standards were analysed using reversed phase HPLC and using an 
internal standard each time. Internal standards are important for improving the precision 
and accuracy of results obtained by correcting analytical variability.  Solvent A (mobile 
phase) consisted of (millipore water with 0.1 % formic acid) and solvent B (stationery 
phase) consisted of (Acetonitrile with 0.1 % formic acid).  
2.5.4 Procedure 
The separation started with 5 % solvent and chromatographic conditions of elution 
continued as follows: 0-5 min, increase of solvent B from 5 to 10 %, 5-20 min, increase 
solvent B to 40 %, 20-25 min, increase of solvent B to 90 %, 25-29 min, isocratic for 4 
min, 29-30 min, decrease solvent B to 5 % and re-equilibration for 3 min at 5 %.  
Standard curves were obtained using different concentrations of standards and were used 
to determine the amounts of specific polyphenols in a food mixture. The peaks were 
identified by use of the retention time, spectra as well as spiking the food samples with 
polyphenols of interest. The retention time of the particular polyphenol obtained in the 
standard analysis gave an estimate of what retention time the same polyphenol is likely 
to have in the food mixture. By comparing the spectra of the particular polyphenol 
standard with that obtained in the food mixture gave an indication of which peak 
represented the particular polyphenol. Finally, spiking was also used to confirm the 
identification of a compound of interest by adding a particular standard to the mixture 
and the peak that gave a corresponding increase was identified as the compound of 
interest. 
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2.5.5 Method optimisation 
Reproducibility of the method was tested by using taxifolin as the internal standard for 5 
different experiments on green tea extract.  It was prepared on the first day of experiments 
and aliquots containing equal amounts were dried and stored at -20 °C in the same way 
as the standards. Taxifolin was used as internal standard for 5 experiments and peak areas 
were compared (table 2-2).  
Experiment Mean peak areas ±SD 
(mAU) 
COV (%) 
1 464.3±39.7  8.5 
2 469.3±23.9  5.1 
3 473.5±16.8 3.4 
4 474.1±7.7 1.6 
5 466.1±4.8 1.0 
Average of All 
Experiments 
468.7±26.2 5.6 
 
Table 2-2: Mean±SD (n=3) peak areas and COV of taxifolin used as an internal standard 
in the characterisation of green tea and green tea polyphenols in 5 different experiments 
using reverse phase HPLC. 
 
The coefficient of variation (COV) obtained from five different experiments was good 
(<10 %) in all the results. Blank and positive samples gave expected results giving an 
indication that the experiments were accurate. From the results shown, the COV reduced 
from the first experiment having the highest 8.5 % to the last experiment having 1.0 % 
showing an improvement in the skills of the analyst, but overall all were below 10 %.  
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2.5.6 Conclusion 
The square of correlation coefficient R2 was good in all the experiments that were carried 
out and was above 0.999 as will be shown in chapter 3. There was a good relationship of 
the standard solutions being measured which were used to determine the amounts of 
polyphenols in the food samples. The method has good specificity and selectivity as it 
was possible to distinguish a particular polyphenol from food extracts that contained a 
mixture of polyphenols. The method was also reproducible hence will be used for the 
quantification of polyphenols in the food extracts to be used in this research.  
2.6 Englyst method for the determination of available 
carbohydrates in bread 
2.6.1 Introduction 
The Englyst method determines the different types of starch by controlled enzymic 
hydrolysis of starch and determines the glucose released using the glucose oxidase 
method. One modification to the method was that the glucose released was determined 
using hexokinase as it has been optimized and validated as discussed in section 2.2. The 
aim of this analysis was to determine the amount of bread to give a certain amount of 
glucose after digestion. 
2.6.2 Materials and reagents 
Sodium acetate buffer (0.1 M, pH 5.2) was prepared by dissolving 13.6 g sodium acetate 
trihydrate in 250 mL saturated benzoic acid solution and 4 mL of 1 M calcium chloride 
added to act as a stabiliser and activator of enzymes. The pH was adjusted to 5.2 with 0.1 
M acetic acid. Using appropriate calculations, a concentration of 140 U/mL 
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amyloglucosidase was prepared from 300 U/mL stock. A stock of 150 mg/mL pancreatin 
was prepared by adding 20 mL millipore water to 3 g pancreatin which was mixed and 
stirred for 10 min. The mixture was placed in centrifuge tubes and centrifuged for 10 min 
at 4000 rpm. Supernatant was placed in another tube and was ready for use. Invertase 
(3000 U/mL) was prepared by dissolving 60 mg of the powder (1 mg = 300 U) in 6 mL 
sodium acetate buffer. The enzyme mixture was prepared by mixing pancreatin (150 
mg/mL), invertase (3000 U/mL) and amyloglucosidase (140 U/mL) in the ratio 1: 13.5: 
9 
2.6.3 Procedure 
Centrifuge tubes (50 mL) were correctly labelled for test samples and glucose standard 
curves. For the test samples, bread samples (1 g) were placed in labelled 50 mL centrifuge 
tubes. Then approximately 50 mg guar and 5 glass balls were added to each tube to help 
with the mixing upon addition of 20 mL acetate buffer. The same was done for the 
standards tubes except that 20 mL of known glucose solution in acetate buffer was added 
in place of the bread sample.  To correct for any glucose present in amyloglucosidase, a 
blank tube was prepared containing glass balls, guar gum and 20 mL acetate buffer. All 
tubes (sample, blank and standards) were treated the same in the following steps.  
The tubes were equilibrated to 37 °C in a water-bath. Thereafter, 5 mL of the enzyme 
solution was added to each tube and time set accordingly from this point allowing at least 
2 min between tubes. The tubes were then placed horizontally in a shaking water-bath at 
37 °C with the glass balls providing the crushing action. 
After 120 min, 0.5 mL of the hydrolysate was removed (without stopping the shaking 
action) and placed in a labelled tube containing 20 mL 66 % ethanol, and mixed well to 
denature the enzymes.  
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The standards, samples and controls were all analysed for amount of glucose using the 
hexokinase assay as described in section 2.2. After correcting for blanks, the standard 
curve equation was used to calculate the amount of glucose in the samples. Knowing the 
amount of bread added in each tube, calculations were done to determine how much 
glucose was released from a gram of bread for use in subsequent calculations. 
2.6.4 Method optimisation 
Linearity was achieved for the glucose standard curve obtained by adding known 
concentrations of glucose in the enzymatic digestion mixture. The repeated curves gave 
similar slope and the coefficient of determination was above 0.99 in all (figure 2-4).  
 
Figure 2-4: Glucose standard curves for three biological triplicates (A, B and C) used for 
the determination of glucose produced after enzymatic hydrolysis of bread (each data 
point being mean±SD n=3). The average of the standard curves (A, B and C) is shown 
in (D) with standard deviation error bars (n=3). 
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Bread samples from four batches were aliquoted and stored in the -20 °C freezer and 
were analysed for the amount of glucose produced after 2 hrs on different days. The aim 
was to determine the reproducibility of the method and to compare the variability 
between different batches of bread as shown in table 2-3. The method was reproducible 
and different batches of bread gave similar results of the amount of glucose released after 
the hydrolysis with low standard deviations.  
Sample/batch 
number 
Glucose  (g/100g bread) 
 
Experiment 
1 
Experiment 
2 
Experiment 
3 
Experiment 
4 
Mean 
±S.D 
within 
batch 
 
1 42.2 43.7 45.1 45.1 44.0±1.4 
2 46 44 44.1 45.7 45±1 
3 44.6 44.1 44.6 45.4 44.7±0.5 
4 45.6 
 
44.6 45.1 45.1 45.1±0.4 
Mean ±S.D 
between 
batches 
44.6±1.7 44.1±0.4 44.7±0.5 45.3±0.3  
Table 2-3: Mean ± S.D (n=4) results of amount of glucose produced (g) from 100 g bread 
for 4 batches of bread. Each batch was analysed 4 times (experiment 1-4) to determine 
variability within each batch and between batches. 
2.6.5 Conclusion 
The method by (Englyst et al., 1992) was validated and gave both good linearity and was 
reproducible. Warburton’s brand of bread did not vary within batches and hence will be 
used in the intervention study meals. 
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2.7 α-Glucosidase assay for the determination of α-
glucosidase inhibition by polyphenols 
2.7.1 Introduction 
Inhibition of α-glucosidase by polyphenols is determined by comparing the enzyme 
activity in the test (with inhibitor) to the control (without inhibitor). Glucose production 
is used as the end point as inhibiting α-glucosidase affects the amount of glucose 
produced from the hydrolysis of disaccharides. Maltose, sucrose or iso-maltose can be 
used as substrates for which the activity can be related to maltase, sucrase and iso-maltase 
respectively obtained from powdered acetone protein extract from rat intestine. The 
method was adapted from Adisakwattana et al. (2009) with some modifications. 
2.7.2 Principle of the method 
The assay involves enzymatic hydrolysis of disaccharides to release glucose and the 
enzymes activities are determined by analysing the amount of glucose produced. By 
comparing the production of glucose in the presence and absence of inhibitors, the 
inhibition of α-glucosidase by plant extracts or pure compounds is determined.  
2.7.3 Chemicals and equipment 
The PHERAstar FS micro-plate reader and 96-well plate compatible for UV reading were 
used for UV absorbance reading at 340 nm. Intestinal acetone powder extract from rat 
intestine, glucose, sucrose, maltose, iso-maltose, sodium phosphate dibasic, sodium 
phosphate monobasic and sodium hydroxide were used for the assay. 
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2.7.4 Preparation of reagents 
Sodium phosphate buffer (10 mM, pH 7.0). 10 mM solutions of sodium phosphate 
monobasic and sodium phosphate dibasic were prepared separately. The buffer was 
prepared by mixing 256.85 mL sodium phosphate monobasic with 243.15 mL sodium 
phosphate dibasic both 10 mM. The pH was adjusted to 7 with sodium hydroxide or 
phosphoric acid. 
Acetone extract of rat intestine. Stock (50 mg/mL) was prepared by mixing with the 
vortex mixer for 30 sec. The supernatant was obtained and placed in a new tube after 
micro-centrifuging the mixture at 4000 rpm for 10 min. 
2.7.5 Determination of assay conditions  
2.7.5.1 Sucrose apparent km determination for assay substrate concentration 
The aim of this experiment was to determine the substrate concentrations (sucrose, 
maltose and iso-maltose) to use in the α-glucosidase inhibition assays.  
Different concentrations of sucrose were prepared ranging from 1 to 100 mM. The assay 
was prepared by adding 200 µL substrate (for each sucrose concentration), 100 µL PBS, 
mixed well and allowed to equilibrate to 37 °C in the water-bath for 5 min. To start the 
reaction, 200 µL (20 mg/mL) RIP (previously warmed to 37 °C) was added to the assay 
mixture, mixed gently and placed in the water-bath for 20 min. After 20 min, the reaction 
mixture was placed in the hot water-bath at 100 °C for 10 min to stop the reaction by 
denaturing the enzyme. The mixture was cooled to room temperature on ice and samples 
analysed for the amount of glucose produced using the hexokinase assay described in 
section 2.2. The Lineweaver-Burk and Hanes-Woolf transformations were used to obtain 
the apparent km value (Lineweaver and Burk,1934). 
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Figure 2-5: The Lineweaver-Burk (A) and Hanes-Woolf (B) plots showing the 
relationship between the substrate concentration [S] and the enzyme rate [V] used to 
determine the apparent kinetic parameter km with sucrose as substrate. Each data point 
being mean±SD, n=3. 
The km values obtained for sucrose were 15.8 and 16.1 mM and hence 16 mM will be 
used as the substrate concentration because it is recommended to use the km value as it 
is optimal for all types of inhibitors. Higher than km favours uncompetitive whilst lower 
than km favours competitive inhibitors (Acker and Auld, 2014). This is because for 
competitive inhibition, the inhibitor binds to the active site where the substrate usually 
occupies the enzyme thereby competing with the substrate ability to bind. So as the 
substrate concentration increases above the km value, there is a higher probability of the 
substrate occupying the active site over the inhibitor at a fixed inhibitor concentration. 
For uncompetitive inhibition, the inhibitor binds to the enzyme only when the enzyme is 
already bound to the substrate molecule. Therefore at concentrations lower than the km 
value,there are fewer substrate-enzyme complexes existing which results in a lower 
probability of uncompetitive inhibitors to inhibit the enzyme  (Acker and Auld, 2014). 
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2.7.5.2 Iso-maltose apparent km determination 
The same procedure used for sucrose was used and used different iso-maltose 
concentrations ranging from 1 to 10 mM to obtain the Lineweaver-Burk and Hanes-
Woolf plots. 
 
Figure 2-6: The Lineweaver-Burk (A) and Hanes-Woolf (B) transformations showing 
the relationship between the substrate concentration [S] and the enzyme rate [V] used to 
determine the apparent kinetic parameter km with iso-maltose as substrate. Each data 
point being mean±SD, n=3. 
 
The apparent km values obtained for iso-maltose were 5.7 and 5.6 mM for the 
Lineweaver-Burk and Hanes-Woolf transformations respectively. A concentration of 6 
mM substrate concentration for iso-maltose will be used as recommended to be optimal 
(Acker and Auld, 2014). 
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2.7.5.3 Maltose apparent km determination 
The same procedure as for sucrose km determination was performed except that the 
different sucrose concentrations were replaced with different maltose concentrations 
ranging from 1 to 20 mM to obtain the Lineweaver-Burk and Hanes-Woolf 
transformations. 
 
Figure 2-7: The Lineweaver-Burk (A) and Hanes-Woolf (B) transformations showing 
the relationship between the substrate concentration [S] and the enzyme rate [V] used to 
determine the apparent kinetic parameter km with maltose as substrate. Each data point 
being mean±SD, n=3. 
The apparent km values obtained for maltose were 3 and 3.3 mM for the Lineweaver-
Burk and Hanes-Woolf transformations respectively. A concentration of 3 mM substrate 
concentration for maltose will be used as recommended to be optimal (Acker and Auld, 
2014). 
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2.7.5.4 Sucrase reaction time and enzyme concentration 
The aim of this experiment was to determine the optimum reaction time and enzyme 
concentration when using sucrose, iso-maltose and maltose as substrates and rat intestinal 
acetone powder (RIP) as the source of the enzymes. This combination needs to be in the 
linear range of the enzyme activity versus incubation time. This is important to avoid 
misinterpretation of results as reduced glucose production may be due to other factors 
like depleted substrate or enzyme when not in the linear range. 
Using 16 mM sucrose concentration (apparent km value) as substrate concentration in 
the assay, 3 enzyme concentrations were used for 3 different sets of samples treated 
exactly the same and only differing in enzyme concentration used. The three enzyme 
concentrations were 10, 20 and 30 mg/mL RIP in assay. All the three sets were then 
incubated for different times from 5 min to 60 min. This was achieved by removing the 
tubes for each set time out of the water-bath and immediately placing them in the hot 
water-bath at 100 °C to denature the enzymes. The 0 min incubation reaction tubes had 
their enzyme denatured immediately by placing the tubes in the water-bath immediately 
after adding the enzyme to the reaction tube. The amount of glucose produced for each 
sets of tubes were determined using the hexokinase as described in section 2.2. The 
amount of glucose produced versus incubation time was then plotted and is shown in 
figure 2-8.  
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Figure 2-8: Different enzyme concentrations (10, 20 and 30 mg/mL) and different 
incubation times (0 – 60 min) were used to obtain the amount of glucose produced from 
sucrose. Glucose produced versus incubation time was plotted to show the pattern of 
enzyme activity at different concentrations and incubation times. Each data point being 
mean±SD, n=3. 
 
All the 3 different enzyme concentrations used gave a linear relationship for the 60 min 
of incubation time tested. It was therefore decided to maintain the 20 mg/mL for 20 min 
as was in the adapted method (Adisakwattana et al., 2009). 
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2.7.5.5 Iso-maltase reaction time and concentration 
The same procedure was used with iso-maltose and the amount of glucose produced 
versus incubation time was plotted. 
 
Figure 2-9: Different enzyme concentrations (10, 20 and 30 mg/mL) and different 
incubation times (0 – 60 min) were used to obtain the amount of glucose produced from 
iso-maltose. Glucose produced versus incubation time was plotted to show the pattern of 
enzyme activity at different concentrations and incubation times (A). B shows that 
linearity was better observed in 20 min. Each data point being mean±SD, n=3. 
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Similar to sucrase, all 3 different enzyme concentrations showed linearity for the 
incubation times tested from 5 to 60 min although had not so good coefficient of 
determination R2 ≥ 0.98. Linearity clearly shown with R2 ≥ 0.99 when only plotted up to 
20 min (figure 2-7B). Hence 20 mg/mL for 20 min will also be used for iso-maltase. 
2.7.5.6 Maltase reaction time and concentration 
The same procedure was used with maltose and the amount of glucose produced versus 
incubation time was plotted. 
 
Figure 2-10: Different enzyme concentrations (10, 20 and 30 mg/mL) and different 
incubation times (0 – 40 min) were used to obtain the amount of glucose produced from 
maltose. Glucose produced versus incubation time was plotted to show the pattern of 
enzyme activity at different concentrations and incubation times. Each data point being 
mean±SD, n=3. 
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2.7.5.7 Conclusion 
The α-glucosidase inhibition assay was optimised and conditions to be used are; substrate 
concentrations of 16, 6 and 3 mM for sucrose, iso-maltose and maltose. For sucrase and 
iso-maltase, enzyme concentration of 20 mg/mL RIP in assay and 4 mg/mL for maltase. 
All assays were to have a reaction time of 20 min as the activity of all enzymes was in 
the linear range. 
2.7.6 Procedure for α-glucosidase inhibition by polyphenols 
A total of 200 µL substrate, 50 µL sodium phosphate buffer (PBS) and 50 µL of inhibitor 
were mixed and pre warmed to 37 °C in a water-bath for 5 min. For the control assay, 
the inhibitor was replaced by 50 µL PBS. To start the assay, 200 µL of the enzyme 
preparation from powdered acetone protein extract from rat intestine also pre-warmed to 
37 °C was added to the mixture (substrate, PBS and inhibitor) and mixed. The resulting 
mixture was incubated for 20 min at 37 °C in the water-bath. After 20 min, the tubes 
were placed in the water-bath at 100 °C to denature the enzymes.  After cooling the assay 
mixtures to room temperature, SPE was carried out if the polyphenol/s reacted with 
hexokinase reagent and lastly hexokinase assay was performed as described in section 
2.2. If the polyphenol used as the inhibitor does not react with hexokinase reagent, the 
SPE step was omitted. The rate of enzyme inhibition is calculated as a percentage of the 
control (without inhibitor) using the formula:             
% = Abs Control – Abs sample x 100 
                  Abs for control 
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Figure 2-11: The flow diagram of α-glucosidase inhibition by polyphenols. The potential 
inhibitor was tested to determine if it reacted with hexokinase reagent. If reactive, then a 
solid phase extraction step (a) to remove the polyphenols was incorporated before 
performing the hexokinase assay. 
2.8 Method set-up and optimization of the α-amylase 
inhibition assay by polyphenols 
2.8.1 Introduction 
As in the case of α-glucosidase inhibition assay, inhibition of α-amylase by polyphenols 
is determined by comparing the enzyme activity in the test (with inhibitor) to the control 
(without inhibitor). The measurement of the reducing ends in the products of starch 
hydrolysis (maltose, maltotriose and α-limit dextrins) is used as the end point as 
inhibiting α-amylase affects the amount of the products produced from the hydrolysis of 
starch (amylose and amylopectin), amylose or amylopectin. The method involving 
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dinitrosalicylic (DNS) acid was adapted from Adisakwattana et al. (2009) and was 
optimised and modified by Nyambe-Silavwe et al. (2015). 
2.8.2 Principle of the method 
The assay determines the inhibition of human salivary α-amylase by polyphenols by 
comparing the amount of product produced from enzyme hydrolysis of starch in the 
presence and absence of polyphenols by measuring their reducing ends. The enzyme α-
amylase hydrolyses starch to produce maltose, maltotriose and α-limit dextrins. The 
presence of a free carbonyl group (C=O) in reducing sugars, enables them to participate 
in an oxidation-reduction reaction with DNS. The aldehyde functional group of the 
reducing sugar gets oxidised into a carboxyl group and the 3, 5-dinitrosalicylic acid gets 
reduced to 3-amino, 5-nitrosalicylic acid.  
 Aldehyde group      oxidation           carboxyl group 
3,5-dinitrosalicylic acid      reduction              3-amino, 5-nitrosalicylic acid 
This reaction cause a colour change from yellow to orange or red, depending on the 
concentration of the reducing sugars produced. By reading absorbance of the coloured 
product, the amount of maltose equivalents/ reducing sugar ends produced can be 
calculated using the standard curve equation for maltose. 
2.8.3 Chemicals and equipment 
Micro-plate reader, 96-well plate for 540 nm and micro-plate sealing film were used for 
absorbance reading. Human salivary α-amylase type IX-A (1 unit will liberate 1.0 mg of 
maltose from starch in 3 min at pH 6.9 at 20 °C), maltose, amylose, amylopectin, sodium 
potassium tartrate, 3,5-dinitrosalicylic acid, disodium hydrogen phosphate (Na2HPO4 
anhydrous), sodium dihydrogen phosphate (NaH2PO4 anhydrous), sodium chloride 
(NaCl), sodium hydroxide (NaOH) and epigallocatechin gallate (EGCG) were used in 
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the assay. Oasis MAX cartridge 1 mL (30 mg) and 3 mL (60 mg) and the polyphenols 
phloridzin and gallic acid were also used in the assay. All the reagents were of the highest 
purity and standards were ≥98 % 
2.8.4 Preparation of reagents 
Amylopectin (0.93 mg/mL) The stock solution for amylopectin was prepared by 
dissolving 9.3 mg amylopectin in 10 mL boiling millipore water and was stirred on a hot 
plate for not more than 10 min until dissolved and clear.  
Amylose (2.5 mg/mL) Amylose stock solution was prepared by adding 100 µL absolute 
ethanol to 25 mg amylose followed by addition of  1 mL millipore water and 200 µL 
0.1M NaOH. The mixture was stirred on a hot plate at 100 °C until all amylose had 
dissolved (maximum 15 min). It was cooled to room temperature and a reasonable 
amount of millipore water just below 10 mL mark was added. The pH was adjusted to 
6.9 with HCl or NaOH and volume adjusted to 10 mL with millipore water.  
Phosphate-buffered saline (PBS) 0.1M, pH 6.9 Disodium hydrogen phosphate 
(Na2HPO4 anhydrous, 10.9 g), sodium dihydrogen phosphate (NaH2PO4 anhydrous, 3.2 
g) and 90 g sodium chloride (NaCl) were all dissolved in 1 L millipore water and pH was 
adjusted to 6.9 with either 1 M NaOH or phosphoric acid.  
Human salivary amylase (117.5 U/mL) According to supplier’s recommendation, 1 
mg/mL α-amylase gives 117.5 U/mL and was dissolved in 0.1 M PBS and stored in 
aliquots at -20 °C. The required concentration for the assay (1.25 U/mL) to give 0.5 U/mL 
in total assay volume was prepared by appropriate dilutions from the 117.5 U/mL stock. 
Sodium potassium tartrate solution, 5.3 M (Reagent A) This was prepared by 
dissolving 12 g sodium potassium tartrate in previously heated 8 mL of 2 M NaOH at 
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50-70 °C. It was then heated directly on a heating/stir plate with constant stirring to 
dissolve taking the precaution not to boil the solution. 
3,5- Dinitrosalicylic acid solution (DNS), 96 mM (Reagent B) This was prepared by 
dissolving 438 mg of DNS in a reasonable amount of millipore water and made up to 20 
mL with millipore water. It was heated directly on a heating/stir plate with constant 
stirring to dissolve at 100 °C and taking the precaution not to boil the solution.  
Colour reagent Solution The colour reagent containing DNS for the final step of the 
assay was prepared by slowly adding reagent A to reagent B with continuous stirring. It 
was diluted to 40 mL with millipore water. The quantities of reagent A, B and millipore 
water were adjusted 10 times and the solution was stored in an amber bottle at room 
temperature with expiry after 6 months. 
2.8.5 Determination of assay conditions 
2.8.5.1 Amylose and amylopectin km determination for assay substrate 
concentration 
The aim of this experiment was to determine the substrate concentrations (amylose and 
amylopectin) to use in the inhibition assay. Different amylose and amylopectin 
concentrations ranging from 0 to 1 mg/mL were used in the determination of km. An 
assay volume of 500 µL was used containing 200 µL amylopectin/amylose, 100 µL PBS 
(0.1 M, pH 6.9) and the reaction was started with the addition of 200 µL human salivary 
α-amylase. The assay mixture was incubated for 10 min at 37 °C and the reaction was 
stopped by adding 1 mL of DNS to each tube and placing them in the 100 °C water-bath 
(GLS Aqua 12 plus) for another 10 min. After assay tubes were cooled to room 
temperature, 250 µL from each tube was put in a 96 well plate and absorbance read at 
540 nm in a PHERAstar FS micro-plate reader. By using a maltose standard curve, the 
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rate of the enzyme reaction was determined and the Lineweaver-Burk and Hanes-Woolf 
plots were obtained. 
 
Figure 2-12: The Lineweaver-Burk plot showing the relationship between the substrate 
concentration [S] and the enzyme rate [V] used to determine the kinetic parameter km 
with amylose (A) and amylopectin (B) as substrates. Each data point being mean±SD, 
n=3. 
The km values obtained for amylose and amylopectin were 12.9 and 4.8 mg/mL. The 
supplier of amylose and amylopectin recommends a maximum concentration of 2.5 
mg/mL. Hence for amylose this concentration was to be used in all experiments to give 
an assay concentration of 1 mg/mL. Ratios of amylase and amylopectin km values were 
used to calculate the amount for amylopectin (0.93 mg/mL to give 0.38 mg/mL in assay). 
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2.8.5.2 Determination of reaction time and enzyme concentration 
A series of experiments were done to obtain enzyme activities using different enzyme 
concentration and reaction time combinations. The enzyme activity was plotted against 
incubation time to identify linear range of the enzyme activity for amylose (figure 2-13) 
and amylopectin (figure 2-14) substrates. 
 
Figure 2-13: Different α-amylase concentrations (1, 1.5 and 2 U/mL) and different 
incubation times (0 – 16 min) were used to obtain the amount of maltose produced from 
amylose. Maltose produced versus incubation time was plotted to show the pattern of 
enzyme activity at different concentrations and incubation times (A) with each data point 
being mean±SD, n=3. B shows that linearity was observed in 12 min and 0.5 U/mL 
enzyme concentration. Error bars were smaller than data points. 
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Figure 2-14: Different α-amylase concentrations (1, 1.5 and 2 U/mL) and different 
incubation times (0 – 16 min) were used to obtain the amount of maltose produced from 
amylopectin. Maltose produced versus incubation time was plotted to show the pattern 
of enzyme activity at different enzyme concentrations and incubation times (A) with each 
data point being mean±SD, n=3. B shows that linearity was observed in 12 min and 0.5 
U/mL enzyme concentration. 
 
In conclusion, amylose (1 mg/mL) or amylopectin (0.38 mg/mL) substrate 
concentrations, 0.5 U/mL enzyme concentrations in the assay of 500 µl total volume and 
10 min incubation time gives a linear range of the enzyme activity. These conditions will 
be used in all experiments as they represent the optimised conditions.  
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2.8.6 Effect of polyphenols on colour reagent 
Salivary α-amylase hydrolyses starch producing the disaccharide maltose and 
trisaccharide maltotriose and α-limit dextrins. DNS detects the presence of free carbonyl 
group (C=O) in the reducing sugar which gets oxidized to a carboxyl group and 3,5-
dinitrosalicylic acid is reduced to 3-amino-5-nitro salicylic acid. The 3-amino-5-nitro 
salicylic acid produced forms an orange-brown colour and absorbs light at 540 nm.  
 
 
 
Figure 2-15: The colour change observed when 3, 5-dinitrosalicylic acid is reduced to 3-
amino-5-nitro salicylic acid. The intensity of the colour is darker when more reducing 
sugar is present (positive control or less inhibition) and lighter if less (negative control 
or high inhibition). 
 
 
 
 
(Yellow)  Orange-brown 
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The presence of hydroxyl groups in polyphenols makes them good reducing agents and 
hence also able to participate in a redox reaction with DNS, producing an orange brown 
color. This fact was examined by carrying out an experiment where different 
concentrations of polyphenols (500 µL) were mixed with 1 mL DNS, heated in the water-
bath at 100 °C for 10 min and then cooled to room temperature. Absorbance was read at 
540 nm and results were plotted against polyphenol concentrations (figure 2-16).  
 
Figure 2-16: The reaction between EGCG, gallic acid and phloridzin with DNS at 
different polyphenol concentrations. Data points are expressed as mean ± SEM (n=3). 
EGCG has the highest reactivity and it also has the highest number of OH groups which 
make them good reducing agents (Nyambe-Silavwe et al., 2015). 
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Phloridzin, gallic acid and EGCG reacted with DNS in the absence of reducing sugars 
giving an orange brown colour confirming their participation in the redox reaction with 
DNS. Different polyphenols have different reducing capacity and react differently with 
DNS mostly due to the number of OH groups they have. For the three polyphenols above, 
EGCG reacted more, followed by gallic acid and finally phloridzin. Therefore a 
polyphenol removal step using solid phase extraction (SPE) was incorporated into the 
enzyme inhibition assay to ensure that a reaction mixture sample is free from 
polyphenols, which would react with DNS and give an incorrect result. However if a 
particular polyphenol does not react with DNS, the polyphenol removal step is not 
necessary.  
2.8.7 Efficiency of SPE cartridges 
The Oasis Max 1 cc cartridges containing 30 mg of sorbent were conditioned with 1 mL 
of methanol and cartridges were allowed to dry under vacuum (10 Hg) for 10 min. 
Millipore water (1 mL) was used to equilibrate the cartridges before adding 500 mL of 
assay mixture after the inhibition reaction with 100 µM EGCG used as inhibitor.  After 
passing the sample through the cartridge, the filtrate collected was analysed to test the 
efficiency of removal of polyphenols using Oasis MAX SPE cartridge. The concentration 
of 100 µM EGCG was used in the analysis because it was going to be the highest 
concentration to be used in the inhibition experiments.  
HPLC analysis of EGCG was carried out using a UFLCXR Shimadzu system consisting 
of binary pump, a photodiode array with multiple wavelength SPD-20A and a LC-20AD 
Solvent Delivery Module coupled with an online unit degasser DGU-20A3/A5 and a 
thermostat auto-sampler/injector unit SIL-20A (C). The detection was at 280 nm. A two 
phase gradient system consisting  of millipore water with 0.1 % triflouroacetic acid 
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(HPLC grade) as mobile phase A and triflouroacetic acid, acetonitrile, and millipore 
water  (50:49.9:0.1) was employed as mobile phase B. The gradient conditions were as 
follows: The initial conditions started with 92 % A and increasing to 18 % solvent B at 
3.50 min, 32 % B at 18 min, 60 % B at 28 min reaching to 100 % B at 32 min for 4 min, 
returning to the initial conditions for 3.5 min. The column used for the analysis was a 5 
µL Gemini C18 (250 x 4.6 mm, i.d.) with a flow rate of 1 mL/min, column temperature 
set at 35 °C with an injection volume of 10 µL. 
 
Figure 2-17: HPLC chromatogram of 100 µM EGCG (A) before SPE and (B) after SPE. 
The Oasis MAX SPE cartridge gave a removal efficiency of greater than 99 % for 100 
µM EGCG. 
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The removal efficiency of the Oasis MAX SPE cartridge of greater than 99 % will ensure 
that polyphenols are removed before the addition of DNS for the final stage of the 
inhibition assay. 100 µM EGCG being the highest concentration to be used in the assay, 
indicates that lower concentrations would equally be removed efficiently. 
2.8.8 Effect of enzyme and substrate concentration on inhibition 
(IC50) value 
As shown in section 2.8.5.2, it is important to use an optimised enzyme concentration 
which gives a linear relationship with time. Using an enzyme concentration that is not 
optimised can give different results as was observed in the literature where the same 
compounds were reported to have different IC50 values (Nyambe-Silavwe et al., 2015). 
Comparison between results obtained using the optimised 0.5 U/mL and 3 U/mL enzyme 
concentrations gave different results. There are different definitions of IC50  value. One 
defines it as the concentration of an inhibitor that reduces the activity of an enzyme by 
50 %, with 100% being the activity of the enzyme without an inhibitor and 0 % being 
the control not containing either substrate or enzyme and hence no activity. The second 
definition is the concentration of the inhibitor required to bring the enzyme activity  half 
way between the top and bottom plateaus of the curve (Neubig et al., 2003). The first 
definition is adopted for this research, and is the most commonly used because it gives a 
value that can be compared to other inhibitors. The second definition would for example 
show that a poor inhibitor has a low IC50 value compared to a good inhibitor only because 
its maximum inhibition was low and may give a lower value compared to a good inhibitor 
whose half inhibition concentration may be higher because it had a higher maximum 
inhibition. 
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Figure 2-18: Acarbose inhibition of α-amylase using 0.5 U/mL and 3 U/mL enzyme 
concentrations and amylose (A) and amylopectin (B) as substrate. Data points are 
expressed as mean ± SD (n=3). The inhibition curves are different resulting in different 
IC50 values. 
The use of different enzyme concentrations gave very different IC50 values for acarbose 
(table 2-4). 
Substrate Enzyme concentration  
0.5 (U/mL) 3.0 (U/mL) 
 IC50 (µM) 
Amylose  3.5 25 
Amylopectin 7.5 70 
 
Table 2-4: Acarbose IC50 values when different enzyme concentrations were used for 
amylase inhibition. There is a 7 and 9 fold difference in IC50 for amylose and amylopectin 
respectively.  
 
82 
 
   
The use of different enzyme concentrations (optimised 0.5 U/mL and sub-optimal 3 
U/mL), gave a 7 and 9 fold difference in IC50 values for amylose and amylopectin. This 
partly explains the differences observed in the literature for reported IC50 values even for 
the same compounds (Nyambe-Silavwe et al., 2015) 
2.8.9 Optimised assay procedure for amylase inhibition by 
polyphenols  
The assay contained 200 µL each of substrate (amylose 2.5 mg/mL or amylopectin 0.93 
mg/ml) and enzyme (0.5 U/mL), 50 µL phosphate saline buffer (PBS) and 50 µL of 
inhibitor of different concentrations. For the control assay, the inhibitor was replaced by 
an equal volume of PBS. The assay mixture containing the inhibitor, PBS and substrate 
were pre-incubated at 37 °C was added in a water-bath for 5 min and the enzyme also 
pre-incubated at 37 °C to start the assay. The reaction tubes were mixed and incubated 
at 37 °C in the water-bath for 10 min. The reaction was stopped by placing the samples 
in a water-bath (GLS Aqua 12 plus) at 100 °C for 10 min, then cooled down to room 
temperature and centrifuged for 5 min. The sample obtained was used for SPE which 
was carried out using Oasis MAX cartridges to remove polyphenols before adding colour 
reagent solution. To the resulting sample (500 µL), 1 mL of the colour reagent was added 
and heated at 100 °C for 10 min. After cooling to room temperature, 250 µL from each 
tube was place in a 96 well plate and the absorbance was read at 540 nm. The rate of 
enzyme inhibition was calculated as a percentage of the control (without inhibitor) using 
the formula: 
% = Abs Control – Abs sample x 100 
                 Abs for control 
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Figure 2-19: The flow diagram of α-amylase inhibition by polyphenols. The potential 
inhibitor has to be tested if it reacts with hexokinase reagent or not of which the former 
needs to have a solid phase extraction step to remove the polyphenols before performing 
the hexokinase assay (Nyambe-Silavwe et al., 2015). 
 
2.8.10 Conclusion  
For any enzymatic assay, it is important to determine the assay conditions and ensure 
that the optimum conditions are used. The km value needs to be determined so that the 
concentration of the substrate can be approximately equal to the km value. If results are 
to be compared between different substrates, ratios of their km values need to be taken 
into account for the substrate concentration used. Enzyme concentration and incubation 
time need to be in the initial rate of the enzyme activity of which the relationship is linear. 
There is a need to ensure that the detection method does not interfere with the inhibitor, 
and if it is the case, SPE must be employed to remove the polyphenol. The effectiveness 
of an inhibitor is usually determined by IC50 or Ki values with the IC50 being more 
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commonly used and usually compared with that of acarbose (digestive enzyme inhibitor). 
The optimisation of the amylase assay has shown that IC50 is very dependent on assay 
conditions which make it very difficult to compare results in the literature. The different 
assay conditions of importance are substrate type and concentration, enzyme 
concentration and origin, reaction duration, incubation temperature and pH. It is thus 
recommended to use Ki to report the effectiveness of pure compounds as it gives 
comparable results independent of inhibition mode, substrate and detection method. 
2.9 Human Study design 
Before commencing any human intervention study, it is important to choose the design 
of the study and ensure that it is correct for subsequent interpretation of results. Below 
are the different aspects that need to be considered for glycaemic index (GI) studies.  
2.9.1 Subject number, gender and status 
It is generally accepted that a minimum of 10 subjects provides a reasonable degree of 
power and precision (Brouns et al., 2005). However if greater precision and power is 
required, sample size can be increased upwards although this is more costly. When 
recruiting, a 20 % allowance for any drop-outs is recommended for GI studies. Male or 
female can be used as each person is a control of themselves and no differences in 
glycaemic response have been observed between males and females (Wolever and 
Mehling, 2002). Variations of the mean GI values are reported to occur in various groups 
(healthy, pre-diabetic, diabetic type 1 and diabetic type 2). The highest variations have 
been observed in individuals suffering from type 1 diabetes. It is therefore recommended 
that different groups of people as regards to their status should never be mixed in one 
study (Brouns et al., 2005). The subject status also depends on the hypothesis of the study 
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whether testing it in healthy, pre-diabetes or diabetes subjects. In cases where the 
hypothesis is tested in more than one group, data analysis is never to be mixed but treated 
separately. 
2.9.2 Test meal number 
In calculating glycaemic response, it is important to repeat the control meal at least once 
because the response of the test meal is always compared to that of the reference meal 
hence the importance of the reference area under the curve (AUC) being correct. 
Increasing the number of reference food measurement from one to two significantly 
reduced the margin of error whereas taking three or more measurements does not reduce 
it further (Wolever and Mehling, 2003).  
2.9.3 Reference food 
More than 90 % of studies on determination of GI use glucose or white bread as the 
reference food. Glucose was the original reference food and its GI is set to 100 (Jenkins 
et al., 1981). However, the use of glucose as a reference food has been reported to induce 
nausea in individuals when they drink it in the morning after a night fast (Brouns et al., 
2005). White bread is preferred as it is a common food and can be used even in diabetic 
patients. However differences in the composition of white bread may entail that 
comparing results from different studies that used a different loaf of bread may be 
difficult. White bread can thus be used as long as the preparation of the bread is 
standardised. For determining polyphenol effects on GI, the reference meal depends on 
the main digestion step being inhibited. If the main inhibitor is targeting α-amylase, in 
order to test for inhibition, bread should be used as a reference because α-amylase 
hydrolyses amylose and amylopectin in starch (bread) into maltose and other 
disaccharides. Using glucose or sucrose as a reference meal in this situation is not 
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appropriate as the inhibition of α-amylase will have no effect on the amount of glucose 
going into the blood. If the main inhibitors being studied are α-glucosidases, sucrose or 
bread would be ideal reference food because the inhibition of the enzymes can be 
determined by the amount of glucose hydrolysed from either maltose (product of starch 
digestion) or sucrose. Finally if the stage of digestion to be inhibited is glucose transport, 
either glucose, sucrose or starch can be used as reference as the main target is the amount 
of glucose being transported. 
2.9.4 Meal volume, composition and consumption time 
A standardized amount of a drink such as 200 or 250 mL (one glass) should be used 
because increasing the amount of drink increases the area under the glucose response 
curve (Sievenpiper et al., 1998). Water is usually used for this purpose and any other 
water present in the food is not included in the standardised amount. In the case of 
reference food, for glucose, 50 g of glucose should be diluted in 200 or 250 mL water, 
whereas in the case of white bread, a portion containing 50 g of available carbohydrates 
should be given with 200 or 250 mL drink (usually water). The time for fluid ingestion 
should be between 5-10 min and 10-20 min for solids/semi solids. As regards the blood 
sample, it should be taken exactly 15 min after the first sip of the drink or bite of the 
food. 
2.9.5 Amount of carbohydrate and dose 
Available carbohydrate should be determined using validated methods to calculate how 
much bread gives 50 g. Another method called relative glycaemic response (RGE) can 
be used which compares the response from total carbohydrates in 50 g of test food in 
relation to 50 g glucose. Therefore, GI is based on available carbohydrate (CHO) whereas 
RGE is based on total CHO (Brouns et al., 2005). The amount of carbohydrate to be used 
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is dependent on the amount of carbohydrates present in the food. The recommended 
value is 50 g available CHO. In cases where there is a low amount of CHO in the test 
food, 25 g available CHO should be used and consequently compared to 25 g of glucose. 
This is done to avoid using a large meal to make up the 50 g available CHO which would 
be unrealistic. 
2.9.6 Analysis of carbohydrates 
The amount of available carbohydrates can easily be determined using the “Available 
Carbohydrates and Dietary Fibre Assay kit” (by Megazyme) or by the in vitro digestion 
method of Englyst (Englyst et al., 1992) . The assays utilises enzymes which convert the 
product into a measurable substance.  
2.9.7 Time and duration of study and subject preparation  
The test must be done in the morning before 10 am after an overnight fast of between 10-
14 hours. A higher difference in glycaemic response between cereals was observed when 
tested at lunch time compared to the test done at breakfast (Wolever and Bolognesi, 
1996). The recommended duration of the study (all visits) is no more than 4 months. 
When testing more than one food, a reference test should be done at the beginning of the 
test and again after every 6-8 weeks. For purposes of measuring glycaemic responses, it 
is not necessary to control exercise on the day before the test although unusual vigorous 
activity should be avoided. However, the subject should eat a meal of their choice the 
evening before the test but that they should eat the same meal the day before each test 
(Wolever et al., 1991). 
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2.9.8 Blood sampling 
There are different methods and ways in which blood can be sampled with different sites 
giving different concentrations of blood glucose. Fingertip capillary sampling is 
recommended as the blood glucose concentrations are higher in the fingertip capillary 
than in the veins when blood glucose concentrations rise. In the same way when blood 
glucose concentrations fall, the concentration in the fingertip capillary is higher than in 
the vein (Ellison et al., 2002, van der Valk et al., 2002, Yang et al., 2012). However, 
according to the World Health Organisation (WHO) and Food and Agriculture 
Organisation (FAO), despite the criteria for diagnosis of diabetes referring to venous 
plasma glucose, finger prick and venous blood sampling can both be used for GI 
determination (FAO/WHO, 1998). On the other hand, insulin measurements have to be 
done from venous blood due to the higher volume required. With regards to sampling 
times, in healthy subjects blood should be sampled at the fasting stage (0) and then 15, 
30, 45, 60, 90 and 120 min after starting to eat the test meal. Diabetic subjects should be 
sampled at (0) fasting state, then 30, 60, 90, 120, 150 and 180 min after starting to eat 
the test food (Brouns et al., 2005). 
Blood can be processed into serum or plasma depending on the treatment after its 
collection. The difference between the two is their clotting factors. Plasma is the liquid 
part of blood that contains fibrinogen which is essential in blood clotting whereas serum 
is the liquid part obtained after coagulation and does not contain fibrinogen but contains 
proteins like globulins and albumin. Plasma is prepared by centrifugation to isolate blood 
cells which settle at the bottom of the tube leaving plasma above it, containing water and 
clotting factors and tubes with anticoagulants are usually used. Serum is prepared by 
allowing blood to clot after collection and the liquid squeezed out of the clot is serum. A 
study which compared serum and plasma glucose values from the same volunteers, 
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reported that serum gave lower glucose values than plasma values and it is therefore 
recommended to use plasma (Frank et al., 2012).  
2.9.9 Calculating postprandial glucose/insulin response 
Glucose concentrations at different time points are plotted against time to obtain the 
glucose curve. The method commonly used to determine glucose response is that of 
incremental area under the curve (IAUC) which calculates only the area over the baseline 
(fasting blood glucose) and does not take into account the area beneath the curve. The 
general formula for calculating AUC is given by:  
Times are given by t=0, t=1…. t=n (equalling 0, 15….120 min) 
Blood glucose concentrations are G=0, G=1….G=n respectively. The detailed 
calculations are obtained from (Brouns et al., 2005) as follows: 
AUC = ∑ Axx=1n  
Where Ax = the IAUC for the xth time interval 
For the first time interval (x=1), 
If G1 > G0, A1 = (G1 – G0) x (t1 – t0)/2  
Otherwise, A1 = 0 
For the other time intervals (i.e. x > 1) 
If Gx ≥ G0 and Gx-1 ≥ G0, Ax = [(Gx – G0)/2] + [(Gx-1 – G0)/2] x (tx – tx-1) 
If Gx > G0 and Gx-1< G0, Ax = [(Gx – G0)2/ (Gx – Gx-1)] x (tx – tx-1)/2 
If Gx < G0 and Gx-1 > G0, Ax = [(Gx-1 – G0)2/(Gx-1 – Gx)] x (tx –tx-1)/2 
If Gx ≤ G0 and Gx-1 ≤ G0, Ax = 0 
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Chapter 3 . Characterization of polyphenol and fibre-
rich food (PFRF) mixture and bread for intervention 
study test meals. 
Abstract 
In preparation for the human intervention study meals, the PFRF mixture was analysed 
for total polyphenol content, specific major polyphenols and sugar content. Bread 
analysis was also carried out to determine how much bread gave 50 g available 
carbohydrate. The total polyphenol contents were 541±25, 315±2, 303±1, 295±3 and 
217±3 µg/mL GAE ± SD fresh weight for green tea, strawberry, blackcurrant, blackberry 
and apple peel respectively. Specific major polyphenols were 104±0.3, 70.1±0.1, 45±0.1, 
19.9±0.7, 18.2±0.03 and 11.3±0.02 mg/100g of cyanidin-3-O-rutinoside, cyanidin-3-O-
glucoside, EGCG, pelargonidin-3-O-glucoside and phloridzin and quercetin-3-O-
rhamnoside in green tea, blackcurrant, blackberry, strawberry and apple respectively. All 
the constituents of the PFRF mixture had polyphenols in amounts within the Phenol 
Explorer range and specific polyphenols had concentrations higher than the reported IC50 
values for carbohydrase inhibition. The PFRF mixture constituents were used in in vitro 
assays to determine enzyme inhibition potential. In a combination of 10 g each of the 
dried fruits (40 g total), there was a total of 4.3, 2.7 and 0.44 g of fructose, glucose and 
sucrose which were used to standardize the sugar concentrations in the intervention study 
meals. The amount of bread to give 50 g available carbohydrates was determined to be 
109±1.2 g also to be used in the intervention study meals. 
 
91 
 
   
3.1 Introduction 
From the literature, good inhibitors of α-amylase were identified as cyanidin-3-O-
glucoside, cyanidin-3-O-rutinoside (Akkarachiyasit et al., 2011) and epigallocatechin 
gallate (EGCG) (Koh et al., 2010). The α-glucosidase inhibitors are mostly the catechins 
(Honda and Hara, 1993, Ishikawa et al., 2007, Matsui et al., 2007, Kamiyama et al., 
2010) and glucose transport inhibitors were quercetin-3-O-rhamnoside (quercetrin), 
phloridzin and pelargonidin-3-glucoside (Manzano and Williamson, 2010). The best 
sources of the named polyphenols are blackberry, blackcurrant, green tea, apple and 
strawberry (Neveu et al., 2010) hence constituting the polyphenol and fibre-rich food 
(PFRF) mixture. Green tea is the best source of catechins which are the best α-
glucosidase inhibitors especially EGCG (Kamiyama et al., 2010) which also inhibits α-
amylase and glucose transporters (Koh et al., 2010). It was added to the polyphenol-rich 
mixture to be the main α-glucosidase inhibitor but should however also contribute to the 
inhibition of α-amylase and glucose transport. The major polyphenols found in soft fruits 
(blackberry, blackcurrant and strawberry) are the anthocyanidins. The most common 
anthocyanidin aglycones are pelargonidin, cyanidin, delphinidin, peonidin, petunidin and 
malvidin. The named aglycones form conjugates with sugars and organic acids forming 
anthocyanins.  Anthocyanins are water-soluble and they impart blue, purple or red 
colours to plant tissues making berries the richest sources of anthocyanins. Consumption 
of anthocyanin-enriched foods is associated with a reduced risk of chronic diseases such 
as diabetes (Akkarachiyasit et al., 2010). The major polyphenol found in apple is 
phloridzin and together with quercetin-3-O-rhanmoside (quercetrin) have inhibitory 
properties against glucose transporters GLUT2 and SGLT1 (Ader et al., 2001, Cermak 
et al., 2004, Manzano and Williamson, 2010). 
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In order to be used in the human intervention study, the PFRF mixture constituents were 
analysed for total polyphenol contents and specific major polyphenols in order to 
determine the presence of polyphenols and especially the major polyphenols identified 
to have inhibitory properties. This was done to ensure that the PFRF mixture contained 
polyphenols in amounts above the reported IC50 values in order to have an effect in vivo. 
Sugar contents of the PFRF mixture were determined in order to standardize the sugar 
concentrations in the intervention study meals. Bread analysis was also carried out to 
determine how much bread gives 50 g available carbohydrate.  
3.2 Materials and methods 
3.2.1 Determination of total polyphenols in green tea 
The Folin assay described in chapter 2 (2.4) was used for the determination of total 
polyphenols in green tea. It was prepared fresh for each experiment by dissolving the 
powder in millipore water, centrifuged at 4000 rpm for 10 min and supernatant collected 
in a new tube. Appropriate dilutions were made from the 1 mg/mL stock solution. Gallic 
acid standards were prepared as described in chapter 2 (2.4.3). 
3.2.2 Determination of specific polyphenols in green tea 
The HPLC method described in chapter 2 (2.5) was used to identify and quantify the 
main polyphenols in green tea (EGCG, EGC, ECG and EC). The standards EGCG, EGC, 
ECG and EC were analysed separately to obtain retention times, spectra and standard 
curves used for the identification and quantification of polyphenols in green tea. 
The standards were dissolved in 50 % ethanol to a concentration of 1 mg/mL and placed 
in 100 μL aliquots. They were evaporated to dryness in a Genevac (EZ-2 plus model) 
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and stored in the -20 °C freezer until needed. Adding 1 mL 50 % ethanol gave 100 μg/mL 
and then dilutions were made to give different concentrations for the standard curves. 
Green tea (1 mg/mL) was prepared fresh for each experiment by dissolving the powder 
in millipore water. After centrifugation at 4000 rpm for 10 min, supernatant was collected 
in a new tube and appropriate dilutions were made from the 1 mg/mL stock solution. 
3.2.3 Determination of total polyphenols in blackberry, blackcurrant, 
strawberry and apple 
A stock solution of 10 mg/mL was prepared by water extracting polyphenols from 100 
mg freeze-dried fruit in a total volume of 10 ml millipore water. This was done in 3 
stages: the freeze-dried fruit was first vortexed vigorously for 3 min in 5 mL, centrifuged 
at 4000 rpm for 10 min and supernatant placed in a clean tube. This was repeated twice 
with 2.5 mL millipore water each time, giving a total volume of 10 mL.  Appropriate 
dilutions were made from the 10 mg/mL stock solution. Gallic acid standards were 
prepared as described in chapter 2 (2.4.3). The Folin assay described in chapter 2 (2.4) 
was used for the determination of total polyphenols in all the fruits which were obtained 
as freeze-dried powders which were processed from the respective fruits. Freeze-dried 
fruits are produced by drying the previously frozen fruits under vacuum at a low 
temperature under reduced pressure. This is an excellent way of preserving heat sensitive 
materials/compounds in the fruits whilst improving their storage life without addition of 
artificial ingredients, flavouring or colours hence maintaining the natural components of 
the fruits except water. 
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3.2.4 Determination of specific polyphenols in blackberry, 
blackcurrant, strawberry and apple 
The HPLC method described in chapter 2 (2.5) was used to identify and quantify the 
main polyphenols in the fruits. Cyanidin-3-O-rutinoside, cyanidin-3-O-glucoside, 
phloridzin and quercetin-3-O-rhamnoside standards were analysed separately to obtain 
retention times, spectra and standard curves used for the identification and quantification 
of polyphenols in the fruits. The standards were prepared in the same way as the green 
tea polyphenol standards (3.2.2). 
3.2.5 Determination of sugar content in fruits by HPLC 
Analysis was carried out to determine type and contents of sugars naturally present in 
the fruits in order to use the information to standardize the amount of sugars in the 
reference and test meals. The identification and quantification of sugars in the fruits was 
conducted using the method of Tembo, (2017) on a Shimadzu HPLC instrument 
equipped with a model DGU-20 A5 degasser, a LC-20 AD XR pump system, a SIL-20 
AC XR auto sampler (Shimadzu), column oven and a Shimadzu ELSD-LTII low 
temperature evaporative light scattering detector. A sample volume of 10 µL was 
injected, and separations were achieved on a Prevail Carbohydrate ES 5 μm column (250 
mm x 4.6 mm). The column was held at 20 0C, and individual sugars were eluted 
isocratically using a 1 mL/min flow of 75 % acetonitrile. Solutions of standard sugars 
prepared in millipore water with concentrations between 0 and 10 mg/mL were used for 
the calibration curve. The sugars were identified by their retention time characteristics. 
Quantification was achieved using standard calibration curves obtained by plotting area 
versus concentration (r2 > 0.98).  
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3.2.6 Determination of available carbohydrate content in bread 
Bread analysis was carried out as described in chapter 2.6. The aim was to determine the 
amount of bread required to give 50 g of available carbohydrate after 2 hr digestion. 
3.3 Results 
3.3.1 Total polyphenols 
Total polyphenol contents of the PFRF mixture are shown in table 3-1 with the highest 
content being in green tea > strawberry > blackcurrant > blackberry > apple. They all  
had polyphenol contents that fall within the range reported in Phenol Explorer (Neveu et 
al., 2010) except for blackcurrant. 
Extract Green 
tea 
 
Strawberry Blackcurrant Blackberry Apple 
peel 
 
Total 
polyphenols 
(µg/mL GAE) 
± SD 
 
54.1± 2.5 31.5 ± 2.0 30.3 ± 10 29.5 ± 3.0 21.7± 3.0 
Phenol 
Explorer  
range (Neveu 
et al., 2010) 
(µg/mL GAE)  
Fresh weight 
basis 
287-
1029 
72.5 - 443.4 498 - 1410 192.8  
- 1056 
66.2 – 430 
(apple 
dessert 
whole 
raw) 
 
Table 3-1: Total polyphenol contents of the PFRF mixture and the corresponding range 
of amounts as reported in Phenol Explorer. The amounts are expressed in mean±SD 
(n=3). Fresh weight basis is 10 times more of the dry weight according to the freeze dried 
fruits supplier (Healthy supplies UK). Hence to compare with Phenol explorer values, 
the Phenol Explorer values are divided by 10. 
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3.3.2 Specific polyphenols 
3.3.2.1 Green tea 
Green tea was characterized to determine the presence and amounts of the different 
catechins. Standards were used for the identification and quantification of the catechins. 
Standard curves for the catechins were identified separately and standard curves were 
used to quantify them in the green tea. 
 
Figure 3-1: Standard curves for EC, ECG, EGCG and EGC used for the quantification 
of the catechins in green tea. All data points are mean±SD (n=3). 
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Figure 3-2: HPLC chromatogram of green tea: (1) EGC; (2) Caffeine; (3) EC; (4) EGCG; 
(5) Taxifolin (IS); (6) ECG. 
The quantities of the catechins were in the order EGCG>EGC>ECG>EC and were 
199.8± 6.7, 124.4 ± 9.3, 34.4 ± 1.9 and 23.3 ± 2.4 µg/mL giving 435.9, 406.1, 77.6 and 
80.3 µM) respectively (in 1 mg green tea powder/mL). 
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3.3.2.2 Blackcurrant 
Cyanidin-3-O-rutinoside standard curve was used to determine the amount of cyanidin-
3-O-rutinoside and was 10.4±0.03 mg/100 g as determined by HPLC. The concentration 
lies within the range ( 9.3-24.1 mg/100 g DW) as reported in Phenol Explorer (Neveu et 
al., 2010). The polyphenol cyanidin-3-O-rutinoside was in the highest amount in 
blackcurrant powder as shown in Figure 3-3 B. 
 
Figure 3-3: Standard curve (data points represents mean±SD, n=3) for cyanidin-3-O-
rutinoside (A) used for its quantification in 10 mg/mL blackcurrant extract shown in 
chromatogram (B): (1) cyanidin-3-O-rutinoside; (2) myricetin (IS). 
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3.3.2.3 Blackberry 
The polyphenol present in the highest amount in blackberry powder was cyanidin-3-O-
glucoside (figure 3-4B) with a concentration of 7.01 ± 0.01 mg/100 g as determined by 
HPLC. It was slightly lower than the reported (8.52-19.06 DW) Phenol Explorer range  
(Neveu et al., 2010). Cyanidin-3-O-glucoside standard curve was used for the 
quantification. 
 
Figure 3-4: Standard curve (data points represents mean±SD, n=3) of cyanidin-3-O-
glucoside (A) used for its quantification in 10 mg/mL blackberry extract shown in 
chromatogram (B): (1) cyanidin-3-O-glucoside; (2) myricetin (IS). 
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3.3.2.4 Strawberry 
The polyphenol pelargonidin-3-O-glucoside was in the highest amount in strawberry 
powder and the amount was 4.5 ± 0.01 mg/100 g  as determined by HPLC (figure 3-5B). 
The concentration lies within the range (2.03-6.83) reported in literature (Neveu et al., 
2010). 
 
Figure 3-5: Standard curve (data points are mean±SD, n=3) of pelargonidin-3-O-
glucoside used for its quantification in 1 mg/mL strawberry extract as shown in 
chromatogram (B): (1) pelargonidin-3-O-glucoside; (2) hesperetin (IS). 
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3.3.2.5 Apple peel 
The two polyphenols of interest in apple peel powder (phloridzin and quercetin-3-O-
rhamnoside) were identified and the concentrations were 18.2 ± 0.03 and 11.3 ± 0.02 
mg/100 g fresh weight as determined by HPLC (figure3-6B) and quantified with the 
standard curves (figure 3-5A). The values lie above the Phenol Explorer range of 0.64-
9.11and 0.52-5.30. This is because the apple in this study is just the peel which has higher 
concentrations of the polyphenols compared to the whole apple (apple dessert whole raw) 
reported in Phenol Explorer. 
 
Figure 3-6: Standard curves (data points are mean±SD, n=3) for phloridzin and 
quercetrin (A) used for its quantification in apple peel extract as shown in chromatogram 
(B): (1) quercetrin; (2) phloridzin; (3) hesperetin (IS) 
102 
 
   
3.3.2.6 Sugar analysis in fruits 
Fructose, glucose and sucrose were identified in the fruits with fructose being in highest 
amounts followed by glucose and lastly sucrose. 
 
Figure 3-7: Chromatograms of blackcurrant, blackberry and apple (A) showing the 
presence of fructose, glucose and sucrose as identified from comparing with the  
chromatogram of standards (B) which are not representative of amounts but just 
qualitative to show the position of the peaks. 
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The sugars were quantified using fructose, glucose and sucrose standard curves. The 
quantities are as shown in table 3-2 and figure 3-8. 
Fruit Concentration in fruit (g/10 g) 
Fructose Glucose Sucrose 
Apple 0.64± 0.04 0.19± 0.05 0.07± 0.004 
Blackberry 1.25± 0.06 0.93± 0.05 ND 
Blackcurrant 1.10± 0.05 0.60± 0.03 0.04± 0.002 
Strawberry 1.34± 0.04 0.77± 0.03 0.29±0.004 
TOTAL in 40 g 
combination of all 
fruits. 
 
4.3 
 
2.7 
 
0.44 
 
Table 3-2: The amounts of fructose, glucose and sucrose in the fruits expressed as 
mean±SD, n=3. The total in 40 g is the sum of all the sugars in 10 g of each fruit 
(strawberry, blackcurrant, blackberry and apple). 
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Figure 3-8: Amounts of fructose, glucose and sucrose in the dried fruits.  Fructose was 
in highest amounts in all fruits, then glucose and lastly sucrose of which blackberry had 
no detectable sucrose. 
 
3.3.2.7 Bread analysis for available carbohydrates 
The amount of Warburton’s white bread required to give 50 g available carbohydrate 
was determined to be 109±1.2 g bread as shown in table 3-3. Warburton white bread was 
selected because it was readily available at all local stores unlike supermarket branded 
bread which are not available in other stores. 
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Biological triplicates Amount of glucose 
produced from 100g 
bread 
(g/100g) 
Amount of bread to give 
50 g available 
carbohydrate 
(g) 
1 46.4 107.8 
2 45.8 109.2 
3 45.4 110.1 
Average 45.9±0.5 109±1.2 
 
Table 3-3: The amount of glucose produced from enzymatic hydrolysis of  bread 
expressed as g/100 g of bread and was used to calculate the average amount (g) of bread 
required to give 50 g available carbohydrate in g (mean±SD, n=3). 
3.4 Discussion  
The aim of this chapter was to analyse the polyphenol and fibre-rich food (PFRF) mixture 
constituents for total and specific polyphenols to determine their suitability to be used in 
the human intervention study. Available carbohydrates in bread and sugar content of the 
fruits were also determined for the test and control meals study design. Polyphenol 
contents of different foods may differ depending on the variety and brand for processed 
foods. It was thus necessary to analyse the selected sources of polyphenols to ensure that 
they have polyphenols required for the inhibition of digestive enzymes, which is the 
primary aim of this research. 
Typical percentage contents of the major tea polyphenols to the total catechin content are 
EGCG (59 %), EGC (19 %), ECG (13.6 %) and EC (6.4 %) (Hara et al., 2012). The 
green tea for this study had a similar trend of EGCG being in highest concentration (52.3 
%) followed by EGC, ECG and EC with percentages of 32.6, 9.0, and 6.1 % respectively. 
Green tea was selected to be the main inhibitor of α-glucosidase because its major 
catechin (EGCG) gave low IC50 values in vitro (Sucrase 169 μM, Maltase 40 μM (Matsui 
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et al., 2007), Sucrase  100 μM (Honda and Hara, 1993) and Sucrase 130 μM, Maltase 16 
μM (Kamiyama et al., 2010). In addition, EGCG also inhibited amylase as shown in table 
1-1. In order for concentrations to have an effect in vivo, they should be at least 3 times 
more than the in vitro concentrations to allow for intestinal dilutions. This is an important 
aspect to look at when intending to determine the effects of polyphenols in vivo using in 
vitro data because for every 1 L of food, about 2 L of intestinal fluid is produced which 
entails that there will be a threefold dilution of the food in the  stomach (Williamson, 
2013). The results obtained for green tea quantification (435.9, 406.1, 77.6 and 80.3 µM 
for  EGCG, EGC, ECG, EC indicate that EGCG concentration (435.9 µM) is more than 
3 times the in vitro concentrations indicated above that gave 50 % inhibition as shown 
above.  
All the freeze-dried fruits analysed except for apple peel, had polyphenol contents that 
fell within the range reported on Phenol Explorer (Neveu et al., 2010) as shown in table 
3-1. Apple peel had higher (twice the amount) contents of phloridzin and quercetin-3-O-
rhamnoside than the range reported in Phenol Explorer because the values in Phenol 
Explorer are those of apple juice whereas results in this research are for apple peel which 
confirms the fact that the apple peel contains polyphenols in highest amounts. There is 
currently no data for the contents in apple peel on Phenol Explorer. Blackcurrant was 
identified as the best source of cyanidin-3-O-rutinoside which was reported to have very 
good α-amylase inhibition with IC50 of 24.4 μM (Akkarachiyasit et al., 2011). 
Blackcurrant fruit also inhibited human salivary α-amylase due to the presence of 
polyphenols (McDougall et al., 2005).  In the 10 g blackcurrant to be used in the human 
intervention study, there will be 10.4 mg cyanidin-3-O-rutinoside which is sufficient to 
give more than 3 times the IC50 concentration of 24.4 μM when made into a paste with 
100 mL water (10.4 mg/100 mL = 165 µM). Cyanidin-3-O-glucoside inhibited amylase 
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with IC50 value of  300 μM (Iwai et al., 2006). Blackberry was added to the PFRF mixture 
to compliment blackcurrant  as an amylase inhibitor because it has the highest amount of 
cyanidin-3-O-glucoside (Neveu et al., 2010).  There will be 70.1 mg cyanidin-3-O-
glucoside present in the 10 g blackberry for the PFRF mixture which is equally sufficient 
to provide a concentration 3 times more than the IC50 value (70.1 mg/100 mL =1.5 mM).  
Strawberry inhibited human salivary α-amylase with IC50 value of 120 µg phenols/assay 
(McDougall et al., 2005). Together with the other constituents of the PFRF mixture, 
strawberry will contribute to the inhibition of α-amylase although it was included to the 
PRFM as a glucose transport inhibitor. It  inhibited glucose transport with its major 
polyphenol pelargonidin-3-O-glucoside contributing 26 % with an IC50 value of 802 µM 
(Manzano and Williamson, 2010).  10 g of strawberry will provide 45 mg pelargonidin-
3-O-glucoside to the PFRF mixture. Pelargonidin-3-O-glucoside was the only 
polyphenol that did not reach the threefold concentration as it was 1 mM (45 mg/ 100mL) 
compared to the in vitro value of 802 µM. However the fact that the overall inhibition 
will be from a combination of all inhibitors, the amount of pelargonidin-3-O-glucoside 
is still a reasonable amount.  Apple inhibited glucose transport with the major polyphenol 
phloridzin contributing 52 % with IC50 of 146 µM. Quercetin-3-rhamnoside also found 
in apple contributed 26 % with IC50 of 31 µM (Manzano and Williamson, 2010). Apple 
was added to the PFRF mixture to act as a glucose transport inhibitor in the PFRF mixture 
and will provide 18.2 mg phloridzin (18.2 mg/100 mL = 417 µM) and 11.3 mg quercetin-
3-O-rhamnoside (252 µM) in 100 mL which are also enough to give at least  threefold 
higher the in vitro IC50 concentration in vivo. 
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3.5 Conclusion 
Green tea from Nestle will be used in the PFRF mixture as the main inhibitor of α-
glucosidase as it contains polyphenols in quantities that will potentially have an effect in 
vivo. Blackberry and blackcurrant from Healthy Supplies will be used as the main 
amylase inhibitors leaving strawberry and apple as the main inhibitors of glucose 
transport. This will mean that all the three stages of carbohydrate digestion (α-amylase 
and α-glucosidase catalyzed hydrolysis and glucose transport) will be inhibited. However 
all the constituents of the PFRF mixture will be tested for potential inhibition of α-
amylase and α-glucosidase. If the effects overlapped, it is possible that there would be a 
synergistic effect of the individual ingredients such that inhibition of different stages of 
carbohydrate digestion and absorption were affected. For example green tea was added 
to the PFRF mixture as the inhibitor of α-glucosidase but it is also known to inhibit α-
amylase and glucose transport. This means that in the human intervention study test meal, 
green tea will be expected to contribute to the inhibition of α-amylase together with other 
α-amylase inhibitors (blackberry, blackcurrant and strawberry), inhibit α-glucosidase 
and contribute to the inhibition of glucose transport. The same will apply to the other 
constituents of the PFRF mixture if found to inhibit more than one stage of carbohydrate 
digestion. 
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Chapter 4 . Inhibition of α-amylase and α-
glucosidase by a polyphenol and fibre-rich 
food (PFRF)  mixture in vitro. 
Abstract 
Polyphenols have been shown  to have inhibiting effects on the activities of carbohydrate 
digesting enzymes (Hanhineva et al., 2010). From a literature search, good inhibitors 
(with the lowest IC50 values) of α-amylase were identified as green tea, blackcurrant, 
blackberry and strawberry and green tea as the good inhibitor for α-glucosidase. The 
above will constitute the polyphenol and fibre-rich food (PFRF) mixture. The 
polyphenols from the PFRF mixture were assessed for inhibiting carbohydrate digesting 
enzymes in vitro. Green tea (EGCG 19.6, EGC 11.9, ECG 3.3 and EC 2.1 % by mass in 
the green tea) gave IC50 values of 0.035, 2.02 and 2.31 mg/mL for maltase, isomaltase 
and sucrase inhibition respectively. The IC50 values for α-amylase inhibition using 
amylose as substrate were 0.009, 1.22, 1.5 and 2.47 mg/mL for green tea, blackberry, 
blackcurrant and strawberry respectively. Using amylopectin as substrate gave IC50 
values of 0.025, 1.57, 1.7 and 3.85 mg/mL for green tea, blackberry, blackcurrant and 
strawberry. The PFRF mixture inhibited the digestive enzymes with IC50 values 
achievable in the diet because the values are far less than one standard portion of fruit 
(100 g) or beverage powder (0.5 -1 g) and will thus be used in the test meal for the human 
intervention study to determine the effects of polyphenols from the PFRF mixture on 
glycaemic response in vivo. 
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4.1 Introduction 
Postprandial hyperglycaemia is a risk factor for diabetes (Aston, 2006) which entails that 
strategies to control postprandial hyperglycaemia are considered important in the 
prevention and management of type 2 diabetes. A number of studies have shown that 
some polyphenols have inhibitory effects towards the carbohydrates digesting enzymes 
α-amylase and α-glucosidase (Hanhineva et al., 2010).  
In the previous chapter, the PFRF mixture constituents (green tea, blackberry, 
blackcurrant, strawberry and apple) were analysed to determine the presence of 
polyphenols and were all found to have total and specific polyphenol contents that are 
comparable with those in the literature. The aim of this chapter was to investigate the 
inhibitory properties of the PFRF mixture towards the digestive enzymes α-amylase and 
α-glucosidase which are responsible for the breakdown of dietary carbohydrate into 
glucose. Salivary α-amylase starts the digestion of starch followed by pancreatic α-
amylase and both hydrolyse starch into maltose, maltotriose and malto-oligosaccharides. 
Located on the membrane of the epithelium of the small intestine, membrane bound α-
glucosidase hydrolyses the products of α-amylase hydrolysis producing glucose which is 
then transported into the blood by glucose transporters GLUT2 and SGLT1, resulting in 
a postprandial rise in glucose. Inhibiting α-amylase and α-glucosidase may thus reduce 
the amount of glucose produced and subsequently absorbed in the blood and lower the 
postprandial response in vivo.  
The selection of the constituents of the PFRF mixture was based on their IC50 values 
from other studies (Hanhineva et al., 2010). The inhibitors with the lowest IC50 values 
for α-amylase, α-glucosidase and glucose transport were identified and their best sources 
identified accordingly as shown in table 4-1.  
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Inhibition 
target 
Good polyphenol 
inhibitor in vitro 
(reference) 
IC50 value 
(reference) 
Best food source 
(http://www.phenol-
explorer.eu/) 
 
α-amylase 
 
Cyanidin-3-O-rutinoside 
(Akkarachiyasit et al., 
2011) 
Epigallocatechin gallate 
(Koh et al., 2010) 
Cyanidin-3-O-glucoside 
(Iwai et al., 2006) 
 
24.4 µM 
(Akkarachiyasit 
et al., 2011) 
220 µM (Koh et 
al., 2010) 
300 µM (Iwai et 
al., 2006) 
 
Blackcurrant  
 
 
Green tea 
Blackberry 
α-
Glucosidase 
EGCG (Kamiyama et al., 
2010) (Matsui et al., 
2007) (Honda and Hara, 
1993) 
Sucrase 130 μM, 
Maltase 16 μM 
(Kamiyama et 
al., 2010) 
Sucrase 169 μM, 
Maltase 40 μM 
(Matsui et al., 
2007) 
Sucrase  100 μM 
(Honda and 
Hara, 1993) 
Green tea 
Glucose 
transport 
Phloridzin (Manzano and 
Williamson, 2010) 
 
Quercetin -3-O- 
glucoside (Kwon et al., 
2007) 
Quercetin -3-O- 
rhamnoside (Manzano 
and Williamson, 2010) 
Pelargonidin-3-O-
glucoside (Manzano and 
Williamson, 2010) 
146 µm 
(Manzano and 
Williamson, 
2010) 
64 Μm (Kwon et 
al., 2007) 
31 μM (Manzano 
and Williamson, 
2010) 
802 μM 
(Manzano and 
Williamson, 
2010) 
Apple 
 
 
Blackcurrant  
 
Apple 
 
 
Strawberry 
 
Table 4-1: Selection of PFRF mixture constituents from literature search for polyphenols 
with the lowest IC50 values and their best sources as reported in Phenol Explorer to inhibit 
the three stages of carbohydrate digestion and absorption (starch hydrolysis catalysed by 
α-amylase and α-glucosidase and glucose transport). 
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The PFRF mixture constituents were analysed for inhibitory activities in vitro to 
determine their suitability to be used in vivo. Different concentrations of polyphenols 
were tested as inhibitors in the assays to obtain dose-dependent inhibition curves from 
which IC50 values were calculated. If shown to be good inhibitors of α-amylase and α-
glucosidase, it is hypothesized that the PFRF mixture have the potential to lower 
postprandial glucose in vivo and will thus be used in the human intervention study. 
4.2 Inhibition of human salivary α-amylase by PFRF  
4.2.1 Inhibition by Green tea and EGCG 
Green tea was added to the PFRF mixture as the main α-glucosidase inhibitor. However 
since it also inhibits α-amylase, its inhibitory potential towards α-amylase was also 
determined as it would also contribute to the inhibition. Green tea as analysed by HPLC 
(discussed in chapter 2) contained: EGCG 19.6, EGC 11.9, ECG 3.3 and EC 2.1 % by 
mass in the green tea. The main catechin EGCG in green tea was also used as an inhibitor 
in the α-amylase inhibition assay. 
4.2.1.1 Materials and methods 
The materials and methods are as described in detail in chapter 2 (2.1 and 2.8). Green tea 
(1 mg/mL) was prepared fresh for each experiment by vortex mixing the powder in 
millipore water. It was centrifuged at 4000 rpm for 10 min and supernatant collected in 
a new tube. Appropriate dilutions were made from the 1 mg/mL stock solution to give a 
concentration range from 0 to 50 μg/mL green tea in the assay. 
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4.2.2  α-Amylase inhibition by fruits 
The freeze-dried fruits (blackberry and blackcurrant) were included in the PFRF mixture 
as the main inhibitors of α-amylase. However although freeze-dried strawberry was 
added to the PFRF mixture as the main inhibitor of glucose transport together with apple, 
it is also reported to be a good inhibitor of α-amylase and its inhibitory potential was also 
determined as well as that of freeze-dried apple peel. 
4.2.2.1 Materials and methods 
The materials and methods are as described in detail in chapter 2 (2.1 and 2.8).  
4.2.2.2 Sample preparation and Solid Phase Extraction (SPE) recovery 
Stock solutions of 10 mg/mL of water extracts of the fruits were prepared by vortex 
mixing 100 mg freeze-dried fruit in a total volume of 10 ml millipore water. This was 
done in stages by first adding 5 mL water, vortexed vigorously for 3 min, centrifuged at 
4000 rpm for 10 min and supernatant placed in a clean tube. This was repeated twice 
with 2.5 mL water each time, giving a total volume of 10 mL.  Solid phase extraction 
was carried out to remove sugars as they would interfere with the assay because the final 
stage of the assay measures the reducing ends of the reducing sugars produced. Hence 
the presence of other reducing sugars not produced from the hydrolysis of starch would 
interfere with the results.  The Oasis Max 3 cc cartridges containing 60 mg of sorbent 
were conditioned with 1 mL of methanol and cartridges were allowed to dry under 
vacuum (10 Hg) for 10 min. Millipore water (1 mL) was used to equilibrate the cartridges 
before adding 1 mL of the fruit extract sample (10 mg/mL).  After passing the sample 
through the cartridge, the cartridges were washed with 1 mL of 50 mM sodium acetate 
pH 7 buffer containing 5 % methanol. Polyphenols were eluted with 1 mL methanol for 
the first wash, then with 2 % formic acid in methanol for three washes. Eluents were 
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dried using a Genevac and stored in the -20 ˚C freezer until needed. Recovery analysis 
was determined to determine the recovery percentage of polyphenols after SPE. This was 
carried out by determining the amount of the major polyphenols in each fruit before and 
after SPE. Percentage recovery was calculated as: 
Amount of polyphenol after SPE    X 100 
Amount of polyphenol before SPE 
The sugar free samples were used in all inhibition assays by making appropriate 
concentrations and dilutions from the stock. 
4.3 Inhibition of rat intestinal α-glucosidase 
4.3.1 α-Glucosidase inhibition by green tea and EGCG 
As the main inhibitor of α-glucosidase in the PFRF mixture, green tea and its main 
catechin EGCG were used in the inhibition assay to determine their potential as α-
glucosidase inhibitors. Different concentrations were used to obtain dose-dependent 
inhibition curves to be used in the calculation of IC50. 
4.3.1.1 Materials and methods 
The materials and methods are as described in detail in chapter 2 (2.1 and 2.7). Green tea 
(1 mg/mL) was prepared in the same way as in the α-amylase inhibition determination 
above (4.2.1.1). 
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4.3.2  α-Glucosidase inhibition by fruits 
Although the freeze-dried fruits were included in the PFRF mixture as the main inhibitors 
of α-amylase (blackberry and blackcurrant) and glucose transport (strawberry and apple) 
from the literature search which identified them accordingly for having the lowest IC50 
values, their potential as α-glucosidase inhibitors was also determined as they would 
contribute to the inhibition if found to be inhibitors. 
4.3.2.1 Materials and methods 
The materials and methods are as described in detail in chapter 2 (2.1 and 2.7) and sample 
preparation is the same as in the α-amylase inhibition (4.2.2.2). Similar to the α-amylase 
assay, sugar free water extracts of the fruits after SPE were used as the presence of 
glucose would affect the results because the final stage of the α-glucosidase assay utilizes 
the hexokinase assay to measure the amount of glucose produced and hence the 
concentration in the assay volume. The presence of glucose in the fruit water extracts 
(inhibitor) would add to the concentration of glucose and hence overestimate the amount 
being determined. The presence of extra glucose in the fruit water extracts (inhibitor) 
would result in lowered inhibition % as inhibition is calculated by comparing the amount 
of glucose produced in the test assay compared to the amount produced in the control 
assay as shown in chapter 2.7.6. The rate of enzyme inhibition is calculated as a 
percentage of the control (without inhibitor) using the formula:               
  % = Abs Control – Abs sample x 100 
                Abs for control 
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4.4 Results 
4.4.1 α-Amylase inhibition by green tea and EGCG 
Inhibition curves for green tea (fig 4-1) on α-amylase were obtained by using different 
inhibitor concentrations and different substrates (amylose and amylopectin). Green tea 
dose-dependently inhibited human salivary α-amylase and IC50 values of 0.009±0.001 
and 0.025±0.001 mg/mL were obtained using amylose and amylopectin as substrate 
respectively (fig 4-1) and (table 4-1). 
 
Figure 4-1: Inhibition curves for green tea on α-amylase using amylose (A) and 
amylopectin (B) as substrate.  All data points are mean ±SD, n=3. The curves were used 
to obtain the IC50 values. 
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Enzyme  
substrate 
Green tea 
IC50 values 
(µg/mL) 
EGCG IC50 
values 
(µM) 
Acarbose IC50 
values 
(µM) 
EGCG Ki 
values 
(µM) 
α-amylase 
amylose 
8.9±0.1 5.3±0.6 3.5±0.3 0.3±0.6 
α-amylase 
amylopectin 
25±1 24±4 7.6±0.8 4.5±4.5 
 
Table 4-2: Experimental IC50 values of green tea, EGCG and acarbose of α-amylase 
inhibition and Ki values of EGCG using amylose and amylopectin as substrates.  
Acarbose was used as a positive control. All values are expressed as mean±SD, n=3. 
 
Similar to green tea, EGCG dose-dependently inhibited α-amylase with IC50 values of 
5.3±0.6 and 24±4 µM (table 4-1) for amylose and amylopectin respectively. For EGCG, 
in addition to IC50 values, Ki values (the intersection point of all the lines) were also 
determined (fig 4-2) using amylose (A) and amylopectin (B) as substrate. Different 
substrate and inhibitor concentrations were used to obtain the Ki values of 0.3±0.6 and 
4.5±4.5 µM (table 4-2).  
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Figure 4-2: Determination of Ki values for EGCG inhibition of α-amylase using amylose 
(A) and amylopectin (B) as substrate. Different concentrations of the inhibitors EGCG 
up to 70 µM and substrate concentrations up to 1 mg/mL were used to determine the 
interaction between the enzyme and inhibitor for Ki determination (intersection point of 
all the lines). All data points are mean ±SD, n=3.  
Ki 
Ki 
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4.4.2 α-Amylase inhibition by fruits 
Freeze-dried blackberry, blackcurrant and strawberry dose-dependently inhibited α-
amylase with amylose and amylopectin as substrates (fig 4-3). Apple peel powder did 
not inhibit at the highest concentration tested (4 mg/mL). The IC50 values were 
1.22±0.02, 1.5±0.1and 2.47±0.31 mg/mL for blackberry, blackcurrant and strawberry 
using amylose as substrate and 1.57±0.21, 1.7±0.1 and 3.85±0.05 mg/mL using 
amylopectin as substrate respectively. 
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Figure 4-3: Inhibition curves for freeze-dried strawberry, blackcurrant and blackberry on 
α-amylase using amylose (A) and amylopectin (B) as substrate. All data points are mean 
±SD, n=3. The curves were used to obtain the IC50 values. 
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4.4.3 α-Glucosidase inhibition by green tea and EGCG 
The inhibitory potential of green tea and its main catechin EGCG on α-glucosidase was 
determined by using rat intestinal powder as the source of the enzymes. Maltose, sucrose 
and isomaltose were used as substrates in independent experiments. Green tea dose-
dependently inhibited rat α-glucosidase with IC50 values of 0.035±0.005, 2.02±0.01 and 
2.31±0.02 mg/mL for maltase, iso-maltase and sucrase respectively (fig 4-4). 
 
Figure 4-4: Inhibition curves for green tea on rat maltase, sucrase and iso-maltase using 
maltose, sucrose and iso-maltose as substrate. All data points are mean ±SD, n=3. The 
curves were used to obtain the IC50 values.  
 
Similarly, EGCG inhibited rat maltase at the highest concentration tested (100 µM) with 
IC50 value of 14 µM. Different substrate and inhibitor concentrations were used to obtain 
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the Ki value of 21.7±1.8 µM (fig 4-5). However, rat sucrase and iso-maltase were 
inhibited weakly with percentages less than 20 % at 100 µM.  
 
Figure 4-5: Determination of Ki values for EGCG inhibition of rat maltase using maltose 
as substrate. Different concentrations of EGCG up to 25 µM and maltose (2, 3, 4 and 5 
mM) were used to determine the interaction between the enzyme and inhibitor for Ki 
determination. All data points are mean ±SD, n=3. 
4.4.4 α-Glucosidase inhibition by fruits 
The freeze-dried fruits blackberry, blackcurrant strawberry and apple peel did not inhibit 
α-glucosidase at the highest concentration (4 mg/L) tested. 
 
-Ki 
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4.4.5 SPE recovery 
The major polyphenols in all the fruits gave good recovery (≥ 90 %) after solid phase 
extraction using Oasis Max cartridges (table 4-3).   
Fruit  Polyphenol  
 
Recovery after SPE (%)  
Apple  Phloridzin 94±1 
Quercetin-3-O-rhamnoside 97±2 
Blackberry  Cyanidin-3-O-glucoside 97±3 
Blackcurrant  Cyanidin-3-O-rutinoside 90.0±0.7 
Strawberry  
 
Pelargonidin-3-O-
glucoside 
95.0±0.2 
 
Table 4-3: Solid phase extraction recovery of the main polyphenols found in freeze-dried 
apple peel, blackberry, blackcurrant and strawberry expressed as percentages (4.2.2.2). 
All values are expressed as mean±SD, n=3. 
4.5 Discussion 
Salivary and pancreatic α-amylase catalyse the hydrolysis of the endo α-1,4-glycosidic 
bonds into maltose, maltotriose and α-limit dextrins from starch. Then α-glucosidases 
hydrolyse the terminal α-1,4-glycosidic bonds linking the glucose residues to release 
glucose which is transported into the blood by glucose transporters. The inhibition of α-
amylase and α-glucosidase can thus reduce the amount of glucose produced and 
subsequently transported into the blood which can be considered to be an effective tool 
in the prevention and management of diabetes type 2.  
The PFRF mixture components inhibited the digesting enzymes α-amylase and α-
glucosidase in vitro. Green tea and EGCG showed inhibition towards both human 
salivary α-amylase and rat α-glucosidase. EGCG gave an IC50 value (5.3 µM) close to 
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that of the drug acarbose (3.5 µM) which is a known α-amylase and α-glucosidase 
inhibitor used in the management of type 2 diabetes. These results agree with previous 
studies (Tadera et al., 2006, Koh et al., 2010, Forester et al., 2012).  Koh et al. (2010) 
reported an IC50 value of 1.4 mM for EGCG and 4.2 and 4.4 mg/mL of two different 
green tea plants. Although inhibition was reported, the IC50 values were higher than those 
obtained in the present study (5.3 and 24 µM) for EGCG using amylose and amylopectin 
as substrate. The IC50 value was also higher for green tea which was 8.9 and 25 µg/mL 
green tea powder for amylose and amylopectin as substrate. The differences observed 
could be due to a number of reasons including: the catechin content of the green tea used 
as their total polyphenols were 101 mg GAE/g green compared to 541 mg GAE/g green 
tea in this study, rice starch was used as substrate compared to amylose and amylopectin 
used in this study and finally the use of a different method and assay conditions which 
as discussed by Nyambe-Silavwe et al. (2015), can lead to varying results could add to 
the differences observed.   
For α-glucosidase inhibition, results of the present study agree with the literature showing 
that green tea catechins are the best inhibitors of α-glucosidase (Honda and Hara, 1993, 
Matsui et al., 2007, Kamiyama et al., 2010). The 1C50 values obtained for EGCG were 
16 and 40 µM for maltase and 130 and 169 µM for sucrase (Matsui et al., 2007, 
Kamiyama et al., 2010). The results are comparable to the present study results which 
gave IC50 of 14 µM for maltase and less than 50 % for sucrase at the highest concentration 
tested of 100 µM. Similarly, green tea inhibited α-glucosidase in this study and agrees 
with the literature where inhibition by green tea was reported with  IC50 value of just 
below 200 µg/mL total phenolics (Kwon et al., 2008).  
The freeze-dried fruits blackberry, blackcurrant and strawberry all inhibited human 
salivary α-amylase. A previous study (McDougall et al., 2005) showed that strawberry 
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and blackcurrant inhibited human salivary α-amylase with strawberry being a better 
inhibitor than blackcurrant whereas blackcurrant was better than strawberry in the 
present study. The difference could be attributed to different polyphenol contents due to 
different cultivars of fruits being used. At the highest concentrations tested, the freeze-
dried fruits did not show inhibition towards α-glucosidase. Freeze-dried apple peel did 
not show inhibition towards neither α-amylase nor α-glucosidase, but will however still 
be used in the PFRF mixture for purposes of inhibiting glucose transport (Johnston et al., 
2002, Manzano and Williamson, 2010). 
4.6 Conclusion 
The PFRF mixture components (green tea powder, freeze-dried blackberry, blackcurrant 
and strawberry) inhibited human salivary α-amylase in vitro with IC50 values that can be 
achieved in the diet after taking into account 3 fold stomach dilutions because for every 
1 L of food consumed, about 2 L of intestinal fluid is produced which entails a threefold 
dilution of the food in the  stomach (Williamson, 2013). Together with green tea that 
inhibited rat α-glucosidase and apple and strawberry that have been shown to inhibit 
glucose transport (Johnston et al., 2002, Manzano and Williamson, 2010), the PFRF 
mixture has the potential to reduce postprandial glucose in vivo by inhibiting the 3 stages 
of carbohydrate digestion (α-amylase and α-glucosidase hydrolysis of starch and glucose 
transport into the blood). Hence it will be used in the human intervention study to 
determine the effects of polyphenols on glycaemic response. 
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Chapter 5 . Human intervention study to 
determine the effects of polyphenol and 
fibre-rich food (PFRF) mixture on 
glycaemic response in vivo. 
Abstract 
There is increasing evidence that low glycaemic index diets reduce the risk of developing 
type 2 diabetes. Polyphenol and fibre-rich foods have the potential to affect postprandial 
glycaemic responses by reducing glucose absorption, and so decreasing the glycaemic 
response of foods when consumed together. This is the first study to examine the effects 
of a meal comprised of components designed to inhibit each stage of the biochemical 
pathway leading up to the appearance of glucose in the blood. The aim was to test 
whether polyphenol and fibre-rich foods analysed for in vitro inhibition in chapter 4, 
could attenuate post-prandial blood glucose in healthy volunteers when added to a source 
of carbohydrate (starch in bread). A randomized, single blind crossover study was 
conducted on 16 healthy volunteers. The volunteers were fasted and attended four visits: 
two control visits (bread, water, and balancing sugars) and two test visits where they 
consumed single and double dose of the PFRF mixture together with bread and water. 
Blood samples were collected at 0 (fasted), 15, 30, 45, 60, 90, 120, 150 and 180 min post 
consumption. Plasma glucose was lower after consumption of both doses compared to 
controls: Lower dose, change in incremental area under the curve (IAUC) =-27.4±7.5 % 
(mean ± SD) p<0.001; higher dose, IAUC=-49.0±15.3 %, p<0.001); insulin IAUC was 
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also attenuated by -46.9±13.4% (mean ± SD; p<0.01). The PFRF have a pronounced and 
significant effect on postprandial blood glucose and insulin response in humans.  
5.1 Introduction 
Diabetes is a global problem and scientific evidence suggests that postprandial 
hyperglycaemia in humans has a major role to play in the development of type 2 diabetes 
(Salmeron et al., 1997, Steven et al., 2002, Hodge et al., 2004, McKeown et al., 2004). 
Low glycaemic index (GI) diets show favourable changes in health markers which 
include fasting blood glucose (Livesey et al., 2008a), plasminogen activator inhibitor-1 
(Järvi et al., 1999) and glycated proteins (Brand-Miller et al., 2003, Livesey et al., 
2008a). Having low glycaemic index (GI) foods in the diet or components that reduce 
the GI of other foods is thus a good intervention in reducing the risk (Livesey et al., 
2008b). Low carbohydrate and low GI diets have promising effects in diabetes 
management (Ajala et al., 2013). Strategies to reduce the glycaemic index of foods, even 
without altering the total carbohydrate content, are therefore of growing interest for 
reducing diabetes risk and maintaining a more “healthy diet”. A number of related factors 
influence the glycaemic index and response and they include: the nature and amount of 
carbohydrate, the rate of carbohydrate digestion in the gastrointestinal tract, the rate of 
absorption of the resulting glucose, the insulin response to the absorbed sugar, and the 
intrinsic insulin sensitivity (Augustin et al., 2002). The presence of naturally-occurring 
polyphenols have been associated with low glycaemic index foods for many decades 
(Thomson and Yoon, 1984). Fibre can also play a role in reducing hyperglycaemia, by 
delaying glucose absorption, increasing insulin secretion and sensitivity, and binding of 
bile acids (Scazzina et al., 2013). In addition, soluble fibre attenuates postprandial 
glucose by increasing the viscosity in the gastrointestinal tract which disturbs 
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carbohydrate breakdown and glucose absorption (Dikeman and Fahey Jr, 2006). Possible 
mechanisms by which polyphenols may affect post-prandial glycaemia are the inhibition 
of carbohydrate-digesting enzymes and glucose transporters, stimulation of pancreatic β-
cells to secrete insulin, activation of insulin receptors, modulation of the release of 
glucose from the liver, and effects on intracellular signalling pathways and gene 
expression (Hanhineva et al., 2010, Williamson, 2013). The potential action of 
polyphenols can be compared to that of acarbose, an α-glucosidase and α-amylase 
inhibitor, which reduces diabetes risk (Hanefeld et al., 2008). The Study To Prevent Non-
Insulin dependent Diabetes Mellitus (STOP-NIDDM) trial in impaired glucose tolerant 
(IGT) subjects showed a 36% risk reduction in the progression to diabetes after treatment 
with acarbose (Chiasson, 2006). The use of a diet-related intervention either on its own 
or in combination with acarbose would be an alternative to the use of acarbose alone, 
which can lead to side effects such as flatulence, nausea and diarrhoea (Coniff et al., 
1995, Chiasson et al., 2002). 
Some polyphenols inhibit starch-digesting enzymes (α-amylase and α-glucosidase), in 
addition to glucose transporters SGLT1 (SLC5A1) and GLUT2 (SLC2A2) (Hanhineva 
et al., 2010). Most intervention studies so far have focused on the effect of polyphenols 
with the endogenous carbohydrates already present in the food, but addition of 
polyphenols and fibre to reduce the glycaemic index of that food has not been fully 
explored, but is the normal way in which most foods are consumed i.e. as a total meal in 
combination with other foods.  
In this study, the hypothesis that a combination of components in the diet (polyphenols 
and fibre) capable of inhibiting the different stages of starch digestion would reduce 
postprandial blood glucose and insulin using a randomized, controlled, single blind, 
crossover intervention was thus tested. The test diet was designed to consist of inhibitors 
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for every stage of carbohydrate digestion. It consisted of α-amylase inhibitors (green tea, 
freeze-dried blackberry, blackcurrant and strawberry), α-glucosidase inhibitor (green tea) 
and glucose transport inhibitors (freeze-dried apple peel and strawberry). All freeze-dried 
fruits also contained fibre which is expected to contribute to the effects on glycaemic 
response. 
5.2 Experimental methods 
5.2.1 Subjects  
The recruitment of subjects was carried out at the University of Leeds, School of Food 
Science and Nutrition, Leeds, UK. Poster advertisements around the University of Leeds 
notice boards were used to recruit interested potential volunteers, who were then 
screened for fasting plasma glucose (required to be between 3.9 and 5.9 mmol/L). They 
were then asked to assess themselves using criteria to ensure they could be classified as 
healthy and free of symptomatic disease. The eligibility criteria were: Aged 18-75, 
apparently healthy, not diabetic, not on long term prescribed medication, not pregnant 
nor lactating, and not on a special diet (e.g. for losing weight or fruit supplements). In 
total, 16 healthy volunteers aged 26 ± 4 y with BMI of 24 ± 3 kg gave their written 
informed consent and completed the 4 study visits as shown in Figure 5-1. Fasting plasma 
glucose and insulin concentrations were 4.8 ± 0.1 mmol/L and 24 ± 10 pmol/L 
respectively.  
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Figure 5-1: Participant enrolment flow diagram showing the randomization of 
participants in groups for the allocation of the order of meals. It also shows the number 
of participant’s plasma analysed from each randomized intervention.  
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5.2.2 Study design 
A randomized, controlled, single blind, crossover intervention was carried out on a total 
of 16 healthy volunteers with the primary outcome of post-prandial blood glucose area 
under the curve. Due to the nature of the test meals, it was impossible to blind 
participants. However analysis of the plasma samples was blinded and was only 
unblinded after data analysis. Subjects were cannulated (forearm vein) by a research 
nurse to ensure comfortable collection of blood samples. Each participant had four visits, 
two of which were reference meals (the first and last visits) and two visits were test meals 
(single and double dose of PFRF), administered in a randomized pattern.  
All meals contained 109.0 ± 1.2 g white bread (50 g available carbohydrate as analysed 
by the method of Englyst (Englyst et al., 1992) explained in detail in chapter 2. The 
higher dose consisted of 1 g green tea powder in 200 ml drinking water, with 20 g each 
of apple peel, blackberry, blackcurrant and strawberry freeze-dried powders mixed with 
drinking water to make a paste and spread on the bread. The reference meal included 0.8, 
5.4 and 8.6 g of sucrose, glucose and fructose respectively dissolved in 200 ml drinking 
water to standardize the amounts of sugars present in the extracts of the high dose. The 
lower dose of the test meal contained half the amount of fruits and green tea with half 
the amounts of balancing sugars dissolved in 200 ml drinking water to equalize the 
amount of sugars present in all doses. A polyphenol and fibre-rich food (PFRF) 
containing polyphenols that are effective inhibitors of different stages of starch digestion 
and absorption was used in this study. It comprised of an α-glucosidase inhibitor (green 
tea) (Honda and Hara, 1993, Matsui et al., 2007, Kamiyama et al., 2010), α-amylase 
inhibitors (green tea, blackberry, blackcurrant and strawberry) ( McDougall et al., 2005, 
McDougall and Stewart, 2005, Forester et al., 2012) and glucose transport inhibitors 
(apple peel and strawberry) (Kobayashi et al., 2000, Hossain et al., 2002, Manzano and 
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Williamson, 2010), with all fruits also providing fibre. The PFRF components were 
analysed for total polyphenol content, specific major polyphenols and for α-amylase and 
α-glucosidase inhibition in vitro (chapter 4). Figure 5-2 shows a summary of the study 
design from recruitment of volunteers to analysis of plasma. 
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Advertisement              Volunteers asked to complete pre study questionnaire             fasting glucose screening             sign consent form      
                 First visit                             Second visit                              Third visit                                       Fourth visit 
                                          One week                         One week                            One week                      
Volunteers consumed meals in either one of the four randomised order options. 
                                                       
Control (bread, water, sugars)   High dose (bread, fruits, green tea)     Low dose (bread, fruits, green tea, sugars)     Control (bread, water, sugars)    
Control (bread, water, sugars)    Low dose (bread, fruits, green tea, sugars)      High dose (bread, fruits, green tea)   Control (bread, water, sugars)   
Control (bread, water, sugars)    High dose (bread, fruits, green tea)      Control (bread, water, sugars)   Low dose (bread, fruits, green tea, sugars)       
Control (bread, water, sugars)    Low dose (bread, fruits, green tea, sugars)      Control (bread, water, sugars)   High dose (bread, fruits, green tea)       
 
 
Venous blood collection at    0, 15, 30, 45, 60, 90, 120, 150 and 180 minutes Processed into plasma 
and stored at -80 °C 
Glucose and Insulin 
analysis 
Figure 5-2: Flow diagram summarizing the design for the intervention study from recruitment of volunteers to analysis of the plasma samples for 
glucose and insulin.
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5.2.3 Test meals 
All meals contained 109.0 ± 1.2 g white bread (50 g available carbohydrate as analysed 
by the method of Englyst (Englyst et al., 1992) The higher dose consisted of 1 g green 
tea powder in 200 ml drinking water, with 20 g each of apple peel, blackberry, 
blackcurrant and strawberry freeze-dried powders mixed with drinking water to make a 
paste and spread on the bread. The reference meal included 0.8, 5.4 and 8.6 g of sucrose, 
glucose and fructose respectively dissolved in 200 ml drinking water to standardize the 
amounts of sugars present in the extracts of the high dose. The volunteers consumed the 
reference meal on two of the visits to determine any variability in the measurements 
(Brouns et al., 2005). The lower dose of the test meal contained half the amount of fruits 
and green tea with half the amounts of balancing sugars dissolved in 200 ml drinking 
water to equalize the amount of sugars present in all doses.  
5.2.4 Study protocol 
The University of Leeds, Faculty of MaPS and Engineering Ethics Committee (MEEC) 
approved the study protocol (MEEC 12-037) (appendix 1) and the protocol was 
registered with ClinicalTrials.gov, ID number NCT01994135. Each participant had one 
visit per week and hence did the study in 4 weeks with body weight and height 
measurements taken on the first visit. On each visit, a cannula was inserted in the forearm 
of the subject. A fasting blood sample was taken and after that the volunteer consumed 
the meal and the timer started upon first bite or sip. The volunteers consumed the whole 
meal and blood was collected after 15, 30, 45, 60, 90, 120, 150 and 180 min. Neither 
harm nor side effects were incurred during the consumption of the meals. Blood samples 
were collected in fluoride/oxalate and ethylenediaminetetraacetic acid (EDTA) tubes for 
glucose and insulin measurements respectively and immediately placed on ice. The tubes 
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were then centrifuged within 15 min at 4000 g at 4°C for 15 min. Thereafter, plasma was 
placed in storage tubes and stored at -80°C. Plasma glucose concentrations were 
determined using hexokinase linked to NADH oxidation and insulin concentrations by 
immunoassay. Both the methods are described in detail in chapter 2 (2.2 and 2.3). 
5.2.5 Statistical analysis 
The incremental areas under the glucose curves (IAUC) were calculated for each subject 
for each visit using the trapezoidal rule. Data were analysed using the two tailed paired 
T-test analysis and results were confirmed by using the one factor repeated measures 
analysis of variance (ANOVA) between the two references, reference and dose 1, 
reference and dose 2 and between lower and higher dose. Sample size was determined 
by designing the trial to have 90% power to detect a clinical difference of 15% IAUC 
between test and reference meal. For a power calculation, the following information is 
required:  
1)  A significance level at which the chance of wrongly concluding that a difference 
exists when in fact there is no real difference (type 1 error) one is willing to tolerate. 
Typically a 5% level of significance is chosen to reflect a 95% confidence α = 0.05. 
2) A desired power at which the chance of correctly detecting a difference when the 
difference truly exists one wishes to achieve. A conventional power is either 80 or 90% 
and will use the latter. 
3) Specifying a clinically meaningful difference in terms of the primary endpoint denoted 
by Δ. For this study, clinically significant difference can either be the difference between 
healthy range and pre-diabetic range, pre-diabetic range and diabetes or from healthy to 
diabetic. For the purpose of getting a clinically meaningful difference in terms of  glucose 
IAUC, we will consider the difference between healthy range and pre-diabetic range  
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although only healthy volunteers will be recruited. The difference in fasting plasma 
glucose from the highest concentration  in normal range of 5.9 mmol/L to that of the pre-
diabetic one of 6.9 mmol/L gives a 14.5 % change from the calculation: 
 (6.9 – 5.9) /6.9  X 100, hence will use a decrease of 15 %. 
4) Knowledge regarding the standard deviation of the primary endpoint calculated as: 
Standard deviation X 100 = CV %.  
         Mean 
An average of 11.9% was obtained from three references; (Josic et al., 2010) who had 
13.9 %, (Johnston et al., 2003) with 12.2 % and (Wu et al., 2012) with 9.7 %. 
By using statistics tables (Machin et al., 2009) with the above information assuming 
normal distribution and paired t-test, 
Δ = 15 % / 11.9 % = 1.218 approximately 1.200 
α = 2-sided 0.05 
Power 1 – β = 0.90, gives 15 participants  
The above calculation was also verified by SPSS statistics software (version 21) as 
follows:  
To determine the estimated sample size for two-sample comparison of means when 
testing the hypothesis (Ho) that the mean in population 1 (m1) (consuming the control 
meal) is equal to the mean in population 2 (m2) (consuming the test meal). 
Ho: m1 = m2 
 Assumptions:  
alpha =   0.0500 (two-sided) 
         power =   0.9000 
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            m1 =      200 
            m2 =      230 
           sd1 =       25 
           sd2 =       25 
         n2/n1 =     1.00 
Estimated required sample sizes: 
            n1 =       15 
            n2 =       15 
The study required 15 participants each for reference and test meal. Each participant 
being a control of themselves, a minimum of 15 participants were thus required. 
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5.3 Results 
5.3.1 Post-prandial plasma glucose  
The plasma glucose concentrations as analysed by hexokinase (chapter 2.2), were used 
to obtain the average postprandial glucose readings and the curves were obtained (fig 5-
3) for each meal (control, low dose and high dose) for 16 volunteers.  
 
Figure 5-3: Average glucose curves after consumption of reference, test meal dose 1 and 
test meal dose 2 for 16 volunteers with 3 technical replicates each. There is a decrease in 
the area under the curve and the peak rise in glucose concentration between the control 
and test meals. All data points represent mean ± S.D, n=16. 
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Both the low and the high dose test meals containing PFRF showed a significant decrease 
in a dose-dependent manner in the glucose IAUC compared to the control meals (Figure 
5-4), - 27.4±7.52 % (mean ± SD; p<0.01) and -49.0±15.3 % (p<0.01) respectively, with 
no significant difference between the two reference (control) meals. The peak glucose 
concentration was also significantly lower in both PFRF test meals compared to the 
reference meals.  
 
Figure 5-4: Average glucose IAUC (A) and peak glucose concentration from fasting after 
consumption of reference, test meal dose 1 and test meal dose 2 for 16 volunteers. There 
is a significance difference between IAUC of reference meals and test meals as well as 
between the peak rises in glucose concentration (B), p<0.01 (**), no significant 
difference (ns) (p>0.05). 
5.3.2 Post-prandial plasma insulin  
The Mercodia insulin ELISA method (described in chapter 2.3), was used to determine 
the plasma insulin concentrations which were used to obtain the average postprandial 
insulin readings and the curves were obtained (fig 5-5) for the control and high dose for 
16 volunteers.  
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Figure 5-5: Average postprandial insulin curves after consumption of control and test 
meal for 16 volunteers with 3 technical replicates each. There is a decrease in the area 
under the curve and the peak rise in insulin concentration between the control and the 
test meal. All data points represent mean ± S.D, n=16. 
 
There was a reduction in insulin IAUC for the PFRF meal compared to the reference 
meal of - 46.9±13.4 % (mean ± SD) (p<0.01) (Figure 5-5). The PFRF meal also 
attenuated the peak postprandial insulin concentration, and any differences had 
disappeared by 120 min. 
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Figure 5-6: Average insulin IAUC (A) and peak insulin concentration from fasting after 
consumption of control and test meal for 16 volunteers. There is a significance difference 
between IAUC of control meal and test meal as well as between the peak rises in insulin 
concentration (B), p<0.01 (**). 
 
5.3.3 Inter-individual differences  
Inter-individual differences were observed in this study in both postprandial glucose and 
insulin IAUC (table 5-1). The decrease (%) in glucose IAUC for dose 2 test meal 
compared to control meal for 16 volunteers varied from 30.4 to 87.3 %. Similarly the 
decrease (%) in insulin IAUC for dose 2 test meal compared to control meal varied from 
28.1 to 67.8 % There was no correlation (Pearson correlation coefficient of -0.219) 
between insulin and glucose IAUC % difference between control and dose 2 test meals 
(fig 5-7).  
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Figure 5-7: Correlation of insulin and glucose IAUC difference (%) between control and 
dose 2 test meals shows no correlation with Pearson correlation coefficient = -0.219 
(n=16 each for glucose and insulin). 
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Participant 
number 
Decrease (%) in IAUC between control 
meal and dose 2 test meal 
Glucose Insulin 
1 38.7 33.9 
2 62.4 28.1 
3 87.3 31.6 
4 71.2 58.9 
5 42.7 37.6 
6 49.2 67.6 
7 42.2 25.3 
8 30.4 46.6 
9 39.9 39.5 
10 53.1 43.9 
11 61.9 49.3 
12 35.5 50.0 
13 34.4 67.8 
14 41.0 55.9 
15 53.3 53.4 
16 37.2 60.0 
 
Table 5-1: Percentage decrease in IAUC of insulin and glucose between control and test 
meal dose 2. There are inter-person differences in the decrease (%) for both the 
postprandial IAUC of glucose and insulin. There are also differences in the individual 
corresponding decrease in postprandial IAUC of insulin in comparison to glucose IAUC 
change. 
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5.3.4 Correlations between postprandial glucose and insulin IAUC.  
There was positive correlation between insulin and glucose IAUC for both the reference 
meals (A) and dose 2 test meals (B) with Pearson correlation coefficient = 0.621 and 
0.568 respectively.  
 
Figure 5-8: Correlation between insulin and glucose IAUC for both the reference (    ) 
and test  (    ) (n = 16) dose 2 meals with Pearson correlation coefficient = 0.412.  
5.3.5 Correlations between insulin sensitivity and insulin release 
The homeostasis model assessment (HOMA) tool was used to estimate insulin resistance 
and β-cell function. It  is a validated clinical and epidemiological tool which is a 
mathematical calculation that utilises fasting glucose and insulin concentrations (Wallace 
et al., 2004). HOMA-IR is HOMA of insulin resistance with the formula: fasting blood 
glucose (mmol/L) x fasting blood insulin (µLU/ml)/ 22.5 and  HOMA-B is that of β-cell 
function/insulin release with the formula: 20 x fasting insulin concentration (µLU/ml)/ 
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fasting glucose concentration (mmol/L) - 3.5 (Wallace et al., 2004). There was a positive 
correlation (Pearson correlation coefficient = 0.616) between HOMA-IR and HOMA-B 
showing that the more insulin sensitive a volunteer was, the less insulin was produced by 
the β-cells of the pancreas (fig 5-9). 
 
Figure 5-9: Correlation between insulin sensitivity (HOMA-IR) and insulin release 
(HOMA-B) using fasting insulin and glucose concentrations data from the volunteers 
(n=16). There is positive correlation with Pearson correlation coefficient = 0.962.  
 
The healthy range for HOMA-IR is 0.5-1.4 with 1.0 as the average. HOMA-IR <1.0 
indicates being very insulin sensitive, >1.9 early insulin resistance and >2.9 indicates 
significant insulin resistance. HOMA-IR and HOMA-B were calculated for all 16 
volunteers (table 5-2). 
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Participant 
number 
Fasting glucose 
mean±S.D 
(mmol/L) 
Fasting insulin 
mean±S.D 
 (pmol/L) 
HOMA-IR HOMA-B 
1 4.2±0.12 9.9±3.2 0.3 47.2 
2 5.2±0.28 15.7±5.6 0.6 31.3 
3 4.5±0.34  23.7±10.4 0.8 75.4 
4 4.5±0.42  20.0±14.2 0.7 64.5 
5 4.3±0.09 31.5±0.6 1 130.4 
6 5.0±0.34 41.0±9.7 1.5 91.7 
7 4.8±0.13   37.7±10.7 1.3 94.4 
8 5.0±0.19 25.8±6.4 1 59.0 
9 4.7±0.06 24.7±1.8 0.9 71.7 
10 4.4±0.14 23.1±4.5 0.8 85.8 
11 4.6±0.14 23.8±2.8 0.8 72.2 
12 4.4±0.40 22.6±3.3 0.7 88.6 
13 4.4±0.35 14.0±4.0 0.5 50.5 
14 4.6±0.16   29.2±10.2 1 88.5 
15 4.3±0.22 17.5±4.3 0.6 75.4 
16 4.9±0.24 134.9±15.3 4.8 333.0 
Table 5-2: Fasting glucose and insulin plasma concentrations of volunteers used in the 
determination of HOMA-IR and HOMA-B.   
5.4 Discussion 
Consumption of foods rich in polyphenols and fibre (PFRF) together with bread resulted 
in a highly significant dose-dependent lowering of the glucose area under the curve and 
lower peak concentration, and an associated attenuation of insulin. The effect is most 
likely due to in vitro inhibition of human salivary α-amylase (mainly green tea, 
blackberry, blackcurrant and strawberry), α-glucosidase (green tea), and glucose 
transport (green tea, apple and strawberry  Kobayashi et al., 2000, Manzano and 
Williamson, 2010), and additionally also the effect of fibre (Weickert and Pfeiffer, 2008, 
Anderson et al., 2009). Although it is not possible to define the exact contribution of 
inhibition of the different steps (inhibition of α-amylase, α-glucosidase or glucose 
transport) to the attenuation of blood glucose, we would speculate that partial inhibition 
of multiple steps is important for the observed effect on the glycaemic response. These 
147 
 
   
reductions in glycaemic response can play a major long term role in the management or 
risk reduction of diabetes type 2, comparable to the drug acarbose (Hanefeld et al., 2008), 
since high concentrations of postprandial glucose lead to insulin resistance, pancreatic 
exhaustion, glucose intolerance and an increased  insulin demand (Willett et al., 2002).  
Inter-individual differences were observed and this would be an important aspect to 
consider in the development of functional foods for the prevention and management of 
type 2 diabetes. However the PFRF mixture had a positive effect on all volunteers as they 
all responded by having a decreased glycaemic response compared to the control meal. 
Although there was an overall decrease for each volunteer in the postprandial glucose 
and insulin IAUC after a test meal (with the PFRF mixture) compared to the control meal, 
the differences varied from 30.4 to 87.3 % and from 25.3 to 67.8 % for glucose and 
insulin respectively (table 5-1). This was confirmed by the lack of correlation between 
insulin and glucose IAUC difference (%) between the controls and dose 2 test meals 
(figure 5-7) because volunteers had different glucose and insulin responses. This shows 
that the same dose of polyphenols from the PFRF mixture results in different percentage 
decrease in different individuals. For the differences observed in the glucose IAUC 
between individuals, this could be due to many reasons including the amount of digestive 
enzymes. The amount of intestinal fluids produced may also be different between 
individuals resulting in different dilution effects (Williamson, 2013). For the non-
correspondence in the insulin IAUC with the glucose IAUC, differences could be due to 
differences in insulin sensitivity between individuals. To explain the inter-individual 
variation observed in the results of this study in terms of insulin sensitivity, the 
homeostasis model assessment (HOMA) tool was used to estimate insulin resistance and 
β-cell function or insulin release. Out of the 16 volunteers used in this study, one 
(volunteer 16) had significant insulin resistance with HOMA-IR of 4.8 (table 5-2) and 
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had a corresponding higher value of insulin release (HOMA-B) of 333. Volunteer 16 was 
23 years old with BMI of 29.6, fasting plasma glucose of 4.9±0.2 mmol/L and fasting 
insulin concentration of 134.9 ±15.3 pmol/L. The BMI (29.6) places the volunteer in the 
overweight category (25-29.9) which is one of the risk factors for developing type 2 
diabetes and partly explains the insulin resistance status. The fasting plasma glucose is 
however still in the normal healthy range (3.9 – 5.9 mmol/L) which indicates that the β-
cells of the pancreas were still able to produce enough insulin to keep the plasma blood 
glucose in the healthy range although the high fasting insulin concentration shows that 
the β-cells were overproducing insulin to enable the removal of excess glucose from the 
blood. At the time of screening, only fasting glucose concentration was checked that’s 
why the volunteer was considered healthy based on the fasting plasma glucose reading. 
On the other hand, although volunteers 6 and 7 had HOMA-IR values of 1.5 and 1.3, 
which are very close to the cut off value of 1.4 for the healthy range, their values are still 
lower than 1.9 which is the value indicating early insulin resistance. Moreover, their 
fasting insulin values were in the healthy range (41.0 and 37.7 pmol/L) which are less 
than 62.5 pM (Johnson et al., 2010) and are hence not insulin resistant. Volunteer 1 had 
the lowest fasting insulin concentration of 9.9 pmol/L and also had a corresponding lower 
HOMA-IR value of 0.3 (very insulin sensitive). 
Therefore, differences in insulin sensitivities of the volunteers could be one of the reasons 
for the inter-individual variations observed. However despite all the inter-individual 
variations, the PFRF mixture affected all volunteers above the clinically significant 
difference of 15 % reduction on postprandial glucose and insulin IAUC even including 
volunteer 16 who had significant insulin resistance.  
A limited number of studies have reported the effects of isolated polyphenols or 
polyphenol containing foods or extracts on post-prandial glycaemia (Johnston et al., 
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2002, Johnston et al., 2003, Bryans et al., 2007, Hlebowicz et al., 2007, Tsujita et al., 
2008, Tsujita and Takaku, 2008, Josic et al., 2010, Clegg et al., 2011, Linderborg et al., 
2012, Törrönen et al., 2012, Chai et al., 2013, Coe et al., 2013, Schulze et al., 2014, 
Makarova et al., 2015) but the results are  mixed with only some studies reporting 
significant differences between test meal and reference meal, and sometimes only at one 
or two time points, possibly owing to the use of different sugar sources, for example 
glucose ( Johnston et al., 2002, Johnston et al., 2003, Bryans et al., 2007, Linderborg et 
al., 2012, Schulze et al., 2014, Makarova et al., 2015) or sucrose (Törrönen et al., 2012). 
A limited number of starch-based interventions, using rice, pancakes and white bread, 
have also shown mixed results (Hlebowicz et al., 2007, Tsujita and Takaku, 2008, Josic 
et al., 2010, Clegg et al., 2011, Coe et al., 2013). All of these studies above have not 
designed the study meal by considering the mechanism by including foods capable of 
attenuating the rate of each step of the digestive process. No significant difference was 
observed when a starch based meal (pancakes) was used together with 100 g berries as 
the source of polyphenols (Clegg et al., 2011). When used alone, green tea as the sole 
source of polyphenols also did not give a significant difference in the IAUC (Josic et al., 
2010). There was a significant difference in the IAUC when apple juice was used as a 
polyphenol source and  the decrease was clearly attributed to the inhibition of glucose 
transporters by polyphenols in apple especially phloridzin (Johnston et al., 2002).  
Polyphenols and fibre (14.7g) (Linderborg et al., 2012), present in lingonberries, nulled 
the glycaemic effect of the endogenous sugars present in the lingonberries. The PFRF 
mixture had fibre contents of 0.22, 0.53, 0.43 and 0.2 g/100g DW in apple peel, 
blackberry, blackcurrant and strawberry respectively giving the total amount of 1.1 g in 
the high dose and half the amount in the low dose. On its own fibre was not expected to 
have an effect on the postprandial glucose response because an average of >25 and > 38 
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g/day is recommended in order to have beneficial health benefits (Weickert and Pfeiffer, 
2008). An average of 15 g/day fibre treatment for 5 weeks lowered the fasting plasma 
insulin values and increased insulin sensitivity (Anderson et al., 2009). Consumption of 
6-20 g/day of fibre for ten weeks of treatment also reported significant reductions in both 
fasting plasma glucose and insulin (Anderson et al., 2009). Both studies indicate that at 
least more than 6 g/day of fibre was needed in order to have effects on glycemic response. 
Hence a conclusion can be made that the 1.1 g of fibre present in the PFRF mixture was 
not entirely responsible but contributed to the observed effects. In vitro, polyphenols, 
phenolic acids and tannins in strawberry and apple reduced glucose transport using caco-
2 intestinal cell monolayers by inhibiting the glucose transporters SGLT1 and GLUT2. 
Phloridzin contributed 52% (IC50 = 146 μM) and pelargonidin-3-O-glucoside (IC50 = 802 
μM) 26% to the total inhibition by apple and strawberry extracts respectively (Manzano 
and Williamson, 2010). These concentrations, together with those obtained for α-amylase 
and α-glucosidase inhibition (chapter 4), were theoretically obtained in the gut lumen 
(table 1) after taking into consideration calculated 3-fold dilution of consumed 
substances (Williamson, 2013). For example, the IC50 value for α-amylase inhibition by 
green tea was 0.009 mg/ml in vitro, 3-fold dilution in vivo would require 0.027 mg/ml in 
the original sample, and the test meals contained 2.5 and 5 mg/ml in the low and high 
dose respectively. It is therefore proposed that polyphenols and fibre present in the PFRF 
mixture act together by inhibiting α-amylase, α-glucosidase and glucose transporters and 
leading to the observed reduced glycaemic response in vivo. The observed reduction in 
postprandial blood glucose and insulin could play a major role in management and 
reducing the risk of type 2 diabetes, since hyperglycaemia is a risk factor for developing 
insulin resistance, impaired glucose tolerance and consequently type 2 diabetes. 
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5.5 Conclusion 
Polyphenols and fibre present in fruits, together with a cup of green tea, have a 
pronounced lowering effect on postprandial glucose and insulin when consumed together 
with a starch food (bread), owing to inhibition of the different stages of starch digestion. 
For the current study, the inhibition of the different stages of digestion contributed to the 
overall inhibition because some studies that have used either one of the PFRF mixture 
components either did not report any significant difference between control and test meal 
(Josic et al., 2010) or reported a difference smaller (Johnston et al., 2005) than that found 
in this study. Hence to determine the importance and contribution of each step, this can 
be done either with well-designed in vitro assays and models or in vivo by carrying out 
separate human intervention studies using each component of the PFRF mixture 
separately as the test meal. 
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Chapter 6 . The effects of pomegranate 
polyphenols from different food matrices 
(food supplements and juice) on glycaemic 
response in healthy volunteers  
Abstract 
Results from chapter 5 have shown that together with lifestyle changes such as weight 
loss and physical activity, polyphenols have the potential to be used as functional foods 
in the prevention and management of type 2 diabetes, as the polyphenol-rich foods 
significantly reduced the postprandial glucose area under the curve as well as the glucose 
peak. The aim of this study was to determine the effects of polyphenols from a single 
source (pomegranate) on glycaemic response in vivo when consumed together with a 
source of carbohydrate (starch in bread) using pomegranate polyphenols in different food 
matrices (supplements and juice). Pomegranate extract dose-dependently inhibited 
human salivary α-amylase, maltase and sucrase in vitro with IC50 values of 0.06±0.01, 
1.0±0.1 and 1.2±0.3 mg/mL respectively. One of its major polyphenols, punicalagin, also 
dose-dependently inhibited α-amylase with an IC50 value (9 µM) which is comparable to 
that of acarbose (3.5 µM), a well-known anti-diabetic drug. Two randomized, controlled 
crossover studies were conducted independently on 16 healthy volunteers for each study 
who were fasted and attended control (bread, water and balancing sugars if applicable) 
and test visits where a source of polyphenols (supplements or juice) were consumed 
together with bread. There was a significant difference between postprandial glucose 
IAUC (-33.1±18.1 %, p <0.01) of control and test in the pomegranate juice study and no 
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significant difference when pomegranate capsules were used. The food matrix containing 
the polyphenols may play a role in the differences observed as it determines the speed of 
dissolution for availability of polyphenols to interact with digestive enzymes.  
6.1 Introduction 
There is growing evidence that certain polyphenols have the potential to lower 
postprandial blood glucose when consumed together with a starch meal due to inhibition 
of digestive enzymes α-amylase and α-glucosidase, as well as glucose transporters 
(Hanhineva et al., 2010, Williamson, 2013). A recent review recommended that a 
combination of polyphenols with the potential to inhibit the named different stages of 
carbohydrate digestion and metabolism would be the best strategy (Williamson, 2013). 
In the previous chapter (Chapter 5), a polyphenol and fibre-rich food (PFRF) mixture 
designed to contain polyphenols that had the potential to inhibit different stages of 
carbohydrate digestion was shown to have a significant effect on the postprandial glucose 
IAUC and peak rise in glucose. In order for polyphenols to be utilized in the prevention 
and management of diabetes type 2, functional foods or food supplements could be 
developed. The rise in diet related diseases such as type 2 diabetes (Shaw et al., 2010) 
requires a corresponding increase in research relating to the development of functional 
foods which should provide physiological benefits and play a role in disease prevention 
and management, in addition to their basic nutritional functions (Viuda-Martos et al., 
2010). 
Pomegranate qualifies to be a potential functional food as it has been used in folk 
medicine for years due to its reported therapeutic qualities which include anti-diabetic 
properties (Viuda-Martos et al., 2010). The beneficial effects of pomegranate are 
attributed to the presence of polyphenols, and research on its anti-diabetic and anti-
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atherosclerotic effects have intensified in the past ten years (Medjakovic and Jungbauer, 
2013).  Different parts (peels, seed, leaves, fruit) of the pomegranate plant have bioactive 
properties attributed to its polyphenols, which include punicalagin, ellagic and gallic 
acids in addition to tannins and anthocyanins (Banihani et al., 2013).  
A number of possible mechanisms by which pomegranate polyphenols confer the anti-
diabetic properties have been proposed and may include; attenuation of glycaemic 
response by lowering fasting and postprandial glucose concentration (Jafri et al., 2000, 
Parmar and Kar, 2008), increasing  insulin sensitivity and release (Medjakovic and 
Jungbauer, 2013, Parmar and Kar, 2008), reducing intestinal glucose absorption, 
promoting the synthesis of glycogen (Parmar and Kar, 2008) prevention of 
gluconeogenesis (Viuda‐Martos et al., 2010) and up regulation of glucose transporter 
type 4 (GLUT4) mRNA expression which modulates glucose transporter expression and 
consequently glucose levels (Medjakovic and Jungbauer, 2013). Other mechanisms are 
through their anti-atherosclerotic and anti-inflammatory effects. Anti-atherosclerotic 
properties are through increasing the activities of paraoxinase 1 (PON1), the major anti 
atherosclerotic component of high density lipoprotein (HDL), and superoxide dismutase 
(SOD), which catalyses the conversion of the superoxide radical into oxygen (Banihani 
et al., 2013). Many of these effects are mediated through the activation of peroxisome 
proliferator-activated receptor (PPAR) pathways. This property is exhibited by drugs that 
are used to treat insulin resistance by sensitising the cells to the presence of insulin by 
activating PPAR-γ (Medjakovic and Jungbauer, 2013). Pomegranate and its polyphenols 
have been proven to act as modulators of PPAR-γ. Incubating either pomegranate juice, 
punicalagin or gallic acid with macrophages reduced oxidative stress in macrophages as 
a result of its stimulation by PPAR-γ release/action and the effects were cancelled when 
PPAR-γ was inhibited (Shiner et al., 2007, Mueller and Jungbauer, 2009). PPAR-γ also 
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plays a role in the anti-inflammatory effects of pomegranate. The loss of the PPAR-γ 
gene led to the loss of the anti-inflammatory properties of pomegranate polyphenol 
punicic acid as demonstrated in PPAR-γ null mice (Hontecillas et al., 2009). 
A recent review reports that the mechanisms by which pomegranate polyphenols confer 
the anti-diabetic properties are not fully understood (Banihani et al., 2013). However, to 
establish the functions of pomegranate towards diabetes type 2 management and 
prevention, the mechanisms need to be identified in vitro and confirmed in vivo 
especially in humans in order to render scientific support. Among other mechanisms 
proposed, carbohydrase inhibition is not mentioned as one of the possible mechanisms, 
and hence the aim of this study was to determine whether pomegranate inhibits the 
digestive enzymes α-amylase and/or α-glucosidase and therefore affects glycaemic 
response in vivo. Pomegranate extract and its major polyphenols punicalagin, gallic acid 
and punicalin were tested for α-amylase and α-glucosidase inhibition in vitro. Thereafter 
two randomized crossover studies were conducted on 16 healthy volunteers using 
pomegranate supplements (double blind) and pomegranate juice as sources of 
polyphenols independently. 
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6.2 Experimental methods 
6.2.1 Materials 
Organic pure pomegranate juice, pomegranate extract which was produced from pressed 
pomegranate residue obtained during pomegranate juice processing. It included 
membranes and remaining seed from which juice had been removed.  
Human salivary α-amylase, rat intestine powder, sucrose, maltose, D-glucose, glucose 
and fructose for human consumption, ellagic acid, punicalagin, an isomeric mixture of 
punicalagin A and B, and punicalin, a mixture of A and B, whose sources are listed in 
chapter 2.1 were used in this chapter. 
For blood glucose readings, materials used were glucometer, test strips, gloves, cotton 
balls, pricking device and lancets. 
6.2.2 Pomegranate analysis 
6.2.2.1 Polyphenol characterization by HPLC  
Polyphenol determination was carried out according to the method of (Kerimi Nyambe, 
unpublished data). Briefly juice samples were centrifuged and filtered and filtrates were 
directly injected on an Agilent 1200 HPLC system equipped with a photodiode array 
detector and an ion-trap mass spectrometer detector. Quantification of punicalin and 
punicalagin was performed at 360 nm with the calibration curve of punicalagin. Ellagic 
acid was quantified using the calibration curve of ellagic acid.  
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6.2.2.2 Sugar analysis by HPLC  
The identification and quantification of sugars in the fruits was conducted according to 
the method by (Ifie et al., 2016) on a Shimadzu HPLC instrument equipped with a model 
DGU-20 A5 degasser, a LC-20 AD XR pump system, a SIL-20 AC XR auto sampler 
(Shimadzu), column oven, a diode array detector system (SPD-M20A) and a Shimadzu 
ELSD-LTII low temperature evaporative light scattering detector. A sample volume of 
10 µL was injected, and separations were achieved on a Prevail Carbohydrate ES 5 μm 
column (250 mm x 4.6 mm). The column was held at 20 0C, and individual sugars were 
eluted isocratically using a 1 mL/min flow of 75 % acetonitrile. Solutions of standard 
sugars prepared in millipore water with concentrations between 0 and 10 mg/mL were 
used for the calibration curve. The sugars were identified by their retention time 
characteristics. Quantification was achieved using standard calibration curves obtained 
by plotting area versus concentration (R2 > 0.98). Data from the sugar analysis allowed 
balancing of the control samples for glucose and fructose naturally present in the 
pomegranate juice.  
6.2.3 Enzyme assays in vitro 
The inhibition potential of pomegranate extract on starch-digesting enzymes α-amylase 
and α-glucosidase was tested in vitro as described in chapter 2.7 and 2.8 for α-glucosidase 
and α-amylase respectively. The major polyphenols in the pomegranate juice were also 
tested in vitro for human salivary α-amylase and rat α-glucosidase. Stocks of 50 mM of 
punicalagin, punicalin and ellagic acid were prepared in 100% DMSO  and kept at -20 
C. Fresh aliquots were diluted with 50 % ethanol to the required final concentration in 
the assay. 
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6.2.4 Subjects  
Adverts were placed around the University of Leeds notice boards for the recruitment of 
volunteers and interested potential volunteers expressed their interest by means of email. 
An invitation email was then sent to them for the screening exercise for which they were 
asked to come in a fasted state. The screening and recruitment was done at the School of 
Food Science and Nutrition, University of Leeds. Pre-study questionnaires were used to 
enable the potential volunteers to assess themselves as being healthy and free of 
symptomatic diseases. They were also screened for their fasting blood glucose using a 
standard glucometer and the acceptable range was from 3.9 to 5.9 mmol/L. Other 
eligibility criteria included: Aged 18-75, apparently healthy, not diabetic, not on long 
term prescribed medication, not pregnant nor lactating, and not on a special diet (e.g. for 
losing weight or fruit supplements). For the pomegranate capsule intervention study, 16 
healthy volunteers aged 26 ± 6 y with body mass index (BMI) of 23 ± 2 kg/m2 gave their 
written informed consent and completed the 3 study visits (fig 6-1). Fasting plasma 
glucose concentrations were 4.7 ± 0.4 mmol/L. For the pomegranate juice study, 16 
volunteers aged 31 ± 5 y with BMI of 23 ± 3 kg/m2 and fasting blood glucose of 4.7 ± 
0.5 mmol/L completed the 4 study visits (fig 6-2).  
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Figure 6-1: Participant enrolment flow diagram showing the randomization of participants in groups for the allocation of the order of meals.      
It also shows the number of participants whose plasma glucose readings were used for data analysis. 
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Figure 6-2: Participant enrolment flow diagram showing the randomization of participants in groups for the allocation of the order of meals. 
It also shows the total number of participants whose plasma glucose readings were used for data analysis.
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6.2.5 Study design 
6.2.5.1 Intervention study using pomegranate capsules as source of polyphenols 
A randomized, controlled, double blinded crossover intervention was carried out and 
each volunteer attended three visits; reference (400 mg placebo capsules), test dose 1 
(200 mg placebo and 200 mg pomegranate supplement) and test dose 2 (400 mg 
pomegranate supplement). All meals contained 200 mL drinking water and 109.0 ± 1.2 
g white bread (50 g available carbohydrate as analysed by the method of (Englyst et al., 
1992) and explained in detail in chapter 2.6). Bread was consumed 5 min after taking the 
supplements to allow for dissolution of polyphenols from the capsules. The meals were 
administered in a randomized pattern as shown in figure 6-1 and a glucometer was used 
to instantly measure the blood glucose for each time point. 
6.2.5.2 Intervention study using pomegranate juice as source of polyphenols 
A randomized, controlled, crossover intervention was conducted and each volunteer had 
four visits, two of which were reference meals (200 ml drinking water with balancing 
sugars - 10.4 g glucose and 10.9 g fructose) and two were test meals of the same dose 
(200 ml pure pomegranate juice). Similarly all meals contained 109.0 ± 1.2 g white bread 
and were consumed in a randomized pattern as shown in figure 6-2. The bread and juice 
were consumed simultaneously and a glucometer was used to measure blood glucose 
concentrations at different time points.  
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6.2.6 Study protocol 
The study protocols MEEC 12-037 (amended) (appendix 2) and MEEC 14-029 
(appendix 3) were approved by the University of Leeds Faculty of Mathematics and 
Physical Sciences (MaPS) and Engineering Ethics Committee (MEEC) for the 
pomegranate supplements and juice studies respectively. They were registered with 
ClinicalTrials.gov with ID numbers NCT02486978 and NCT02624609. On each visit, 
fasting blood glucose was measured with a glucometer after finger prick and afterwards 
the volunteer consumed the meal and the timer started upon first bite or sip. The 
volunteers consumed the whole meal in less than 15 min and blood glucose was again 
measured at 15, 30, 45, 60, 90, 120, 150 and 180 min post meal consumption. Neither 
harm nor side effects were incurred during the consumption of the meals or during the 
finger prick and measurement of blood glucose.  
6.2.7 Glucose reading by glucometer  
6.2.7.1 Principle of the method  
Glucose meters or glucometers are medical devices designed for individual use by 
diabetic’s individuals for the determination of glucose concentrations in the blood. The 
glucometer uses electrochemical test strips to measure the concentration of glucose in 
the blood. A small drop of blood to be tested is placed on a disposable test strip that is 
used for the glucose measurement. Each strip contains an enzyme called glucose oxidase 
which reacts with the glucose in the blood sample to form gluconic acid. Also present in 
the testing strip is a chemical called ferricyanide which reacts with gluconic acid to form 
ferrocyanide. Ferrocyanide enables the device to run an electronic current through the 
blood sample on the strip. The current then reads the ferrocyanide and determines how 
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much glucose is in the blood sample on the testing strip and displays the concentration 
on the screen of the glucometer (Louie et al., 2000).  
6.2.7.2 Procedure 
After the volunteer is seated in a chair, with gloves on, the volunteer’s hand was 
positioned with the palm-side up. The fingertip was cleaned with a disinfection swab by 
starting in the middle and working outward to prevent contaminating the area and the 
area was allowed to dry. Thereafter pressure was applied to the selected finger to help 
the blood to flow. The finger was held and a new sterile lancet/pricking device was placed 
on the centre of the fingertip and was firmly pressed to puncture the fingertip. The first 
drop of blood was wiped out with a sterile pad or cotton ball as it may contain excess 
tissue fluid. Thereafter a drop of blood was correctly placed onto the testing strip 
(inserted into the glucometer) and the glucose concentration was read and recorded. A 
cotton wool ball or pad was placed over the puncture site and the volunteer held it for a 
few minutes to stop any bleeding. If need be, a plaster could be placed afterwards. 
6.2.7.3 Glucometer validation  
During the intervention study using PFRF mixture (chapter 5), a glucometer was used 
for blood glucose readings from potential volunteers during the screening exercise. For 
each volunteer, 3 readings were obtained. Thereafter, each volunteer attended 4 visits 
and each time fasting blood was collected and later analysed for glucose concentration 
using the hexokinase assay. The hexokinase assay results and glucometer readings were 
tabulated and the average of all the fasting blood glucose readings obtained from both 
the glucometer and hexokinase assay was calculated and standard deviations for each 
volunteer was approximately ±0.1 which is an acceptable deviation (table 6-1).  
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Even if the use of a glucometer is a different method to the hexokinase assay for the 
determination of blood/plasma glucose, due to the fact that they are based on different 
enzymes (glucose oxidase and hexokinase) the fasting glucose results were comparable 
as shown in table 6-1 and hence it was decided to use the glucometer in this intervention 
study. 
Volunteer code Glucose concentration (mmol/L) Average 
of all 
(mmol/L) 
SD 
Hexokinase results Glucometer 
readings 
1 4.1 4.1 4.3 4.3 4.4 4.3 4.4 4.3 0.058 
2 5.5 5.2 5.2 4.8 5.3 5.1 5.2 5.2 0.100 
3 4.4 4.2 4.6 5.0 5.3 5.1 5 4.8 0.153 
4 4.7 4.0 4.5 5.0 4.9 5 5 4.7 0.058 
5 4.3 4.4 4.3 4.2 4.5 4.6 4.6 4.4 0.058 
6 5.5 4.8 4.9 4.8 5.4 5.5 5.4 5.2 0.058 
7 4.7 4.9 4.7 5.0 5 5.3 5.1 5.0 0.153 
8 5.2 4.9 4.9 4.8 5 5 4.9 5.0 0.058 
9 4.6 4.7 4.7 4.6 4.7 4.7 4.5 4.6 0.115 
10 4.5 4.2 4.5 4.4 4.3 4.5 4.3 4.4 0.115 
11 4.7 4.4 4.6 4.7 4.7 4.9 4.9 4.7 0.115 
12 4.4 4.0 4.1 4.9 4.3 4.4 4.3 4.3 0.058 
13 4.0 4.3 4.8 4.6 4.8 4.8 5 4.6 0.115 
14 4.4 4.6 4.6 4.8 4.6 4.8 4.6 4.6 0.115 
15 4.2 4.6 4.1 4.2 4.3 4.4 4.2 4.3 0.100 
16 4.7 4.8 5.2 4.7 5.1 5.0 5.3 5.0 0.153 
 
Table 6-1: Comparison of fasting blood glucose readings obtained on the same volunteers 
using two different methods; hexokinase n=4 and glucometer n=3. The average of the 
combination of all the fasting glucose values obtained from both methods (n=7) was 
obtained for each volunteer and SD was approximately ±0.1. 
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6.2.8 Statistical analysis 
The trial was designed to have 90 % power to detect a clinical difference of 15 % IAUC 
between test and reference meal. A power calculation was performed to determine the 
sample size required to achieve the above conditions. Estimated sample size for two-
sample comparison of means: Test Ho: m1 = m2, where m1 is the mean in population 1 
and m2 is the mean in population 2. 
Assumptions: alpha =   0.05 (two-sided), power =   0.9000, m1 = 200, m2 = 230, sd1 = 
25, sd2 = 25, n2/n1 = 1.0. Estimated required sample sizes: n1 = 15, n2 = 15 as explained 
in detail in 5.2.5. 
Since a crossover design was used, a total of 15 participants in total were required since 
each volunteer consumed both diets (control and test). The trapezoidal rule was used to 
calculate the incremental area under the glucose curves (IAUC) for each volunteer as 
described in chapter 2.1.9. Data analysis was performed by the two tailed paired T-test 
and confirmed with the one factor repeated measures analysis of variance (ANOVA). 
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6.3 Results 
6.3.1 Pomegranate analysis 
Both the pomegranate extract and juice were analysed to determine the quantities of their 
main polyphenols punicalin, punicalagin and ellagic acid (table 6-2). 
  Punicalagin  Punicalin  Ellagic 
acid 
hexose   
Ellagic 
acid 
Juice  Concentration 
(mg/L) 
61.94±0.57 357.25±1.11 14.15±0.10 23.95±0.26 
Concentration 
in juice (µM) 
57 460 30 79 
Per dose in 
200 mL juice 
(g) 
12.4 71.5 2.8 4.8 
Capsules Amount 
(mg/g) 
121 6 5.9 101 
Concentration 
in 200 mL 
millipore 
water (µM) 
221 15 64 669 
Per high dose 
of 400 mg 
capsule (mg) 
48 2.4 5.9 40.4 
 
Table 6-2: Major polyphenol content of pomegranate juice and extracts used in the 
intervention studies. Results are expressed as mean values of three replicates. 
 
The extract and juice were also analysed for sugar contents in order to use the information 
in the design of the human intervention studies test meals for purposes of balancing the 
amount of sugars in the test and control meals. Moreover, the information was necessary 
in order to remove the sugars if present for the enzyme assays as the presence of sugars 
would interfere with the results (because the end point of the assay measures the amount 
of maltose or glucose produced for the amylase and glucosidase assay respectively 
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(chapter 2.7 and 2.8). Both the juice and extract contained glucose and fructose with the 
amounts in the extract being negligible (table 6-3). 
 
  Glucose  Fructose  
Juice  Concentration (mg/mL) 
mean±SD 
51.8±0.1 54.7±0.1 
Amount per dose in 200 mL 
(g) mean±SD 
10.357±0.098 10.929±0.091 
Capsules  Concentration (mg/mL) 8.3x10-6 6.6x10-6 
Amount per high dose (400 
mg) dissolved in 200 mL 
millipore water (mg) 
3.3x10-6 2.6x10-6 
 
Table 6-3: Sugar content of pomegranate juice and extracts used in the intervention 
studies. Pomegranate capsules had very little glucose and fructose and thus was not 
corrected for in the control meal. Results are expressed as mean values of three replicates. 
6.3.2 Inhibition of α-amylase and α-glucosidase activities 
Inhibition of human salivary α-amylase and rat α-glucosidase by pomegranate extract 
was determined and dose-dependently inhibited the digestive enzymes (fig 6-3) α-
amylase, maltase and sucrase with IC50 values of 0.06±0.01, 1.0±0.1 and 1.2±0.3 mg/ml 
respectively (table 6-4). 
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Figure 6-3: Inhibition of human salivary α-amylase (■) using amylose as substrate and 
rat intestinal α-glucosidase using maltose (●) and sucrose (▲) as substrates by 
pomegranate extract.  
 
The inhibition potential of the major polyphenols in pomegranate: ellagic acid, punicalin 
and punicalagin were also determined. Punicalagin inhibited α-amylase with IC50 value 
of 9±1and Ki of 10.1±0.6 µM. Ellagic acid (26.5±0.5%) and punicalin (29.9±0.9 %) 
slightly inhibited α-amylase at 200 µM (table 6-4). Neither of the major polyphenols 
showed any inhibition towards α-glucosidase at 200 µM. 
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Enzyme IC50 (mg/ml) IC50 (µM) Inhibition at: 
 50 and 200 µM 
 Pomegranate 
extract 
Acarbose Punicalagin Punicalin Ellagic 
acid  
Amylase  0.06 ± 0.01  3.5 ± 0.2 9 ± 1 23.9±2.8 
29.9±0.9  
27.2±2.8 
26.5±0.5 
Maltase 1.0 ± 0.1 0.43 ± 0.1 NI  NI  NI  
Sucrase 1.2 ± 0.3 12 ± 2 NI  NI  NI  
 
Table 6-4: Experimental IC50 values for human salivary α-amylase using amylose as 
substrates and α-glucosidase using maltose and sucrose as substrates for acarbose and 
pomegranate extract and its major polyphenols (n=3), NI = no inhibition at 200 µM. 
Increasing the concentration for punicalin and ellagic acid 4 fold did not increase the 
inhibition for ellagic acid and only slightly for punicalin which could be indicative of 
maximum inhibition being attained. 
6.3.3 Post-prandial blood glucose – pomegranate supplements  
There was no significant difference (p > 0.05) between IAUC of the reference, low dose 
and high dose when pomegranate supplements were given (fig 6-4 and table 6-5) with 
values of 159 ± 57, 183 ± 87 and 184 ± 61 respectively. The peak glucose concentrations 
were also not significantly different (p > 0.05) with values of 6.8 ± 1, 6.8 ± 0.8 and 6.7 
± 0.9 mmol/L for reference, low dose and high dose respectively (Figure 6-4 and table 
6-5). 
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Intervention study Test meal IAUC 
(mmol/L.min) 
 
Peak glucose 
(mmol/L) 
Pomegranate 
capsules 
Reference 
 
159 ± 57 6.8 ± 1.0 
200 mg 
pomegranate 
capsules  
183 ± 87 6.8 ± 0.8 
400 mg 
pomegranate 
capsules  
184 ± 61 6.7 ± 0.9 
 
Table 6-5: Average IAUC and peak glucose concentration values for test and control 
meals for the pomegranate supplements study. All values are mean ± SD, n=3. 
 
Figure 6-4: Average glucose curves after consumption of control, test meal dose 1 and 
test meal dose 2 for 16 volunteers (A). All data points represent mean ± S.D, n=16. There 
is no significance difference (ns) between IAUC of reference meals and test meals (B) 
as well as between the peak rises in glucose concentration (C). 
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6.3.4 Post-prandial blood glucose – pomegranate juice 
Based on the in vitro data showing that punicalagin inhibited α-amylase, the hypothesis 
that this inhibition would be sufficient to affect the post-prandial response of bread as an 
added cooked starch source was tested. A randomized, controlled, crossover intervention 
was conducted on 16 healthy volunteers, and the control and treatment were both 
performed twice on the same volunteers, making a total of 4 visits for each volunteer. 
There was a significant difference (p<0.01) for both the IAUC and peak glucose 
concentration between the reference and test meal (fig 6-5 and table 6-6). Pomegranate 
juice brought about a decrease in the glucose IAUC of -33.1±18.1 % (p = 0.000005) 
n=16). No significant difference was observed between the two control meals, nor 
between the two test meals (p>0.05) (fig 6-5 and table 6-6). 
 
Intervention study 
 
 
Test meal IAUC 
(mmol/L.min) 
 
Peak glucose 
(mmol/L) 
Pomegranate juice Reference 
 
202 ± 61 7.9 ± 1.0 
Reference  
 
196 ± 69 7.8 ± 0.9 
Test (200 mL 
juice) 
 
136 ± 57 7.2 ± 1.1 
Test (200 mL 
juice) 
 
131 ± 69 7.2 ± 1.2 
 
Table 6-6: Average IAUC and peak glucose concentration values for the test and control 
meals for the pomegranate juice study. All values are mean ± SD, n=3. 
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Figure 6-5: Average glucose curves after consumption of control and test meals both 
consumed on two visits for 16 volunteers (A). All data points represent mean ± S.D, 
n=16. There is significance difference (**) between IAUC of reference meals and test 
meals (B) as well as between the peak rises in glucose concentration (C). There is no 
significance difference (ns) between the two controls meals nor between the two test 
meals. 
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6.4 Discussion 
Diabetes risk can be reduced by consumption of low glycaemic index foods and 
unavailable carbohydrates (Livesey et al., 2008a). Inhibition of carbohydrate digestive 
enzymes (α-amylase and α-glucosidase) is one of the potential mechanisms by which this 
can be achieved, and is the mechanism by which acarbose acts during the treatment of 
diabetes. Pomegranate juice reduced the glycaemic response in healthy volunteers after 
its consumption with bread. However there was no significant difference between the 
IAUC of the test meals (bread, water, low and high dose of pomegranate supplements) 
and the control meal (bread, water and placebo capsules).  
In vitro studies showed that pomegranate polyphenol punicalagin inhibited human 
salivary α-amylase enzyme and not rat α-glucosidase. The IC50 of punicalagin was very 
low (9 µM) comparable to that of acarbose (3 µM) which showed that it was the major 
α-amylase inhibitor in pomegranate. Other polyphenols punicalin and ellagic acid also 
inhibited α-amylase by 29.9±0.9 and 26.5±0.5 % respectively at 200 µM concentration.  
The concentration of punicalagin in the juice (57 µM) was about six times the IC50 
concentration and was therefore justified to use the juice in the human intervention study 
as it was more than the suggested concentrations  of at least 3 times more than the IC50 
value to allow for intestinal dilutions (Williamson, 2013). The total ellagic acid 
concentration in the juice was 109 µM and it only gave 28 % inhibition at 200 µM in 
vitro. Although punicalin was in the highest concentration in the juice of 460 µM, it only 
gave 23.9 % at 50 µM and 29.9 % inhibition at 200 µM which indicates a less inhibition 
despite a fourfold increase of punicalin concentration. Taking into consideration the 
intestinal dilutions of which the concentration of polyphenols should be at least 3 times 
more than the IC50 value (Williamson, 2013), it can be concluded that ellagic acid and 
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punicalin contributed little to the inhibition of amylase, hence making punicalagin the 
major inhibitor. However, although the three major polyphenols (punicalagin, punicalin 
and ellagic acid) did not inhibit α-glucosidase, the extract did (fig 6-3 and table 6-4). The 
inhibition could be from other polyphenols in pomegranate or contribution of each 
polyphenol combined together. Therefore the inhibition of α-glucosidase and α-amylase 
together contributed to the glucose lowering effects observed in the pomegranate juice 
intervention study. 
Although there was no significant difference in glycaemic response when the capsules 
were used in the intervention study, pomegranate extract also inhibited human salivary 
α-amylase with an IC50 value of 60 µg/ml, which is more than three times when compared 
to 2 mg/mL (400 mg in 200ml water) from the capsules, and the same applies to its 
inhibition of α-glucosidase (fig 6-3 and table 6-5). Moreover, the major human salivary 
α-amylase inhibitor, punicalagin, was at higher concentration (221 µM) compared to the 
concentration in the juice (57 µM). These results suggest that the food matrix in which 
the polyphenols are presented also has a role to play in the inhibition process. The 
observed differences in the results could be due to two possible reasons; absence of 
polyphenols in the supplements or unavailability of the polyphenols due to lack of 
stomach mixing and solubility. The former was ruled out because the amount of the 
extract and the concentration of punicalagin in the pomegranate capsules as analysed by 
HPLC were more than three times higher than the in vitro IC50 values of 60 µg/mL and 
9 µM respectively, with the latter being comparable to that of acarbose (3.5 µM) which 
is a known drug used in diabetes treatment.  The solubility or stomach mixing effects of 
the pomegranate supplements is therefore the most possible reason why no effect of 
postprandial glucose IAUC was observed because the polyphenols were not present in 
solution to inhibit the enzymes at the time of starch digestion.  
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The pomegranate juice intervention study results are in agreement with other studies on 
the anti-diabetic effects of pomegranate in which different parts (peels, seed, leaves, 
fruit) of the pomegranate plant have shown anti-diabetic properties with the effects being 
attributed to the presence of polyphenols (Banihani et al., 2013). Different doses of an 
extract from pomegranate flowers had glucose lowering effects on normal fasted rats and 
alloxan induced diabetic rats but the authors could not pinpoint the definitive mechanism 
of action (Jafri et al., 2000). They attributed the effects partly to the stimulation of insulin 
release because they compared the action observed in alloxan (which destroys β-cells) 
induced diabetic rats to the clinically used tolbutamide drug which lowers glucose levels 
by stimulating β-cells to release insulin, since the extract had a greater lowering effect 
compared to the drug tolbutamide. However due to the fact that the glucose lowering 
effect was also observed in normal rats, they suggested that the extract may also have 
effects on non-insulin dependent diabetes possibly by inducing increased peripheral 
utilization of glucose and inhibition of glucose reabsorption in the kidneys (Jafri et al., 
2000). Pomegranate seeds also dose-dependently significantly reduced glucose levels in 
rats after 2 and 12 h by 6  and 40 % with a 150 mg/kg dose, and the reduction increased 
to 7 and 47 % with 300 mg/kg and further increased to 15 and 52 % with 600 mg/kg 
extract after 2 and 12 h respectively (Das et al., 2001). There are a limited number of 
human intervention studies that have examined the health effects of pomegranate (Basu 
and Penugonda, 2009, Banihani et al., 2013). However, it was shown that pomegranate 
reduced the level of lipid peroxidation (LPO) and cellular uptake of oxidized-LDL in 
type 2 diabetes patients which plays an important role in reducing the progression of 
atherosclerosis which may lead to a heart attack or stroke (Basu and Penugonda, 2009). 
Another study showed that consumption of 40 g/day  of concentrated pomegranate juice 
for 8 weeks significantly reduced total cholesterol and low density lipoprotein-
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cholesterol (Esmaillzadeh et al., 2004) which led to a conclusion that consumption of 
concentrated pomegranate juice could modify heart disease risk factors in diabetic 
patients with hyperlipidaemia (Esmaillzadeh et al., 2004).  
Although there was no significant difference in the fasting blood glucose when capillary 
blood versus venous blood was used, this study however shows that the use of capillary 
blood as the sampling site for the determination of blood glucose compared to the vein 
(chapter 5) gives different readings at 180 minutes post meal consumption. This is 
because some of the glucose is consumed by tissue cells as it passes from the arteries, 
through the capillary bed and into the veins (Yang, 2012). This is shown in figure 5-3 
(venous blood sampling) compared to figures 6-4 and 6-5 (capillary blood sampling). 
This confirms the earlier discussion in 2.9.8 that different sites for blood sampling may 
give different glucose concentrations. Readings from the venous blood were below the 
fasting blood glucose (fig 5-3) compared to readings from the capillary which were 
almost the same or slightly above the fasting blood glucose (fig 6-4 and 6-5). Moreover, 
a glucometer tests glucose of whole blood collected from a capillary through a finger 
prick whereas glucose was determined in plasma from blood collected from the vein 
which gives a difference in source (capillary versus vein) as well as nature of the samples 
analysed (whole blood versus plasma). For purposes of comparing results, it is therefore 
important to use one method of blood sampling site and nature for both the reference and 
test meals because the primary endpoint was to compare area under the glucose curve for 
the test meals compared with reference meals. These were maintained in all the 
intervention studies in this research. Moreover, the first intervention study (chapter 5) 
was independent to the second and third (chapter 6), hence it is alright that different 
methods were used. Each method has its own advantages and disadvantages with venous 
glucose measurement being more demanding as it requires pre-analytical conditions 
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compared to capillary blood ( by use of glucometer) whereas on the other hand, venous 
blood allows for the determination of other biomarkers including hormones due to higher 
volumes. This agrees with a study by Yang, 2012 which showed that the fasting capillary 
and venous glucose concentrations did not differ but that the mean venous concentration 
was 35 % lower than that of capillary blood glucose postprandial.  
6.5 Conclusion 
Pomegranate polyphenols have potential anti-diabetic properties as they lowered the 
glycaemic response in healthy volunteers when the juice was consumed together with a 
source of starch (bread). The mechanism of action of pomegranate polyphenols is not 
fully understood (Banihani et al., 2013) and we hereby show for the first time that one 
way by which they infer glucose lowering properties is by the inhibition of the 
carbohydrate digestive enzymes α-amylase and α-glucosidase. On the other hand, 
pomegranate extract in the form of capsules did not alter the glycaemic response in 
healthy humans after consumption with bread. This could be due to delayed solubility 
and stomach mixing effects of the pomegranate supplements and hence lack of 
polyphenols at the time of starch digestion to inhibit α-amylase. Therefore the food 
matrix in which the polyphenols are presented is an important aspect to consider in the 
production of functional foods.  
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Chapter 7 . Summary discussion and 
conclusion 
7.1 Research justification and novelty 
The hypothesis that polyphenols have the potential to affect postprandial glycaemic 
response was tested. The potential of polyphenols to have a lowering effect on glucose 
and insulin after a carbohydrate-rich meal was investigated using a polyphenol and fibre-
rich food mixture in the first instance and then with a single source of polyphenols in 
different food matrices. This property of polyphenols is important in relation to the 
prevention and management of type 2 diabetes of which high postprandial glucose is a 
risk factor (Aston, 2006, Livesey et al., 2008b, A.D.A, 2015). As type 2 diabetes is on 
the rise globally (Dunstan et al., 2002, Wild et al., 2004, Shaw et al., 2010), any 
intervention that can be used to reduce the risk of developing the disease as well as its 
management in diabetic patients would save governments money to overcome the 
burden. Drugs such as acarbose are already being used in some countries for the 
management of type 2 diabetes by acting as inhibitors of carbohydrate digesting 
enzymes. However, the use of acarbose has side effects such as nausea, flatulence and 
diarrhoea (Coniff et al., 1995, Chiasson et al., 2002). Therefore, food based carbohydrase 
inhibitors like polyphenols would provide a better alternative either on their own or in 
combination with acarbose to lessen the side effects. 
The literature review (chapter 1, table 1-1) shows that different polyphenols inhibit the 
carbohydrate digesting enzymes α-amylase and α-glucosidase as well as glucose 
transporters with different inhibition potentials. A number of human intervention studies 
have been carried out with contradicting outcomes with some studies showing no 
179 
 
 
reducing effects of polyphenols on postprandial glycaemic response and a few showing 
an effect as discussed in chapter 5. This could be due to different reasons which mostly 
could be due to the study designs employed and may include: polyphenol dose, food 
matrix used and control sample used whether bread, glucose or sucrose as these may all 
affect the outcome of the study.  
In this research, human intervention studies were designed to address the above issues. 
In the first study (chapter 5) a mixture of polyphenols that have shown inhibitory 
potential towards different stages of starch digestion (α-amylase and α-glucosidase 
catalysed hydrolysis and glucose transport) in vitro was used as a source of polyphenols.  
The justification was that if the potential inhibitors of the different stages of starch 
digestion as shown by in vitro studies can be present in the polyphenol-rich mixture at 
reasonable concentrations (3 times in vitro IC50 value), they can potentially provide one 
of the highest possible inhibitions. The most important objective was to establish whether 
polyphenols have an effect on glycaemic response in vivo or not by starting with one of 
the potential highest possible inhibition due to contradicting results (some studies show 
an effect whereas some don’t show any effects) as discussed in chapter 5. If the highest 
possible combination confers no effect on glycaemic response, then a conclusion can be 
proposed that polyphenols have no effect on postprandial glucose in vivo when consumed 
together with a carbohydrate meal even if they inhibit carbohydrate digesting enzymes 
and glucose transporters in vitro. Two different doses of the polyphenol and fibre-rich 
food (PFRF) mixture were used to determine whether the inhibition was dose-dependent 
as is usually the case in vitro. This information is important for purposes of developing 
functional foods in order to have information on required dosages for different people. 
Future plans were to use single sources of polyphenols as well as different food matrices 
as a way forward in the development/identification of functional foods in the prevention 
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and treatment of type 2 diabetes. The second and third interventions were thus the use of 
pomegranate as a single source of polyphenols but in different food matrices (juice and 
capsules) to determine the effects of different food matrices on the glycaemic response 
as an important aspect to consider when developing functional foods. Pomegranate was 
used because it has been used for ages in folk medicine in the treatment of many diseases 
including type 2 diabetes. A recent review (Banihani et al., 2013) indicated that the 
mechanism of action was not clear and the present research attempted to determine 
whether inhibition of carbohydrate digesting enzymes was one of the mechanisms that 
pomegranate polyphenols act in the treatment of type 2 diabetes by carrying out in vitro 
and in vivo studies. 
Healthy volunteers were used in this research to avoid any risks if the research gave 
opposite effects which could be risky for diabetes patients if the test meals lead to high 
glycaemic response. Bread was used in order to test the inhibition of both α-amylase and 
α-glucosidase because α-amylase catalyses the hydrolysis of starch into disaccharides, 
oligosaccharides and α-limit dextrin after which α-glucosidases catalyse the hydrolysis 
of the products of α-amylase catalysed hydrolysis into glucose. For the PFRF mixture 
study, a mixture of fruits and beverage was based on a portion of fruit (100 g) and a cup 
of tea (200 mL) as well as the pomegranate juice study (glass of juice, 200 mL). The dose 
for the pomegranate capsules study was based on the commonly used dose of 2 capsules 
of 500 mg each for food supplements. In all the studies, the concentrations of polyphenols 
of interest in the food source was also accounted for to ensure that they were at least 3 
times higher than the in vitro IC50 value. This is an important aspect when in vitro studies 
results are to be used as a basis for in vivo studies because there is about 3 times dilution 
of food in vivo due to intestinal fluids produced (Williamson, 2013). 
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The novelty of this research is that this is the first study to use a mixture of polyphenols 
(PFRF) mixture which has the potential to inhibit different stages of carbohydrate 
digestion with the aim to obtain combined effects for maximum inhibition (Nyambe-
Silavwe and Williamson, 2016). Comparison of the effect of pomegranate polyphenols 
on glycaemic response as a single polyphenol source in different food matrices (juice 
and capsules) is also novel. 
7.2 Discussion of outcomes 
The major results outcome for this research are in vitro carbohydrate digesting enzymes 
inhibition by polyphenols using the α-amylase (Nyambe-Silavwe et al., 2015) and α-
glucosidase assays and the corresponding effects on glycaemic response in vivo 
(Nyambe-Silavwe and Williamson, 2016). In addition, the effect of using different food 
matrices to determine the effect of polyphenols on glycaemic response is also a major 
outcome of this research (Chapter 6 and publication in preparation). 
7.2.1 In vitro carbohydrase inhibition 
In vitro enzyme inhibition assays are in agreement with the results from the literature 
which show that different polyphenols have different enzyme inhibition potentials 
(chapter 1, table 1-1). However, results were very incomparable due to a number of 
reasons. As discussed by Nyambe-Silavwe et al. (2015), this could have been due to 
many reasons including differences in inhibition methods. For α-amylase using the 
dinitrosalicylic acid (DNS) detection method, the differences observed were due to type 
and concentration of substrate or enzyme, reaction time, and whether polyphenols react 
with DNS or not which results in false results. The α-amylase inhibition assay was 
optimized as discussed in chapter 2 and in Nyambe-Silavwe et al. (2015) in order to 
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highlight the important aspects to consider in enzyme inhibition assays for purposes of  
conducting the assays and reporting results in a manner that will enable comparison with 
the literature. The primary outcome of the optimization was that when reporting 
inhibition results, all the conditions which were used for the inhibition assays should be 
recorded and optimized conditions should be used in order to have correct interpretation 
of the results. Moreover, in cases where polyphenols react with the detection reagent 
DNS, an additional step should be included just before using DNS to remove polyphenols 
(solid phase extraction) from the reaction sample.  Another important conclusion was 
that for pure compounds, results should be reported as Ki values instead of IC50 values 
as the Ki values do not depend on the assay conditions but it gives comparable results 
independent of inhibition mode, substrate and detection method. 
From all the polyphenols analysed in this research, EGCG and punicalagin had the 
highest inhibition towards salivary amylase with IC50 values of 5.3±0.6 and 9±1 µM 
respectively, and are both very comparable to that of acarbose (3.5±0.3 µM). EGCG also 
gave the highest inhibition with IC50 of 14 µM towards α-glucosidase using maltose as 
substrate. Among the fruit extracts, blackberry had the highest inhibition against salivary 
α-amylase followed by blackcurrant and strawberry. Green tea was the only PFRF 
constituent that inhibited α-glucosidase with IC50 values of 0.035±0.005, 2.02±0.01 and 
2.31±0.02 mg/mL for maltase, iso-maltase and sucrase respectively. Pomegranate extract 
also showed inhibition towards α-glucosidase with IC50 value of 1.0±0.1 and 1.2±0.3 
mg/mL for maltase and sucrase respectively. A number of studies have reported the 
possible mechanisms of action of α-amylase inhibition by polyphenols with the most 
common being via hydrogen bonding between the hydroxyl groups of polyphenols and 
the catalytic residues of the binding sites of the enzyme (Tadera et al., 2006, Lo Piparo 
et al., 2008, Xiao et al., 2013). Computational ligand docking was used to determine the 
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structure-activity relationships of polyphenols in inhibiting α-amylase (Lo Piparo et al., 
2008) and the inhibitory activity of flavonoids was attributed to; the presence of hydroxyl 
groups in particular positions in their structures which results in formation of hydrogen 
bonds with the enzymes binding site side chains of Asparagin197 and Glutamine233 as 
well as the formation of a conjugated π-system between the indole Tryptophan59 and the 
heterocyclic ring (AC) or B-ring of the flavonoids (Lo Piparo et al., 2008). Higher 
inhibition was obtained with galloylated than non galloylated catechins (Xiao et al., 
2013) as validated in this study with EGCG. Ellagitannins are also said to be good 
inhibitors if highly hydroxylated and the presesnce of β-galloyl groups at glucose C-1 
positions (Xiao et al., 2013) as validated in this research by punicalagin. The 
glycosylation of flavonoids also plays a role in the inhibition potential against amylase 
depending on the conjugation site and the sugar moiety. Other structural properties that 
influence inhibition potential include methoxylation and methylation of flavonoids (Lo 
Piparo et al., 2008 and Xiao et al., 2013) as this reduces the number of hydrogen bonds 
that may be formed with the amino acids of the binding site. This agrees with others who 
also showed that the potency of inhibition correlated with the number of hydroxyl groups 
on the B ring of the flavonoids (Tadera et al., 2006). 
7.2.2 Human intervention studies 
This research has shown that polyphenols and possibly other components like fibre found 
in fruits have an effect on glycaemic response in healthy volunteers. The important 
outcomes that arose from this research include; dose dependence effects (PFRF), food 
matrix in which the polyphenols are presented (pomegranate polyphenols study) and 
inter-individual variations (both studies). 
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7.2.2.1 PFRF as source of polyphenols 
The effect of dose on glycaemic response was observed in the intervention study with 
the higher dose giving a greater decrease in glycaemic response. This supports the 
proposal that the inhibition of digestive enzymes and glucose transporters by polyphenols 
contributed highly to the observed reduced glycaemic response when a PFRF was 
consumed by healthy volunteers together with bread. This is because in vitro results 
showed that different polyphenol concentrations have different inhibition effects on 
carbohydrate digestive enzymes. The pattern usually follows an inhibition curve where 
inhibition increases with increasing polyphenol concentration until maximum inhibition 
is reached, after which an increase in concentration gives no further increase in inhibition 
as shown in the inhibition curves in the previous chapters (4 and 6). 
In the production of functional foods, this information is important in order to avoid the 
use of either too low a dose will not be enough to give any significant effects as well as 
too high a dose that does not offer more inhibition potential after maximum inhibition is 
achieved. Instead, inhibition can be increased by combining different polyphenol sources 
with different inhibition targets (α-amylase, α-glucosidase or glucose transporters) which 
was the aim of this study. However, even with the use of a combination of different 
polyphenols to potentially increase the inhibition outcome, a maximum inhibition is still 
expected as all individual polyphenols also reach their maximum inhibition. It is also 
important to ensure that polyphenol sources used show inhibition effects in vitro for them 
to have an effect in vivo. For this research all the polyphenol sources used, were in 
concentrations high enough in concentrations that were at least 3 times higher than the 
IC50 value (Williamson, 2013). 
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7.2.2.2 Pomegranate as source of polyphenols 
This research has shown that the food matrix in which the polyphenols are presented also 
plays a role in the determination of inhibiting potential of polyphenols on carbohydrate 
digestion and glucose transport. Polyphenols need to be in a soluble state in order to 
interact with digestive enzymes and glucose transporters to inhibit their activities. The 
use of pomegranate polyphenols in the form of capsules did not show any inhibition 
properties to the digestive enzymes even though the pomegranate extract gave very high 
inhibition with IC50 value (0.06±0.01 mg/mL) and its main inhibitor punicalagin having 
an IC50 value (9 ± 1 µM) very close to that of acarbose (3.5 ± 0.2 µM) in vitro. However, 
the use of pomegranate juice as a source of polyphenols in the determination of their 
effect on glycaemic response showed a reduced glycaemic response when comparing the 
test (pomegranate juice and bread) and the control (bread and balancing sugars). The 
major difference between the two food matrices was that the polyphenols were already 
in solution in the pomegranate juice compared to polyphenols in the pomegranate 
capsules. This entails that polyphenols were readily available in the juice to interact with 
digestive enzymes which they inhibited. The capsules on the other hand did not provide 
polyphenols readily as the capsules needed to be dissolved first, followed by dissolution 
of the pomegranate powder inside the capsules which would then be available to inhibit 
the enzymes. Without the knowledge of how long this process takes place and in which 
part of the digestive tract, may indicate that the polyphenols where not available at the 
time they needed to be present in the small intestine. 
The use of pomegranate juice also shows that polyphenols reduced the glycaemic 
response in healthy volunteers after a meal with white bread even in the absence of fibre 
compared to the PFRF mixture which had some fibre from the fruits which indicates that 
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polyphenols played a major role and they have the potential to be used as functional 
foods in the prevention and management of type 2 diabetes with or without fibre. 
7.2.2.3 Interpersonal variations 
In all the three intervention studies (PFRF mixture, pomegranate capsules and 
pomegranate juice), there was high variability between volunteers (chapters 5 and 6). 
This agrees with a recent study (Zeevi et al., 2015) which validates the accuracy of this 
data. Their study reported high variability in glycaemic response after consuming 
identical meals in an 800 person cohort of healthy and pre-diabetic volunteers in a total 
of 46,898 meals. However for the repeated tests, there was no intrapersonal variations 
observed which also agrees with the present study results as shown by lack of significant 
difference between the repeated meals (reference meals in the PFRF mixture study and 
both reference and test meals in the pomegranate juice studies) which further validates 
the accuracy and reproducibility of the present research data. This aspect is important in 
the formulation of functional foods as some individuals need higher doses compared to 
others who may get an effect without increasing the dose. The differences could be due 
to many reasons with individual insulin sensitivity and enzyme concentrations being 
some of the reasons as discussed in chapter 6. Other possible reasons as reported by 
(Zeevi et al., 2015) include; genetics, glucose transporters activity levels, lifestyle and 
possibly gut microbiota. Because depending on the baseline microbiota composition of 
an individual, certain effects are expected such as the Anaerostipes genus being 
associated with improved glucose tolerance when present in low levels (Everard et al., 
2011) and both low levels of the Bacteroidetes phylum (Turnbaugh et al., 2009) and 
Alistipes putredinis species (Ridaura et al., 2013) are associated with obesity which is a 
risk factor for type 2 diabetes. Lifestyle can affect postprandial glycaemic response by 
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consistently changing the microbiota composition when consistently consuming bad diet 
(high sugar and fat) (Zeevi et al., 2015). 
7.3 Overall conclusion and future perspectives 
Polyphenols found in fruits (apple, blackberry, blackcurrant, strawberry) also containing 
fibre and green tea (PFRF) mixture significantly reduced the glycaemic response of 
healthy humans by acting in synergy by inhibiting carbohydrate digesting enzymes (α-
amylase and α-glucosidase) and glucose transporters. Polyphenols played a major role 
compared to fibre because when pomegranate juice was used in the intervention study 
(chapter 6) as a source of polyphenols instead of the PFRF mixture (chapter 5), reduced 
postprandial blood glucose was also observed despite the absence of fibre.  
The use of pomegranate as a single source of polyphenols showed that the food matrix 
in which the polyphenols are present plays a major role in the observed outcomes as the 
polyphenols need to be in a soluble state in order to interact with their inhibition targets. 
Polyphenols have the potential to be used in the prevention and management of type 2 
diabetes and functional foods should be developed either on their own or in combination 
with drugs for this purpose. However lifestyle changes such as weight loss and physical 
activity also need to be present in order to achieve the benefits. Moreover, due to 
interpersonal variations observed, personalized doses should be utilized upon 
determination of individual glycaemic responses which may pose a challenge. 
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The objectives of this research have been achieved and they are: 
 Overall the effects of polyphenols on glycaemic response in healthy volunteers 
when consumed together with bread (high glycaemic index food) have been determined 
and polyphenols have a reducing effect on the postprandial blood glucose and insulin. 
 Specifically, the PFRF mixture containing sources of polyphenols with the 
potential to inhibit different stages of carbohydrate digestion produced a significant 
decrease on the postprandial blood glucose and insulin. 
 Increasing the dose of polyphenol sources in the test meals gave lower 
postprandial blood glucose compared to the first dose in healthy volunteers.  
 Food matrix in which the polyphenols are present in the polyphenol source play 
a role in the glycaemic response observed. 
On the basis of the results of this research, more research should be carried out with 
different combinations of polyphenol sources as well as single sources to have a variety 
of combinations for the development of functional foods. Most importantly, future 
intervention studies should include pre-diabetic and diabetic volunteers to determine 
whether the observed beneficial effects of polyphenols on glycaemic response in healthy 
volunteers would be the same in the named groups that need the interventions the most. 
Although no side effects were observed in healthy volunteers, more studies on healthy 
volunteers need to be done to ensure their safety in pre-diabetic and type 2 diabetic 
volunteers. 
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UNIVERSITY OF LEEDS RESEARCH ETHICS COMMITTEE 
APPLICATION FORM 1 
 
Please read each question carefully, taking note of instructions and completing all parts. 
If a question is not applicable please indicate so. The superscripted numbers refer to 
sections of the guidance notes, available at www.leeds.ac.uk/ethics. Where a question 
asks for information which you have previously provided in answer to another question, 
please just refer to your earlier answer rather than repeating information.  
Research ethics training courses: http://www.sddu.leeds.ac.uk/sddu-research-ethics-
courses.html  
To help us process your application enter the following reference numbers, if known and 
if applicable: 
Ethics reference number: MEEC 12-037 
Grant reference and/ or student 
number: 
200358739 
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PART A: Summary 
 
A.1 Which Faculty Research Ethics Committee would you like to consider this 
application?2  
 
 
 
 
 
 
 
 
 
 
A.2 Title of the research3  
Effects of polyphenols on carbohydrase-inhibiting polyphenols on glycaemic 
response. 
 
A.3  Principal investigator’s contact details4 
Name (Title, first name, 
surname) 
Ms Hilda Nyambe 
Position Provisional PhD Student 
Department/ School/ Institute School of Food Science and Nutrition 
Faculty MAPS 
Work address (including 
postcode) 
School of Food Science and Nutrition, University of 
Leeds, LS2 9JT 
Telephone number 07415780195 
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University of Leeds email 
address 
fs07hs@leeds.ac.uk 
 
A.4 Purpose of the research:5 (Tick as appropriate) 
 Research 
 Educational qualification:  Please specify: __Doctor of 
Philosophy_____________________ 
 Educational Research & Evaluation6 
 Medical Audit or Health Service Evaluation7 
 Other 
 
 
A.5 Select from the list below to describe your research: (You may select more 
than one) 
 Research on or with human participants 
 Research with has potential significant environmental impact.8  If yes, 
please give details: 
  
 Research working with data of human participants 
 New data collected by questionnaires/interviews 
 New data collected by qualitative methods 
 New data collected from observing individuals or populations 
 Research working with aggregated or population data 
 Research using already published data or data in the public domain 
 Research working with human tissue samples9 
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A.6 Will the research involve any of the following:10 (You may select more than 
one) 
 
If your research involves any of the following an application must be made to the 
National Research Ethics Service (NRES) via IRAS www.myresearchproject.org.uk 
as NHS ethical approval will be required. There is no need to complete any more of 
this form. Contact governance-ethics@leeds.ac.uk for advice.  
 Patients and users of the NHS (including NHS patients treated in the private 
sector)11 
 Individuals identified as potential participants because of their status as 
relatives or carers of  patients and users of the NHS 
 Research involving adults in Scotland, Wales or England who lack the 
capacity to consent for themselves12 
 A prison or a young offender institution in England and Wales (and is health 
related)14 
 Clinical trial of a medicinal product or medical device15 
 Access to data, organs or other bodily material of past and present NHS 
patients9 
 Use of human tissue (including non-NHS sources) where the collection is 
not covered by a Human Tissue Authority licence9 
 Foetal material and IVF involving NHS patients 
 The recently deceased under NHS care 
 None of the above 
You must inform the Research Ethics Administrator of your NRES number 
and approval date once approval has been obtained.  
 
If the University of Leeds is not the Lead Institution, or approval has been granted 
elsewhere (e.g. NHS) then you should contact the local Research Ethics Committee for 
guidance.  The UoL Ethics Committee need to be assured that any relevant local 
ethical issues have been addressed.  
 
A.7 Will the research involve NHS staff recruited as potential research 
participants (by virtue of their professional role) or NHS premises/ facilities? 
Yes       No         
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If yes, ethical approval must be sought from the University of Leeds. Please note that 
NHS R&D approval is needed in addition, and can be applied for concurrently: 
www.myresearchproject.org.uk.  
Contact governance-ethics@leeds.ac.uk for advice.  
 
 
A.8 Will the participants be from any of the following groups? (Tick as 
appropriate) 
 Children under 1616 
 Adults with learning disabilities12 
 Adults with other forms of mental incapacity or mental illness 
 Adults in emergency situations 
 Prisoners or young offenders14 
 Those who could be considered to have a particularly dependent relationship 
with the investigator, eg members of staff, students17 
 Other vulnerable groups 
 No participants from any of the above groups 
Please justify the inclusion of the above groups, explaining why the research cannot 
be conducted on non vulnerable groups. 
Since adverts will be put around the University campus notice boards, it is very likely 
that students and members of staff may be recruited for the study as they are normally 
around the University campus. This will make it convenient to use students or 
members of staff as there will be no need to travel to get to the School of Food Science 
and Nutrition as they will already be on campus for work or for studies. 
However, participation will be purely voluntary and the participants will not be 
approached directly or forced to take part. If they so wish, they can withdraw from 
participating at any time. 
A Criminal Record Bureau (CRB) check will be needed for researchers working with 
children or vulnerable adults (see www.crb.gov.uk and 
http://store.leeds.ac.uk/browse/extra_info.asp?modid=1&prodid=2162&deptid=34
&compid=1&prodvarid=0&catid=243)  
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A.9 Give a short summary of the research18  
This section must be completed in language comprehensible to the lay person.  Do 
not simply reproduce or refer to the protocol, although the protocol can also be 
submitted to provide any technical information that you think the ethics committee may 
require. This section should cover the main parts of the proposal. 
Consumption of carbohydrate containing foods or sugary drinks brings about changes 
to the blood glucose levels. After a meal or drink, blood glucose levels rise until it 
reaches a peak concentration usually after 30 minutes. When the body senses the 
increase in blood glucose, a hormonal process involving insulin takes place to ensure 
that the glucose is taken up from the blood for storage and where it is needed for energy 
in the body. This process then brings about a decrease in the concentration of glucose 
until it reaches approximately the starting concentration. The original concentration of 
glucose is attained approximately 2 hours after eating or drinking a carbohydrate food 
or sugary drink respectively. 
Different carbohydrates and sugary drinks have different effects on blood glucose 
response depending on the amount as well as the type of carbohydrate. Those that give 
rise to a high glucose response compared to a reference carbohydrate (usually glucose) 
are said to be high glycaemic index (GI) foods and those with a lower glucose response 
compared to a reference carbohydrate (usually glucose) are said to be low glycaemic 
index (GI) foods (Jenkins et al., 2002). 
Research has shown that diets that give rise to a high glucose response are associated 
with a number of abnormalities like increased metabolic syndrome (Aston, 2006). 
Metabolic syndrome mostly comprises of insulin resistance and glucose intolerance 
which gives an increased risk of type 2 diabetes (McKeown et al., 2004) It also gives 
rise to other conditions like high blood pressure (arterial hypertension), elevated blood 
insulin levels (hyper-insulinemia), elevated amounts of fat in the liver (fatty hepatosis) 
and elevated amounts of lipids in the blood (dyslipidemia). After type 2 diabetes 
become clinically apparent, the risk of cardiovascular disease also rises (Beilby, 2004). 
Research has also shown that foods/drinks which raise blood glucose levels gradually 
(low GI) rather than rapidly (high GI) have health benefits which include reducing the 
risk of metabolic syndrome (Barclay et al., 2008). In vitro studies have shown that 
polyphenols found in fruits, vegetables and plant based foods have a positive effect on 
carbohydrate metabolism and can lower the blood glucose levels (Hanhineva et al., 
2010). 
This research will determine whether the presence of polyphenols in the diet has any 
lowering effect on the blood glucose levels and hence the glycaemic index of foods. 
This will be determined by asking volunteers to consume polyphenol rich drink/food 
together with white bread and determine the glycaemic response. The GI of bread will 
be determined initially as a reference. 
Analysis will be done by measuring blood glucose response to white bread alone as 
reference and then to white bread with test sample containing polyphenols and then 
determine GI and see how the GI of bread will be affected. Other analyses to be done 
are plasma insulin, glucagon, gastric inhibitory polypeptide (GIP) and glucagon like 
peptides-1 (GLP-1) as they all relate to glycaemic response. 
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A.10 What are the main ethical issues with the research and how will these be 
addressed?19 
Indicate any issues on which you would welcome advice from the ethics committee. 
Participation of human volunteers addressed by informed consent 
Prior to commencement of the study, potential volunteers will be given a clear, concise 
Participant Information Sheet (appendix 1) and Informed Consent Form (appendix 2) 
by the investigator to read, complete and sign in their own time. The investigator will 
answer all questions to the satisfaction of the individual and will not influence the 
decision of taking part in the study. The participants will be free to withdraw from the 
study at any point without providing a reason. The written consent form will be signed 
and dated at least 2 days prior to enrolment in the study by the volunteers and the 
Investigator. It will be photocopied and one copy will be kept by the Investigator (for 
the study records) and one by the volunteer. Participation by the volunteers is 
conditional upon receiving the written consent by the volunteer.  
Gathering of personal data addressed by confidentiality and data protection  
Candidates will be asked to complete a questionnaire (appendix 3) in order to assess 
their suitability for the study. The information pertains to their lifestyle and may be 
considered a sensitive issue, however each volunteer will be assured of confidentiality 
and that participation is entirely voluntary. The information on the questionnaire will 
include height, weight, gender, age and relevant medical history.  
Confidentiality of all participants’ information will be maintained. Identification will 
be coded using random ID numbers that will be assigned on the day of study. All data 
collected will be treated as confidential and stored securely in a locked filling cabinet 
according to current University regulations. The linkage between individual identity 
and ID number will be kept in written form only and stored in a locked filling cabinet 
in a restricted access area, thus it will not be possible to identify individual participants 
from the ID numbers. Data evaluation will only be performed using ID numbers. In 
accordance with the University guidelines on the password protected M-drive of the 
University server, anonymised data will be stored for at least 5 years. 
Blood sample collection addressed by presence of experienced nurse 
To minimise any risk linked to venous blood collection, an experienced nurse will be 
present during the study to draw the venous blood (4 ml) samples from the elbow pit 
using a cannula. The use of a cannula will avoid the repeated insertion of a needle at 
every withdrawal. Capillary blood samples (200 µl) will be collected from participants 
by means of a finger prick using a sterile puncture device designed for this purpose for 
each time point. The finger prick protocol is the WHO/FAO 1998 glycaemic index 
approved protocol. Moreover research has shown that for blood glucose 
measurements, fingertip capillary blood is recommended as it is sensitive to changes 
in blood glucose concentrations compared to other sites. This is crucial due to the 
nature of the study design as blood will be collected at different times and hence we 
aim to get the real blood glucose concentration for each time point. It has been reported 
that the blood glucose concentrations are higher in the fingertip capillary than in other 
sites when blood glucose rise. In the same way when blood glucose concentrations 
fall, the concentrations in the fingertip capillary is lower than in other sites (Ellison, et 
al., 2002 and Van Der Valk, et al., 2002). Moreover, there is controversy on this issue 
as other researchers like Yang et al., 2012 have reported that the venous blood is better 
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for glucose analysis. We therefore aim to compare the results as well so that we can 
contribute to the knowledge about this issue. 
For finger prick, since 7 points will be needed (0, 15, 30, 45, 60, 90, 120) thus we will 
aim to prick one finger once per session. An allowance of only two visits per week 
will also help in the healing of the pricks as well as one week rest after the 2 visits/ 
before the last 2 visits. 
The analyses of the blood samples will be blood glucose, insulin, glucagon, GIP and 
GLP-1 concentrations. Blood collected from the participants will be rendered acellular 
within 1 hour of collection before storage. For the standard protocol being used for 
removing cellular debris, see Appendix 4. 
Ethics Committee Approval 
This human study protocol will be submitted to the Faculty of Mathematics and 
Physical Sciences Ethics committee at the University of Leeds, UK. 
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PART B: About the research team 
B.1  To be completed by students only20 
Qualification working 
towards (eg Masters, PhD) 
PhD 
Supervisor’s name (Title, 
first name, surname) 
Professor Gary Williamson 
Department/ School/ 
Institute 
School of Food Science and Nutrition 
Faculty MAPS 
Work address (including 
postcode) 
School of Food Science & Nutrition, University of 
Leeds, LS2 9JT 
Supervisor’s telephone 
number 
0113 343 8380 
Supervisor’s email address g.williamson@leeds.ac.uk 
Module name and number (if 
applicable) 
 
 
B.2  Other members of the research team (eg co-investigators, co-supervisors) 21 
Name (Title, first name, 
surname) 
 
Position  
Department/ School/ Institute  
Faculty  
Work address (including 
postcode) 
 
Telephone number 
Email address 
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Part C: The research 
C.1 What are the aims of the study?22 (Must be in language comprehensible to a lay 
person.) 
1. To determine the effects of polyphenol rich mixture/food on glycaemic 
index and glycaemic response. 
2. To determine the effect of different doses of polyphenol rich mixture on 
postprandial plasma glucose, insulin, glucagon, GIP and GLP-1 responses 
of healthy humans and humans with metabolic syndrome. 
 
C.2 Describe the design of the research. Qualitative methods as well as 
quantitative methods should be included. (Must be in language comprehensible to 
a lay person.) 
It is important that the study can provide information about the aims that it intends to 
address. If a study cannot answer the questions/ add to the knowledge base that it 
intends to, due to the way that it is designed, then wasting participants’ time could be 
an ethical issue. 
Subject preparation 
Unusual vigorous activity should be avoided and subjects should eat a meal of their 
choice the evening before the test and should eat the same meal the day before each 
test. 
 
Study Design 
  
A minimum of 10 subjects per group will be recruited most likely 12 participants will 
be recruited. The first group will be healthy individuals and the second will be those 
with metabolic syndrome. The study will involve 4 visits with each visit not lasting 
more than 4 hours.  
 
Subjects will be expected to arrive at the school of food science and nutrition in the 
morning before 10 am after an overnight fast of between 10-14 hours. They will be 
asked to rest for 10 minutes during which they can report on what they had the previous 
evening prior to the fast. Body weight, height and blood pressure measurements will 
also be taken. Thereafter, a cannula will be inserted by a nurse in the participants elbow 
pit to avoid the use of a needle for every blood withdrawal. After the participant rests 
for another 5 minutes, the fasting capillary and venous blood samples will be collected. 
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The subject will then be asked to eat or drink the food test sample as shown in the 
appendix 5. Then about 200 µl capillary blood and 4 ml venous blood will be drawn 
at 15, 30, 45, 60, 90, 120, 150 and 180 minutes post consumption of the test food. 
 
The Latin square design will be used to randomize which test food will be consumed 
by which volunteer on different days as shown in appendix 5. However the first and 
last visit will be the same for everyone as it will be the reference test (bread, natural 
yoghurt and water). 
 
Sample analysis 
For glucose analysis, blood samples will be collected in glucose preservation 
fluoride/oxalate tubes and placed on ice until they are centrifuged within 30 minutes. 
Centrifugation will be done at 3,500g at 4°C for 10 minutes. The acellular plasma 
fraction will be collected and stored in micro centrifuge tubes at -80°C until required 
for analysis. The hexokinase assay (commercially available kit and is commonly used) 
will be used to determine glucose concentration in the plasma samples. The cells in 
the cellular fraction will be destroyed by treating them with a disinfectant using the 
guidelines from the manufacturer.  
For the analysis of insulin, glucagon, GIP, GLP-1, blood samples will be collected in 
heparinised tubes and immediately placed on ice until they are centrifuged within 30 
minutes. Centrifugation will be done at 3,500g at 4°C for 10 minutes. The acellular 
plasma fraction will be collected and stored in micro centrifuge tubes at -80°C until 
required for analysis. Elisa assay kits (commercially available kits) will be used for 
plasma insulin, glucagon, GIP and GLP-1 measurements. 
 
Statistical analysis  
For each time point, blood glucose, insulin, glucagon, GIP and GLP-1 concentration 
will be analysed to show whether there is any significant difference with that of the 
reference by using the Students T-test. This will also be done for the different study 
groups. 
Polyphenol analysis 
The amount of polyphenols present in the test foods will be analysed by the Folin-
Ciocalteu assay and by high performance liquid chromatography (HPLC) 
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C.3 What will participants be asked to do in the study?23
 
(e.g. number of visits, 
time, travel required, interviews) 
 
What will participants be asked to do in the study 
 
Participants will be asked to complete a pre study questionnaire (appendix 3) to 
determine their suitability for the study as well as have their fasting glucose checked 
using a glucometer. Then if they qualify, they will be asked to complete the consent 
form. (Appendix 2) 
 
The study is to be done over 4 visits with each visit not lasting more than 4 hours. 
Preferably twice a week according to which days are convenient for the volunteer but 
with at least one day in between the two visits. With one week washout period in 
between the two weeks, gives a total of three weeks. 
 
Subjects will be expected to arrive at the school of food science and nutrition in the 
morning before 10 am after an overnight fast of between 10-14 hours. The participants 
will be asked to have a meal of their choice the night before the study day but should 
consume the same meal on all the days and a record of what they eat should be availed. 
They will be asked to rest for 10 minutes during which they can report on what they 
had the previous evening prior to the fast. Body weight, height and blood pressure 
measurements will also be taken. Thereafter, a cannula will be inserted by a nurse in 
the participants elbow pit to avoid the use of a needle for every blood withdrawal. 
After the participant rests for another 5 minutes, fasting venous and capillary blood 
samples will be collected. 
 
The subject will then be asked to eat or drink the food test sample as shown in the 
appendix 6. Then about 200 µl capillary blood and 4 ml venous blood will be drawn 
at 15, 30, 45, 60, 90, 120, 150 and 180 minutes post consumption of the test. 
 
 
C.4 Does the research involve an international collaborator or research 
conducted overseas:24 
(Tick as appropriate)  
Yes       No 
If yes, describe any ethical review procedures that you will need to comply with 
in that country: 
 
Describe the measures you have taken to comply with these: 
Include copies of any ethical approval letters/ certificates with your application. 
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C.5 Proposed study dates and duration  
Research start date (DD/MM/YY): As soon as ethical approval is obtained. 
 Research end date (DD/MM/YY): 31/09/2016 
 
Fieldwork start date (DD/MM/YY):  
Fieldwork end date (DD/MM/YY):  
 
 
C.6. Where will the research be undertaken? (i.e. in the street, on UoL premises, in 
schools)25 
 On University of Leeds premises. 
 
 
RECRUITMENT & CONSENT PROCESSES 
How participants are recruited is important to ensure that they are not induced or 
coerced into participation. The way participants are identified may have a bearing on 
whether the results can be generalised. Explain each point and give details for 
subgroups separately if appropriate. 
C.7 How will potential participants in the study be:  
(i) identified? 
 
Codes will be used to identify individual subjects and no personal details will be 
referred to in this study as reported in A10. Personal details will only be used to check 
suitability at the recruitment stage. 
 
During the first contact with the potential participant, the main investigator will assign 
a code number to the participant which will be used to identify the participant 
throughout the study. An intermediate person who will never have any contact with 
the participants will be matching the names and give the corresponding codes to the 
Investigator. 
 
(ii) approached?  
 
Advertisements (appendix 6) in the form of posters and emails to the staff and students 
in the school of Food Science and Nutrition as well as other parts of the University of 
Leeds campus will be used. 
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(iii) recruited?26 
 Subjects will be recruited from the university of Leeds staff and Students. Written 
informed consent will be obtained from the volunteers and participation can be 
withdrawn at any time without giving a reason. 
 
 
C.8 Will you be excluding any groups of people, and if so what is the rationale for 
that?27 
Excluding certain groups of people, intentionally or unintentionally may be unethical 
in some circumstances.  It may be wholly appropriate to exclude groups of people in 
other cases 
Selection criteria is shown in appendix  
 
 
Group 1 – Healthy subjects 
 
Not diabetic 
Fasting glucose (blood glucose level before breakfast) 3.9-5.9 mmol/L  
Not on long term prescribed medication (except contraceptives) 
Not pregnant or lactating 
Not on special diet (for losing weight or fruit extracts supplements) 
Aged 18-75 
 
Group 2 – Metabolic syndrome risk group 
 
Not diabetic 
With fasting glucose (blood glucose level before breakfast) in the range of 6.0 – 8.0mmol/l  
Not on long term prescribed medication (except contraceptives) 
Not pregnant or lactating 
Not on special diet (for losing weight or fruit extracts) 
Aged 18-75 
C.9 How many participants will be recruited and how was the number decided 
upon?28 
It is important to ensure that enough participants are recruited to be able to answer 
the aims of the research. 
 
According to a review on Glycaemic index methodology by Brouns et al., 2005, which 
looked at a number of papers on glycaemic index methodology, the conclusion was 
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that a minimum of 10 subjects is required for such type of study for each group and so 
will use 12-15 to allow for volunteers who may discontinue. 
 
From experience in the school from previous human studies, the number suggested 
above is achievable and in the rare case that it’s not achieved, recruitment will continue 
until the required number is obtained as the study is only 3 weeks in total per 
participant and so can be done at any time of the recruitment process. 
 
If you have a formal power calculation please replicate it here. 
Remember to include all advertising material (posters, emails etc) as part of your 
application 
 
C10 Will the research involve any element of deception?29  
If yes, please describe why this is necessary and whether participants will be informed 
at the end of the study. 
No 
 
C.11 Will informed consent be obtained from the research participants?30  
Yes       No 
If yes, give details of how it will be done. Give details of any particular steps to 
provide information (in addition to a written information sheet) e.g. videos, 
interactive material. If you are not going to be obtaining informed consent you will 
need to justify this.  
Volunteers will receive a participant information sheet and informed consent form 
after a positive reply to the recruitment advertisement. Volunteers will consent in 
writing prior to commencement of the study. The main investigator will verbally 
explain the participant information sheet and informed consent form and questions 
from the volunteer will be answered at any time. The prospective participant will have 
1-2 days prior to commencement of the study to decide, sign and return the completed 
informed consent form (two copies where one copy remains with the participant and 
the other copy for the research records) both to be co-signed by the main investigator. 
 
If participants are to be recruited from any of potentially vulnerable groups, give 
details of extra steps taken to assure their protection. Describe any arrangements to 
be made for obtaining consent from a legal representative. 
 
Copies of any written consent form, written information and all other explanatory 
material should accompany this application. The information sheet should make 
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explicit that participants can withdraw from the research at any time, if the research 
design permits.  
Sample information sheets and consent forms are available from the University ethical 
review webpage at 
http://researchsupport.leeds.ac.uk/index.php/academic_staff/good_practice/planning
_your_research_project-1/approaching_and_recruiting_participants-1.  
 
C.12 Describe whether participants will be able to withdraw from the study, and 
up to what point (eg if data is to be anonymised). If withdrawal is not possible, 
explain why not. 
 
Volunteers will be informed that they can withdraw from the study at any time without 
giving any reason and without any negative consequences. 
 
C.13 How long will the participant have to decide whether to take part in the 
research?31 
It may be appropriate to recruit participants on the spot for low risk research; however 
consideration is usually necessary for riskier projects. 
 
2 days prior to commencement of the study. 
 
C.14 What arrangements have been made for participants who might not 
adequately understand verbal explanations or written information, or who have 
special communication needs?32 (e.g. translation, use of interpreters etc. It is 
important that groups of people are not excluded due to language barriers or 
disabilities, where assistance can be given.) 
 
Participants will be expected to understand the English language. Email and phone 
contact details will be provided on the recruitment advert and information sheet. 
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C.15 Will individual or group interviews/ questionnaires discuss any topics or 
issues that might be sensitive, embarrassing or upsetting, or is it possible that 
criminal or other disclosures requiring action could take place during the study 
(e.g. during interviews or group discussions)?33 The information sheet should 
explain under what circumstances action may be taken. 
Yes       No                 If yes, give details of procedures in place to deal with 
these issues.  
 
C.16 Will individual research participants receive any payments, fees, 
reimbursement of expenses or any other incentives or benefits for taking part in 
this research?34 
Yes       No 
If Yes, please describe the amount, number and size of incentives and on what basis 
this was decided. 
 
Participants will receive breakfast/snack after collection of blood (3 hours after 
consumption of test food) if they wish. A monetary reward of £15 for each visit will 
be given at the end of the study. 
 
 
 
RISKS OF THE STUDY 
C.17 What are the potential benefits and/ or risks for research participants?35  
 
There is very low risk to the participants as the method used is a World Health 
Organisation (WHO) approved and very common method. Moreover, a nurse will be 
present to draw the blood. Breakfast will be provided after blood collection. There are 
no direct benefits to the participants although the consumption of polyphenol rich test 
samples may have beneficial effects to the participants who may not normally have 
them in their diets. Moreover the results of the study may help to add to the knowledge 
on how diet may affect health. 
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C.18 Does the research involve any risks to the researchers themselves, or people 
not directly involved in the research? Eg lone working36  
Yes       No 
If yes, please describe: 
__________________________________________________ 
Is a risk assessment necessary for this research?  
NB: Risk assessments are a University requirement for all fieldwork taking place 
off campus. For guidance contact your Faculty Health and Safety Manager or 
visit http://www.leeds.ac.uk/safety/fieldwork/index.htm.  
Yes       No         If yes, please include a copy of your risk assessment form 
with your application.  
 
 
DATA ISSUES 
C.19 Will the research involve any of the following activities at any stage 
(including identification of potential research participants)? (Tick as appropriate) 
 Examination of personal records by those who would not normally have 
access 
 Access to research data on individuals by people from outside the research 
team 
 Electronic transfer of data 
 Sharing data with other organisations 
 Exporting data outside the European Union 
 Use of personal addresses, postcodes, faxes, e-mails or telephone numbers 
 Publication of direct quotations from respondents 
 Publication of data that might allow identification of individuals to be 
identified 
 Use of audio/visual recording devices 
 FLASH memory or other portable storage devices 
 Storage of personal data on or including any of the following: 
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 Manual files  
Home or other personal computers 
 Private company computers 
 Laptop computers 
 
C.20. How will the research team ensure confidentiality and security of personal 
data? E.g. anonymisation procedures, secure storage and coding of data.37 You 
may wish to refer to the data protection and research webpage.  
 
See the answer explained in question A.10 
 
 
C.21 For how long will data from the study be stored? Please explain why this 
length of time has been chosen.38  
RCUK guidance states that data should normally be preserved and accessible for ten 
years, but for some projects it may be 20 years or longer.  
Students: It would be reasonable to retain data for at least 2 years after publication 
or three years after the end of data collection, whichever is longer. 
 
5 years  
 
CONFLICTS OF INTEREST 
C.22 Will any of the researchers or their institutions receive any other benefits or 
incentives for taking part in this research over and above normal salary or the 
costs of undertaking the research?39  
Yes       No 
If yes, indicate how much and on what basis this has been decided 
____________________________________________________________________
______ 
 
C.23 Is there scope for any other conflict of interest?40 For example will the 
research funder have control of publication of research findings? 
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Yes       No        If yes, please explain 
_________________________________________________ 
 
 
C.24 Does the research involve external funding? (Tick as appropriate) 
Yes       No        If yes, what is the source of this funding? 
___________________________________ 
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PART D: Declarations 
 
Please submit your form by email to J.M.Blaikie@leeds.ac.uk or if you are in the Faculty 
of Medicine and Health FMHUniEthics@leeds.ac.uk. Remember to include any 
221 
 
 
supporting material such as your participant information sheet, consent form, interview 
questions and recruitment material with your application.  
 
Checklist: 
 
 I have used layman’s terms to describe my research (applications are reviewed 
by lay members of the committee as well). 
 I have answered all the questions on the form, including those with several parts 
(refer to the guidance if you’re not sure how to answer a question or how much 
detail is required) 
 I have included any relevant supplementary materials such as  
 Recruitment material (posters, emails etc) 
 Sample participant information sheet 
 Sample consent form. Include different versions for different groups of 
participants eg for children and adults. 
 If I am not going to be using participant information sheets or consent forms I 
have explained why not and how informed consent will be otherwise obtained. 
 If you are a student have you discussed your application with your supervisor 
and are they satisfied that you have completed the form correctly? (This will 
speed up your application).  
 I have submitted a signed copy of my application. (If you are a student your 
supervisor also needs to sign the form).  
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MEEC 12-037 Ethical application - Appendix 1 
Participant’s information sheets 
Research Project Title 
Effects of carbohydrase-inhibiting polyphenols on glycaemic response in vivo 
You are being invited to take part in a research project. Kindly read carefully all the 
information given as it is important that you understand why the study is going to be 
done and what it will involve. Before making any decision, if there is anything that is not 
clear, feel free to ask us and take time to decide whether to take part or not. Thank you 
for taking time to read this. 
What is the purpose of the project? 
Carbohydrate rich foods can be said to be high glycaemic index (GI) foods or low 
glycaemic index foods depending on the blood glucose resulting from consumption. High 
GI foods give rise to high blood glucose levels due to being absorbed rapidly whereas 
low GI foods give a lower blood glucose response due to being absorbed slowly. 
Different foods and beverages have different effects on blood glucose levels depending 
on whether they are high GI foods or low GI foods. Observational studies as well as 
research have shown that eating low GI foods rather than high GI foods may have long 
term health benefits. 
The research project will determine whether a polyphenol rich meal will have an effect 
on reducing the GI of foods and hence reduce absorption of glucose. Polyphenols are 
naturally occurring constituents found in fruits and vegetables and other plant derived 
foods like tea and coffee.  
 
Am I a suitable candidate for this study? 
 
Inclusion Criteria for group 1 
 Male or female 
 Aged 18 to 75 years 
 Not diabetic 
 Normal fasting glucose (blood glucose level before breakfast) of 3.9 - 5.9 mmol/L 
 Non-smoker 
 Not pregnant or lactating 
 Not on long term prescribed medication 
 
Inclusion Criteria for group 2 
 Male or female 
 Aged 18 to 75 years 
 Not diabetic 
 Fasting glucose (blood glucose level before breakfast) of 6.0 - 8.0 mmol/L 
 Non- smoker 
 Not pregnant or lactating 
 Not on long term prescribed medication 
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Do I have to take part? 
 
Taking part in this research study is entirely voluntary. You have the right to withdraw 
from it at any time without giving any reason. If you decide to take part, you will be 
given this information sheet to keep and you will be asked to sign a consent form two 
days before starting the study just to indicate that you have understood what it means to 
take part in this research. Even after signing the consent form, you can still withdraw at 
any time if you no longer feel comfortable. 
 
What do I have to do? / What will happen to me if I take part? 
 
The first phase will involve a screening process to come up with the two groups (with 
different fasting glucose levels). This will require you to fast overnight drinking only 
water from 9 pm the previous night and report to the school of Food Science and 
Nutrition before 10 am the following day. Then your fasting blood glucose will be 
measured using a standard glucometer. Afterwards you will be offered breakfast.  
 
After the two groups have been set and if you qualify to take part in this study, you will 
then proceed to take part in the second phase. 
 
The second phase is to be done over 4 visits with each visit not lasting more than 4 hours. 
Preferably twice a week according to which days are convenient for you but with at least 
two days in between the two visits.  
 
You will be expected to arrive at the school of food science and nutrition in the morning 
before 10 am after an overnight fast of between 10-14 hours. You will be asked to have 
a meal of your choice the night before the study day but should consume the same meal 
on all the days prior to the visit and keep a record of what you eat. You will be asked to 
rest for 10 minutes during which you will be asked to report on what food you ate the 
previous evening prior to the fast. Body weight, height and blood pressure measurements 
will also be taken. Then a cannula will be inserted in your elbow pit by the nurse to avoid 
the use of a needle for every blood withdrawal. Thereafter the fasting (time 0 sample) 
glucose blood sample will be collected from the fingertip using the finger prick device 
and from your vein by the nurse.  
 
You will then be asked to eat or drink the food test sample. Then about 200 µl blood will 
be drawn at 15, 30, 45, 60, 90 and 120 minutes after starting to eat the test food from the 
finger prick and venous blood will also be collected by a nurse. 
 
Reference food will be white bread containing 50g available carbohydrate, yoghurt 
(natural, lactose free and fat free) and water. Test food will include a cup of green tea, 
yoghurt (natural, lactose free and fat free) mixed with commercially available fruit 
224 
 
 
extracts and white bread. All the procedures on the participants mentioned above will be 
carried out in an appropriate human study room. 
 
What are the possible disadvantages and risks of taking part? 
 
There is very low risk to the participants as the method used is a World Health 
Organisation (WHO) approved and very common method. If you decide to discontinue 
your involvement in the study, this will not interfere in any way with the manner in which 
you will be treated. All data collected up to the point of withdrawal will only be used if 
the participant consents. If the participant does not want any of their data to be used after 
withdrawal, it will not be included. There are no additional risks involved as the 
procedures are according to standard guidelines. 
 
What are the possible benefits of taking part? 
 
You may not personally benefit from the study but the results may be beneficial for 
advancement of knowledge on nutrition/diet as it relates to human health. 
 
Will my taking part in this project be kept confidential? / What will happen to the results 
of the research project? 
 
Confidentiality will be maintained at all stages of the study as allocation of codes will be 
done from the beginning of the study. Identification will be coded using ID numbers that 
will be assigned on the day of study. All data collected will be treated as confidential and 
stored securely in a locked filling cabinet according to current University regulations. 
The linkage between individual identity and ID number will be kept in written form only 
and stored in a locked filling cabinet in a restricted access area, thus it will not be possible 
to identify individual participants from the ID numbers. Data evaluation will only be 
performed using ID numbers. In accordance with the University guidelines on the 
password protected M-drive of the University server, anonymised data will be stored for 
at least 5 years. When any data needs to be published, the results will be reported in a 
manner without making reference to any individual. If you wish, we can inform you of 
the outcome of the total analysis although you will not be able to identify yourself in any 
results. 
Confidentiality and data protection 
 
Confidentiality of all participants’ information will be maintained.. 
What type of information will be sought from me and why is the collection of this 
information relevant for achieving the research project’s objectives? 
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A questionnaire on suitability to participate will only ask you questions on your general 
health just to ensure that you are suitable for this research. 
 
Who is organising /funding the research? 
 
This research will be conducted at the School of Food Science and Nutrition under the 
supervision of Professor Gary Williamson, Food Biochemistry Group, University of 
Leeds, UK. 
 
Who do I contact for further information? 
 
Hilda Nyambe (Study Co-ordinator) 
School of Food Science and Nutrition 
Faculty of Mathematics and physical Sciences 
University of Leeds 
Email: fs07hs@leeds.ac.uk 
Mobile: 07415780195 
 
Thank you for taking the time to read this information sheet. 
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MEEC 12-037- Appendix 2 
 
Participant Consent Form 
 
Research project title Effects of carbohydrase- inhibiting polyphenols on glycaemic 
response in vivo 
 
Name of researcher Hilda Nyambe 
 
 
Initial the box if  you agree with the statement to the left 
 
1 I confirm that I have read and understand the Participant Information Sheet 
dated (TBC) explaining the above research project and I have had the 
opportunity to ask questions about the project. 
 
 
2 I understand that my participation is voluntary and that I am free to withdraw 
at any time without giving any reason and without there being any negative 
consequences.  In addition, should I not wish to answer any particular 
question or questions, I am free to decline.  In this case I can contact the study 
co-ordinator by email: fs07hs@leeds.ac.uk or mobile: 07415780195 
 
 
3 I understand that my responses will be kept strictly confidential.  I give 
permission for members of the research team to have access to my 
anonymised responses.  I understand that my name will not be linked with 
the research materials, and I will not be identified or identifiable in the report 
or reports that result from the research. 
 
 
4 I agree for the data collected from me to be used in future research.  
 
5 I agree to take part in the above research project and will inform the principal 
investigator should my contact details change. 
 
 
6 I agree to be re-contacted for future research projects related to this study.  
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Name of participant  Date  Signature 
     
     
     
Address of participant  Mobile phone 
number 
 Email address 
     
     
     
Lead Researcher  Date  Signature 
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MEEC 12-037 - Appendix 3 
Pre-Study Questionnaire 
A. Personal Information 
 
Full name: 
 
      Age:      Gender: Male            Female 
 
      Height:       Weight: 
 
       Contact phone no: 
 
 Email address: 
 
 
B. Health History 
 
Q2.   Are you pregnant?  
     Yes     No 
Q3.  Are you breast feeding? 
   Yes      No 
 Q4.           Do you have any of the following diseases/conditions? 
 
 
Diabetes   Yes   No  I don’t know 
Digestive disease 
(e.g. Crohn’s 
disease, celiac 
disease) 
  
Yes  
  
No  
 
I don’t know 
      
Food allergy  
 
If yes state to what 
  
Yes  
  
No 
 
I don’t know 
      
High blood 
pressure 
 Yes  No 
 
I don’t know  
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   Q5.  Do you regularly take any dietary supplements? 
   Yes      No  
 
 Q6.  If yes to Q5 above, what supplements? 
C. Lifestyle 
 
  Q7.  Are you currently taking any long term prescribed medication? 
 
   Yes     No 
 Q8.  Do you smoke? 
                Yes      No 
 Q9.  Are you currently on a special diet (for losing weight or fruit  
extracts supplements)? 
Yes  
(specify) 
No 
 
Q10. Do you do any vigorous intensity sports, fitness or recreational activities that cause 
large increases in breathing or heart rate like running or basketball for at least 10 minutes 
continuously per day? 
 
Yes  
(specify)  
(frequency) 
No 
 
 
Q11. Do you do any moderate intensity sports, fitness or recreational activities that cause a 
small increase in breathing or heart rate such as Yoga, brisk walking, bicycling, swimming or 
golf for at 10 minutes continuously per day? 
 
Yes  No 
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(specify) 
(frequency) 
 
 
 
 
Q12.  Is there any more additional information you wish to give about your health and 
lifestyle? 
 
Yes  
 
No 
 
Q13.       If yes to Q12, kindly write below 
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MEEC 12-037 - Appendix 4 
 
Blood collection and acellular Plasma preparation 
 
Equipment and Materials  
 
0.6 ml fluoride/oxalate collection tubes 
0.6 ml micro centrifuge tubes 
Tube labels 
-4°C centrifuge 
BD Contact –activated Lancets 
Ice box 
Disinfection swabs 
Gloves 
Spray bottle with 70% ethanol  
Plasters  
100 µl pipettes 
Cotton wool balls 
 
Protocol  
 
1. Label all appropriate tubes with all needed information. 
2. After the volunteer is seated in a chair, with gloves on, position the volunteer s 
hand with the palm-side up. 
3. To the selected finger, apply pressure to help the blood to flow. 
4. Clean the fingertip with a disinfection swab by starting in the middle and 
working outward to prevent contaminating the area. Allow the area to dry. 
5. Hold the finger and place a new sterile lancet on the centre of the fingertip and 
firmly press the lancet to puncture the fingertip. 
6. Wipe out the first drop of blood with a sterile pad or cotton ball which may 
contain excess tissue fluid. 
7. Collect approximately 200 µl blood by dropping the blood drops into a sterile 
0.6 ml fluoride/oxalate collection tubes. 
8. After collection, immediately place the tubes on ice. 
9. Place a cotton wool ball or pad over the puncture site and let the volunteer hold 
it for a few minutes to stop the bleeding. If need be, place a plaster afterwards. 
10. Centrifuge the whole blood sample within 15 minutes of collection for 10 
minutes at 3500 X g. 
11. By using a sterile tip, pipette at least 100 µl of supernatant and transfer to a 
labelled 0.5 ml micro centrifuge tube. 
12. Seal and freeze upright at -80°C until required for glucose analysis. 
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Labelling 
 
Labelling will include the following information: 
 
1) Subject ID code 
2) Study code, comprised of test (reference, test dose 1, test dose 2) identification 
and time    point (0,15,30,45,60,90,120,150,180) 
3) Date 
4) Investigator initials 
 
Example 
1) S1R 30 HN 2/5/13 
 
MEANS, Subject Id code 1, Reference sample, 30 minutes time point, Hilda Nyambe 
as Investigator, the date being 2/5/2013 
 
2) S11T1 90 HN 13/6/13 
 
MEANS, Subject Id code 11, test sample dose 1, 90 minutes time point, Hilda Nyambe 
as investigator, the date being 13/6/13 
 
3) S9T2 15 HN 28/7/13 
 
MEANS, Subject Id code 9, test sample dose 2, 15 minutes time point, Hilda Nyambe 
as Investigator, the date being 28/7/13 
 
 
 
 
 
 
 
 
 
 
 
 
233 
 
 
Blood collection form 
 
To be completed by the study co-ordinator 
 
Subject ID code  
Test Sample  
Time point  
Collection time  
Approximate sample 
volume (µl) 
 
Comments  
 
Waste disposal 
 
Diluted bleach will be added to the cellular fractions of the blood samples in the collection 
tubes. These will be left overnight for destruction of cellular fractions and can then be 
discarded within 24 hours in the clinical waste bags. 
 
All other wastes should also be discarded in suitable waste bags. 
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Responsibilities and emergency procedures 
Procedure  Person responsible  Potential Hazards Existing controls Emergency procedures  
Finger prick with 
puncture device 
 
Investigator  Injury and infection  Appropriate human study room will be used. 
 
Use of disinfectant wipes to clean the fingertip area 
before pricking with the puncture device.  
 
Use of one finger per time to avoid pricking the same 
finger more than once per visit. 
Wash thoroughly the injured area with soap and 
warm water and disinfect injured area  
 
Avoid cross contamination and infection by keeping 
own injury covered with waterproof dressing. 
 
Seek immediate medical advice  
Blood collection 
from finger tip 
 
Investigator  Spillage/contamination 
Over bleeding 
Appropriate human study room will be used. 
 
 
Compulsory use of personal protective equipment 
(laboratory coat, gloves, goggles).  
 
Usage of plastic or metal tray to handle blood and plasma 
samples (ease of cleaning any spillage) 
 
Placing a cotton wool ball or pad over the puncture site 
after blood collection and plaster afterwards. 
Use diluted bleach to wash thoroughly the 
contaminated area or spilled area. Disinfect 
contaminated area  
 
Appropriate waste disposal of all samples in closed 
bag that will then be discarded into a clinical waste 
bin bag. 
Place a cotton wool ball and plaster if still bleeding 
and seek immediate medical advice  
Cannular 
insertion and 
blood collection 
 
Nurse Injury and infection 
Contamination  
Appropriate human study room will be used. 
 
 
Certified nurse will insert the cannula into the 
participants and withdraw blood from the participants. 
 
Disinfectant wipes will be used to clean the skin area 
before inserting the cannular. 
 
Nurse will wash his/her hands before proceeding to blood 
withdrawal.  
 
Used needle will immediately be disposed into a bin.  
Wash thoroughly the injured area with soap and 
warm water.  
 
Encourage bleeding by squeezing around the 
injured area and disinfect it. 
 
Avoid cross contamination and infection by keeping 
own injury covered with waterproof dressing.  
 
Seek immediate medical advice  
 
Report incident to safety officer  
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MEEC 12-037 - Appendix 5 
Study design 
Advertisement            Volunteers asked to complete pre study questionnaire             fasting glucose screening             sign consent form              Four visits  
First visit    Second visit    Third visit    Fourth visit 
 
 
                At least 2 days      One week    At least 2 days 
Volunteers will consume 
Bread, yoghurt (natural Bread, yoghurt (natural,  Bread, yoghurt (natural,    Bread, yoghurt (natural, 
lactose and fat free)                 lactose and fat free) fruit                    lactose and fat free), fruit                     lactose and fat free) 
and water   extracts and green tea (dose 1) extracts and green tea (dose 2)   and water 
 
Fingertip blood collection at 0, 15, 30, 45, 60, 90, 120, 150 and 180 minutes 
 Venous blood collection at    0, 15, 30, 45, 60, 90, 120, 150 and 180 minutes 
 
Glucose analysis  
Glucose, insulin, glucagon, 
GIP and GLP-1 analysis 
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HUMAN STUDY VISITS DESIGN 
 
 1ST VISIT 2ND VISIT 
 
3RD VISIT 4TH VISIT 
Volunteer  1 A B C A 
Volunteer 2 A C B A 
Volunteer 3 A B C A 
 
 1ST VISIT 2ND VISIT 
 
3RD VISIT 4TH VISIT 
Volunteer 4 A C B A 
Volunteer 5 A B C A 
Volunteer 6 A C B A 
 
 1ST VISIT 2ND VISIT 
 
3RD VISIT 4TH VISIT 
Volunteer 7 A C B A 
Volunteer 8 A B C A 
Volunteer 9 A C B A 
 
 1ST VISIT 2ND VISIT 
 
3RD VISIT 4TH VISIT 
Volunteer 10 A B C A 
Volunteer 11 A C B A 
Volunteer 12 A B C A 
 
A= REFERENCE (White bread, natural yoghurt, water) 
B= TEST SAMPLE DOSE 1 (White bread, natural yoghurt with fruit extracts, green tea) 
C= TEST SAMPLE DOSE 2 (White bread, yoghurt with twice the amount of fruit extracts and 
green tea concentration in dose 1) 
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MEEC 12-037 Appendix 6  - Recruitment Poster 
 
 
 
                                                                                                       
 
The study is looking at the effects of polyphenol rich food on blood glucose response. 
Blood glucose will be measured after consumption of test food samples. 
If you need further information about this study, you can contact Hilda Nyambe by an e-mail fs07hs@leeds.ac.uk.  
This study is supervised by Professor Gary Williamson, Food Biochemistry Group, School of Food Science and Nutrition, University of Leeds, UK. 
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Volunteers needed to help investigate the effects of foods on Glycaemic response (blood 
glucose levels). 
 
Are you 
 Healthy male or female aged 18-65 
 Able to attend 4 sessions over three weeks not 
lasting more than 4 hours per session 
 Willing to give small blood samples by finger prick 
and from vein.  
 
 
£15 as a thank you for participating 
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APPENDIX 2 
Ethical review 
NOTICE OF AMENDMENT – MEEC 12-037 
To be completed in typescript by the Principal Investigator in language comprehensible 
to a lay person and submitted to the FREC that gave the favourable opinion of the 
research. Further guidance is available at http://ris.leeds.ac.uk/EthicsAmendment.  
 
Principal Investigator’s details:  
A.1 Name: 
HILDA NYAMBE 
Address: 
 
 
SCHOOL OF FOOD SCIENCE AND NUTRITION 
WOODHOUSE LANE 
LS2 9JT 
Telephone: 07415780195 
Email: fs07hs@leeds.ac.uk 
 
Full title of study: 
 
Effects of carbohydrase-inhibiting polyphenols on 
glycaemic response 
Ethics reference number: MEEC 12-037 
Date study commenced: 4th AUGUST 2014 
Amendment number and date: 08/09/2015 
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Type of amendment (indicate all that apply in bold) 
 
(a) Amendment to information previously given on the University of Leeds ethical review 
application form  
Yes                No            
 
If yes, please refer to relevant sections of the FREC application in the 
“summary of changes” section below. 
 
(b) Amendment to the information sheet(s) and/or consent form(s) for participants, or to any 
other supporting documentation for the study 
 
Yes                No             
 
If yes, please submit all revised documents with new version numbers and 
dates, highlighting new text using a different colour font or the track changes 
feature. 
 
Is this a modified version of an amendment previously notified to the FREC/ School REC 
and given an unfavourable opinion? 
 Yes                No               
Is this an amendment to a project which underwent NHS ethical review? 
 Yes                No               
Is sponsor sign off required for the amendment? 
 Yes                No               
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If applicable, has the amendment been submitted for NHS management permission 
(R&D approval)? 
 Yes                No N/A              
 
Summary of changes 
 
Briefly summarise the main changes proposed in this amendment using language 
comprehensible to a lay person.  Explain the purpose of the changes and their significance for 
the study.  In the case of a modified amendment, highlight the modifications that have been 
made. 
If the amendment significantly alters the research design or methodology, or could otherwise 
affect the scientific value of the study, supporting scientific information should be given (or 
enclosed separately).  Indicate whether or not additional scientific critique has been obtained. 
 
1) The food used in the test meal 
We are changing the food we used for the test meals. We are going to use pomegranate 
juice as well as olives. This is because they are also good sources of carbohydrase-
inhibiting polyphenols. 
 
2) Blood collection 
      There will be no collection of blood as a glucometer will be used to 
      measure blood glucose instantly from a finger prick. 
 
Any other relevant information 
 
Applicants may indicate any specific ethical issues relating to the amendment, on which the 
opinion of the REC is sought. 
The ethical issue is that the foods that were used in the test meal in the original ethical approval 
were different to the ones we want to use now. 
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High risk ethical issues  
(to be completed by applicants who applied for light touch ethical review only) 
 
Yes No 
Does the study involve participants who are particularly vulnerable or unable 
to give informed consent (eg children, people with learning disabilities, your 
own students)? 
  
Will the study require the cooperation of a gatekeeper for initial access to 
groups or individuals who are taking part in the study (eg students at school, 
members of self-help groups, residents of a nursing home)? 
  
Will participants be taking part in the research without their knowledge and 
consent (eg covert observation of people in non-public places)? 
  
Will the study involve discussion of sensitive topics (e.g sexual activity, drug 
use)? 
  
Are drugs, placebos or other substances (e.g food substances, vitamins) going 
to be administered to the participants or will the study involve invasive, 
intrusive or potentially harmful procedures of any kind? 
  
Will blood or tissue samples be obtained from the participants?   
Is pain or more than mild discomfort likely to result from the study?   
Could the study induce psychological stress or anxiety or cause harm or have 
negative consequences beyond the risks encountered in normal life? 
  
Will the study involve prolonged or repetitive testing?   
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Will financial inducements (other than reasonable expenses and compensation 
for time) be offered to participants? 
  
Will the study involve an international collaborator or research conducted 
overseas?  
  
Will the study involve the transfer of data outside the European Economic 
Area? 
  
Are there any potential conflicts of interest?   
Does the research involve any risks to the researchers themselves, or 
individuals not directly involved in the research? 
  
Will the study require ethical review from the NHS? (Refer to 
http://ris.leeds.ac.uk/NHSethicalreview for guidance in identifying 
circumstances which require NHS review) 
  
 
If you answer yes to any of these questions please apply for full ethical review rather 
than an amendment to your light touch application: 
http://ris.leeds.ac.uk/uolethicsapplication.  
 
List of enclosed documents 
Document Version Date 
Amended ethical application form with appendices 2 08/09/15 
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Please submit your form by email to ResearchEthics@leeds.ac.uk or if you are in the Faculty of Medicine 
and Health FMHUniEthics@leeds.ac.uk. 
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APPENDIX 3 
 
 
Please read each question carefully, taking note of instructions and completing all parts. 
If a question is not applicable please indicate so. The superscripted numbers refer to 
sections of the guidance notes, available at www.leeds.ac.uk/ethics. Where a question 
asks for information which you have previously provided in answer to another question, 
please just refer to your earlier answer rather than repeating information.  
 
Research ethics training courses: http://www.sddu.leeds.ac.uk/sddu-research-ethics-
courses.html  
To help us process your application enter the following reference numbers, if known and 
if applicable: 
Ethics reference number: MEEC 14-029 
Grant reference and/ or student 
number: 
200358739 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
UNIVERSITY OF LEEDS RESEARCH ETHICS COMMITTEE APPLICATION 
FORM 
1 
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PART A: Summary 
 
A.1 Which Faculty Research Ethics Committee would you like to consider this 
application?2  
 
 
 
 
 
 
 
 
 
 
A.2 Title of the research3  
Effects of carbohydrase-inhibiting polyphenols on glycaemic response 
 
 
A.3  Principal investigator’s contact details4 
Name (Title, first name, 
surname) 
Ms Hilda Nyambe 
Position Provisional PhD Student 
Department/ School/ Institute School of Food Science and Nutrition 
Faculty MAPS 
Work address (including 
postcode) 
School of Food Science and Nutrition, University of 
Leeds, LS2 9JT 
Telephone number 07415780195 
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University of Leeds email 
address 
fs07hs@leeds.ac.uk 
 
A.4 Purpose of the research:5 (Tick as appropriate) 
 Research 
 Educational qualification:  Please specify: __Doctor of 
Philosophy_____________________ 
 Educational Research & Evaluation6 
 Medical Audit or Health Service Evaluation7 
 Other 
 
 
A.5 Select from the list below to describe your research: (You may select more 
than one) 
 Research on or with human participants 
 Research with has potential significant environmental impact.8  If yes, 
please give details: 
  
 Research working with data of human participants 
 New data collected by questionnaires/interviews 
 New data collected by qualitative methods 
 New data collected from observing individuals or populations 
 Research working with aggregated or population data 
 Research using already published data or data in the public domain 
 Research working with human tissue samples9 
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A.6 Will the research involve any of the following:10 (You may select more than 
one) 
 
If your research involves any of the following an application must be made to the 
National Research Ethics Service (NRES) via IRAS www.myresearchproject.org.uk 
as NHS ethical approval will be required. There is no need to complete any more of 
this form. Contact governance-ethics@leeds.ac.uk for advice.  
 Patients and users of the NHS (including NHS patients treated in the private 
sector)11 
 Individuals identified as potential participants because of their status as 
relatives or carers of  patients and users of the NHS 
 Research involving adults in Scotland, Wales or England who lack the 
capacity to consent for themselves12 
 A prison or a young offender institution in England and Wales (and is health 
related)14 
 Clinical trial of a medicinal product or medical device15 
 Access to data, organs or other bodily material of past and present NHS 
patients9 
 Use of human tissue (including non-NHS sources) where the collection is 
not covered by a Human Tissue Authority licence9 
 Foetal material and IVF involving NHS patients 
 The recently deceased under NHS care 
 None of the above 
You must inform the Research Ethics Administrator of your NRES number 
and approval date once approval has been obtained.  
 
If the University of Leeds is not the Lead Institution, or approval has been granted 
elsewhere (e.g. NHS) then you should contact the local Research Ethics Committee for 
guidance.  The UoL Ethics Committee need to be assured that any relevant local 
ethical issues have been addressed.  
 
A.7 Will the research involve NHS staff recruited as potential research 
participants (by virtue of their professional role) or NHS premises/ facilities? 
Yes       No         
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If yes, ethical approval must be sought from the University of Leeds. Please note that 
NHS R&D approval is needed in addition, and can be applied for concurrently: 
www.myresearchproject.org.uk.  
Contact governance-ethics@leeds.ac.uk for advice.  
 
 
A.8 Will the participants be from any of the following groups? (Tick as 
appropriate) 
 Children under 1616 
 Adults with learning disabilities12 
 Adults with other forms of mental incapacity or mental illness 
 Adults in emergency situations 
 Prisoners or young offenders14 
 Those who could be considered to have a particularly dependent relationship 
with the investigator, eg members of staff, students17 
 Other vulnerable groups 
 No participants from any of the above groups 
Please justify the inclusion of the above groups, explaining why the research cannot 
be conducted on non vulnerable groups. 
Since adverts will be put around the University campus notice boards, it is very likely 
that students and members of staff may be recruited for the study as they are normally 
around the University campus. This will make it convenient to use students or 
members of staff as there will be no need to travel to get to the School of Food Science 
and Nutrition as they will already be on campus for work or for studies. 
However, participation will be purely voluntary and the participants will not be 
approached directly or forced to take part. If they so wish, they can withdraw from 
participating at any time. 
A Criminal Record Bureau (CRB) check will be needed for researchers working with 
children or vulnerable adults (see www.crb.gov.uk and 
http://store.leeds.ac.uk/browse/extra_info.asp?modid=1&prodid=2162&deptid=34
&compid=1&prodvarid=0&catid=243)  
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A.9 Give a short summary of the research18  
This section must be completed in language comprehensible to the lay person.  Do 
not simply reproduce or refer to the protocol, although the protocol can also be 
submitted to provide any technical information that you think the ethics committee may 
require. This section should cover the main parts of the proposal. 
 
Consumption of carbohydrate containing foods or sugary drinks brings about changes 
to the blood glucose levels. After a meal or drink, blood glucose rises until it reaches 
a peak concentration usually after 30 minutes. When the body senses the increase in 
blood glucose, a hormonal process involving insulin takes place to ensure that the 
glucose is taken up from the blood for storage and where it is needed for energy in the 
body. This process then brings about a decrease in the concentration of glucose until 
it reaches approximately the starting concentration. The original concentration of 
glucose is attained approximately 2 hours after eating or drinking a carbohydrate food 
or sugary drink respectively in healthy people. 
Different carbohydrates and sugary drinks have different effects on blood glucose 
response depending on the amount as well as the type of carbohydrate. Those that give 
rise to a high glucose response compared to a reference carbohydrate (usually glucose) 
are said to be high glycaemic index (GI) foods and those with a lower glucose response 
compared to a reference carbohydrate (usually glucose) are said to be low glycaemic 
index (GI) foods (Jenkins et al., 2002) 
Research has shown that diets that give rise to a high glucose response are associated 
with a number of abnormalities like increased risk of metabolic syndrome (Aston, 
2006). Metabolic syndrome mostly comprises of insulin resistance and glucose 
intolerance which gives an increased risk of type 2 diabetes (Mckeown et al., 2004) It 
also gives rise to other conditions like high blood pressure (arterial hypertension), 
elevated blood insulin levels (hyper-insulinemia), elevated amounts of fat in the liver 
(fatty hepatosis) and elevated amounts of lipids in the blood (dyslipidemia). After type 
2 diabetes become clinically apparent, the risk of cardiovascular disease also rises 
(Beilby, 2004) Research has also shown that foods/drinks which raise blood glucose 
levels gradually (low GI) rather than rapidly (high GI) have health benefits which 
include reducing the risk of metabolic syndrome (Barclay et al., 2008). Laboratory 
studies have shown that polyphenols found in fruits, vegetables and plant based foods 
have a positive effect on carbohydrate metabolism and can lower the blood glucose 
levels. (Hanhineva et al., 2010) 
This research will determine whether the presence of polyphenols in the diet has any 
lowering effect on the blood glucose levels and hence the glycaemic index of foods. 
This will be determined by asking volunteers to consume commercially available food 
supplements together with white bread and then determining the glycaemic response. 
The blood glucose response of bread will be determined initially as a control reference. 
All will be consumed in random order. 
Analysis will be done by measuring blood glucose response after consumption of the 
control reference meal and the test meal containing polyphenols and then determining 
the incremental area under the glucose curve. 
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A.10 What are the main ethical issues with the research and how will these be 
addressed?19 
Indicate any issues on which you would welcome advice from the ethics committee. 
Participation of human volunteers addressed by informed consent 
Prior to commencement of the study, potential volunteers will be given a clear, concise 
Participant Information Sheet (appendix 1) and Informed Consent Form (appendix 2) 
by the investigator to read, complete and sign in their own time. The investigator will 
answer all questions to the satisfaction of the individual and will not influence the 
decision of taking part in the study. The participants will be free to withdraw from the 
study at any point without providing a reason. The written consent form will be signed 
and dated at least 2 days prior to enrolment in the study by the volunteers and the 
Investigator. It will be photocopied and one copy will be kept by the Investigator (for 
the study records) and one by the volunteer. Participation by the volunteers is 
conditional upon receiving the written consent by the volunteer.  
Gathering of personal data addressed by confidentiality and data protection  
Candidates will be asked to complete a questionnaire (appendix 3) in order to assess 
their suitability for the study. The information pertains to their lifestyle and may be 
considered a sensitive issue, however each volunteer will be assured of confidentiality 
and that participation is entirely voluntary. The information on the questionnaire will 
include height, weight, gender, age and relevant medical history.  
Confidentiality of all participants’ information will be maintained. Identification will 
be coded using random ID numbers that will be assigned on the day of study. All data 
collected will be treated as confidential and stored securely in a locked filing cabinet 
according to current University regulations. The linkage between individual identity 
and ID number will be kept in written form only and stored in a locked filling cabinet 
in a restricted access area, thus it will not be possible to identify individual participants 
from the ID numbers. Data evaluation will only be performed using ID numbers. In 
accordance with the University guidelines on the password protected M-drive of the 
University server, anonymised data will be stored for at least 5 years. 
Blood sample collection  
Capillary blood glucose will be measured using a commercially available glucometer 
which is available to be bought by any member of the public for less than £50 and 
people already use them on their own. It measures glucose concentrations immediately 
and meets the accuracy requirement for the ISO 15197 standard. A drop of blood is 
enough and is obtained from participants by means of a mild finger prick using a sterile 
puncture device designed for this purpose for each time point. The finger prick 
protocol is the WHO/FAO 1998 glycaemic index approved protocol. Since 9 points 
will be needed (0, 15, 30, 45, 60, 90, 120, 150 and 180) thus we will aim to prick one 
finger once per session. An allowance of only one visit per week will also help in the 
healing of the pricks. 
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Ethics Committee Approval 
This human study protocol will be submitted to the Faculty of Mathematics and 
Physical Sciences Ethics committee at the University of Leeds, UK. 
 
PART B: About the research team 
 
B.1  To be completed by students only20 
Qualification working 
towards (e.g. Masters, PhD) 
PhD 
Supervisor’s name (Title, 
first name, surname) 
Professor Gary Williamson 
Department/ School/ 
Institute 
School of Food Science and Nutrition 
Faculty MAPS 
Work address (including 
postcode) 
School of Food Science & Nutrition, University of 
Leeds, LS2 9JT 
Supervisor’s telephone 
number 
0113 343 8380 
Supervisor’s email address g.williamson@leeds.ac.uk 
Module name and number (if 
applicable) 
 
 
B.2  Other members of the research team (eg co-investigators, co-supervisors) 21 
Name (Title, first name, 
surname) 
Akshay Yashish, Clitheroe Richard and Huang Linlin 
Position Masters students 
Department/ School/ 
Institute 
School of Food Science and Nutrition 
Faculty MAPS 
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Work address (including 
postcode) 
School of Food Science & Nutrition, University of 
Leeds, LS2 9JT 
Telephone number  
Email address  
 
Part C: The research 
 
C.1 What are the aims of the study? 22 (Must be in language comprehensible to a lay 
person.) 
3. To determine the effects of pomegranate and olive supplements on 
glycaemic response in comparison to a reference. 
4. To determine the effect of different doses of the supplements on 
postprandial plasma glucose responses of healthy humans. 
 
C.2 Describe the design of the research. Qualitative methods as well as 
quantitative methods should be included. (Must be in language comprehensible to 
a lay person.) 
It is important that the study can provide information about the aims that it intends to 
address. If a study cannot answer the questions/ add to the knowledge base that it 
intends to, due to the way that it is designed, then wasting participants’ time could be 
an ethical issue. 
Subject preparation 
Unusual vigorous activity should be avoided and subjects should eat a meal of their 
choice the evening before the test and we recommend that they eat the same meal the 
day before each test. 
 
Study Design 
  
In total, 40 healthy participants will be recruited of which some will consume 
pomegranate supplement as test sample and others will consume olive supplement as 
test sample. The study will involve 3 visits with each visit not lasting more than 4 
hours.  
Subjects will be expected to arrive at the school of food science and nutrition in the 
morning before 10 am after an overnight fast of between 10-14 hours. They will be 
asked to rest for 10 minutes during which they can report on what they had the previous 
evening prior to the fast. Body weight and height measurements will also be taken. 
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Thereafter, the fasting capillary blood glucose concentration will be measured with the 
glucometer. 
The subject will then be asked to drink water with either test supplement dose 1 or 
dose 2 or placebo and eat white bread after 5 minutes. Then blood glucose will be 
measured at 15, 30, 45, 60, 90, 120, 150 and 180 minutes post consumption of the test 
food with a glucometer. 
The Latin square design will be used to randomize which test food or reference will 
be consumed by which volunteer on different days as shown in appendix 5.  
Sample analysis 
Blood glucose will be measured using a glucometer at each time point which includes 
a mild finger prick.  
Statistical analysis  
The incremental area under each glucose curve will be calculated using the trapezoid 
rule. The area under the glucose curve for the three visits will be analysed to show 
whether there are any significant differences using the Students paired T-test.  
 
 
 
 
C.3 What will participants be asked to do in the study?23
 
(e.g. number of visits, 
time, travel required, interviews) 
What will participants be asked to do in the study 
Participants will be asked to complete a pre study questionnaire (appendix 3) to 
determine their suitability for the study as well as have their fasting glucose checked 
using a glucometer. The eligibility criteria will be explained to the potential volunteers 
and they will be informed that if their blood glucose falls outside the range, they will 
not be enrolled to take part in the study. If their fasting blood glucose is between 3.9 
and 5.9 mmol/L, they will be enrolled in the study and thus asked to complete the 
consent form. (Appendix 2) 
The study is to be done over 3 visits with each visit not lasting more than 4 hours. Each 
visit will be done once a week according to which days are convenient for the volunteer 
giving a total of three weeks. 
Subjects will be expected to arrive at the school of food science and nutrition in the 
morning before 10 am after an overnight fast of between 10-14 hours. The participants 
will be asked to have a meal of their choice the night before the study day but should 
consume the same meal on all the days and a record of what they eat should be availed. 
They will be asked to rest for 10 minutes during which they can report on what they 
had the previous evening prior to the fast. Body weight and height measurements will 
also be taken. Thereafter, fasting capillary blood concentration will be measured with 
a glucometer. 
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The subject will then be asked to eat and drink the food test sample as shown in the 
appendix 6. Then blood glucose will be measured 15, 30, 45, 60, 90, 120, 150 and 180 
minutes post consumption of the test/reference food using a glucometer. 
 
C.4 Does the research involve an international collaborator or research 
conducted overseas:24 
(Tick as appropriate)  
Yes       No 
If yes, describe any ethical review procedures that you will need to comply with 
in that country: 
Describe the measures you have taken to comply with these: 
Include copies of any ethical approval letters/ certificates with your application. 
 
C.5 Proposed study dates and duration  
Research start date (DD/MM/YY): As soon as ethical approval is obtained. 
 Research end date (DD/MM/YY): 31/09/2016 
Fieldwork start date (DD/MM/YY):  
Fieldwork end date (DD/MM/YY):  
 
 
C.6. Where will the research be undertaken? (i.e. in the street, on UoL premises, in 
schools)25 
 On University of Leeds premises. 
 
RECRUITMENT & CONSENT PROCESSES 
How participants are recruited is important to ensure that they are not induced or 
coerced into participation. The way participants are identified may have a bearing on 
whether the results can be generalised. Explain each point and give details for 
subgroups separately if appropriate. 
C.7 How will potential participants in the study be:  
(i) identified? 
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Codes will be used to identify individual subjects and no personal details will be 
referred to in this study as reported in A10. Personal details will only be used to check 
suitability at the recruitment stage. 
During the first contact with the potential participant, the main investigator will assign 
a code number to the participant which will be used to identify the participant 
throughout the study. An intermediate person who will never have any contact with 
the participants will be matching the names and give the corresponding codes to the 
Investigator. 
(ii) approached?  
Advertisements (appendix 6) in the form of posters and emails to the staff and students 
in the school of Food Science and Nutrition as well as other parts of the University of 
Leeds campus will be used. 
(iii) recruited?26 
 Subjects will be recruited from the university of Leeds staff and Students. Written 
informed consent will be obtained from the volunteers and participation can be 
withdrawn at any time without giving a reason. 
 
C.8 Will you be excluding any groups of people, and if so what is the rationale for 
that?27 
Excluding certain groups of people, intentionally or unintentionally may be unethical 
in some circumstances.  It may be wholly appropriate to exclude groups of people in 
other cases 
Selection criteria is shown in appendix  
Measured 
Fasting glucose (blood glucose level before breakfast) 3.9 -5.9 mmol/L  
 
Self-assessed 
Apparently healthy  
Not diabetic 
Not on long term prescribed medication (except contraceptives) 
Not pregnant or lactating 
Not on special diet (for losing weight or fruit extracts supplements) 
Aged 18-75 
C.9 How many participants will be recruited and how was the number decided 
upon?28 
It is important to ensure that enough participants are recruited to be able to answer 
the aims of the research. 
According to a review on Glycaemic index methodology by Brouns et al., 2005 which 
looked at a number of papers on glycaemic index methodology, the conclusion was 
that a minimum of 10 subjects is required for such type of study for each group 
depending on desired power. In this study a total of 40 participants will be used with 
some to consume pomegranate supplement and others the olive supplement. 
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From experience in the school from previous human studies, the number suggested 
above is achievable and in the rare case that it’s not achieved, recruitment will continue 
until the required number is obtained as the study is only 3 weeks in total per 
participant and so can be done at any time of the recruitment process. 
 
If you have a formal power calculation please replicate it here. 
Estimated sample size for two-sample comparison of means 
 
 
Test Ho: m1 = m2, where m1 is the mean in population 1 
                    and m2 is the mean in population 2 
Assumptions: 
 
         alpha =   0.0500  (two-sided) 
         power =   0.9000 
            m1 =      200 
            m2 =      230 
           sd1 =       25 
           sd2 =       25 
         n2/n1 =     1.00 
 
Estimated required sample sizes: 
 
            n1 =       15 
            n2 =       15 
Since using crossover design this is 15 participants in total as they are testing both 
diets. 
Remember to include all advertising material (posters, emails etc) as part of your 
application 
 
C10 Will the research involve any element of deception?29  
If yes, please describe why this is necessary and whether participants will be informed 
at the end of the study. 
No 
 
C.11 Will informed consent be obtained from the research participants?30  
Yes       No 
If yes, give details of how it will be done. Give details of any particular steps to 
provide information (in addition to a written information sheet) e.g. videos, 
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interactive material. If you are not going to be obtaining informed consent you will 
need to justify this.  
Volunteers will receive a participant information sheet and informed consent form 
after a positive reply to the recruitment advertisement. Volunteers will consent in 
writing prior to commencement of the study. The main investigator will verbally 
explain the participant information sheet and informed consent form and questions 
from the volunteer will be answered at any time. The prospective participant will have 
1-2 days prior to commencement of the study to decide, sign and return the completed 
informed consent form (two copies where one copy remains with the participant and 
the other copy for the research records) both to be co-signed by the main investigator. 
If participants are to be recruited from any of potentially vulnerable groups, give 
details of extra steps taken to assure their protection. Describe any arrangements to 
be made for obtaining consent from a legal representative. 
 
Copies of any written consent form, written information and all other explanatory 
material should accompany this application. The information sheet should make 
explicit that participants can withdrawn from the research at any time, if the research 
design permits.  
Sample information sheets and consent forms are available from the University ethical 
review webpage at 
http://researchsupport.leeds.ac.uk/index.php/academic_staff/good_practice/planning
_your_research_project-1/approaching_and_recruiting_participants-1.  
 
C.12 Describe whether participants will be able to withdraw from the study, and 
up to what point (eg if data is to be anonymised). If withdrawal is not possible, 
explain why not. 
Volunteers will be informed that they can withdraw from the study at anytime without 
giving any reason and without any negative consequences. 
 
C.13 How long will the participant have to decide whether to take part in the 
research?31 
It may be appropriate to recruit participants on the spot for low risk research; however 
consideration is usually necessary for riskier projects. 
2 days prior to commencement of the study. 
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C.14 What arrangements have been made for participants who might not 
adequately understand verbal explanations or written information, or who have 
special communication needs?32 (e.g. translation, use of interpreters etc. It is 
important that groups of people are not excluded due to language barriers or 
disabilities, where assistance can be given.) 
Participants will be expected to understand the English language. Email and phone 
contact details will be provided on the recruitment advert and information sheet. 
 
C.15 Will individual or group interviews/ questionnaires discuss any topics or 
issues that might be sensitive, embarrassing or upsetting, or is it possible that 
criminal or other disclosures requiring action could take place during the study 
(e.g. during interviews or group discussions)?33 The information sheet should 
explain under what circumstances action may be taken. 
Yes       No                 If yes, give details of procedures in place to deal with 
these issues.  
 
C.16 Will individual research participants receive any payments, fees, 
reimbursement of expenses or any other incentives or benefits for taking part in 
this research?34 
Yes       No 
If Yes, please describe the amount, number and size of incentives and on what basis 
this was decided. 
Participants will receive snacks after collection of blood (3 hours after consumption of 
test food) if they wish. A monetary reward of £15 will be given at the end of the whole 
study (3 visits). 
 
 
RISKS OF THE STUDY 
C.17 What are the potential benefits and/ or risks for research participants?35  
There is very low risk to the participants as the method used is a World Health 
Organisation (WHO) approved and very common method. There are no direct benefits 
to the participants although the consumption of polyphenol rich test samples may have 
beneficial effects to the participants who may not normally have them in their diets. 
Moreover the results of the study may help to add to the knowledge on how diet may 
affect health. 
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C.18 Does the research involve any risks to the researchers themselves, or people 
not directly involved in the research? Eg lone working36  
Yes       No 
If yes, please describe: 
__________________________________________________ 
Is a risk assessment necessary for this research?  
NB: Risk assessments are a University requirement for all fieldwork taking place 
off campus. For guidance contact your Faculty Health and Safety Manager or 
visit http://www.leeds.ac.uk/safety/fieldwork/index.htm.  
Yes       No         If yes, please include a copy of your risk assessment form 
with your application.  
 
 
DATA ISSUES 
C.19 Will the research involve any of the following activities at any stage 
(including identification of potential research participants)? (Tick as appropriate) 
 Examination of personal records by those who would not normally have 
access 
 Access to research data on individuals by people from outside the research 
team 
 Electronic transfer of data 
 Sharing data with other organisations 
 Exporting data outside the European Union 
 Use of personal addresses, postcodes, faxes, e-mails or telephone numbers 
 Publication of direct quotations from respondents 
 Publication of data that might allow identification of individuals to be 
identified 
 Use of audio/visual recording devices 
 FLASH memory or other portable storage devices 
 Storage of personal data on or including any of the following: 
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 Manual files  
Home or other personal computers 
 Private company computers 
 Laptop computers 
 
C.20. How will the research team ensure confidentiality and security of personal 
data? E.g. anonymisation procedures, secure storage and coding of data.37 You 
may wish to refer to the data protection and research webpage.  
 
See the answer explained in question A.10 
 
C.21 For how long will data from the study be stored? Please explain why this 
length of time has been chosen.38  
RCUK guidance states that data should normally be preserved and accessible for ten 
years, but for some projects it may be 20 years or longer.  
Students: It would be reasonable to retain data for at least 2 years after publication 
or three years after the end of data collection, whichever is longer. 
5 years  
 
CONFLICTS OF INTEREST 
C.22 Will any of the researchers or their institutions receive any other benefits or 
incentives for taking part in this research over and above normal salary or the 
costs of undertaking the research?39  
Yes       No 
If yes, indicate how much and on what basis this has been decided _ 
 
 
 
___________________________________________________________________ 
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C.23 Is there scope for any other conflict of interest?40 For example will the 
research funder have control of publication of research findings? 
Yes       No        If yes, please explain  
 
 
 
_______________________________________________ 
 
 
C.24 Does the research involve external funding? (Tick as appropriate) 
Yes       No        If yes, what is the source of this funding? _ 
 
 
 
__________________________________ 
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PART D: Declarations 
 
Please submit your form by email to J.M.Blaikie@leeds.ac.uk or if you are in the Faculty 
of Medicine and Health FMHUniEthics@leeds.ac.uk. Remember to include any 
supporting material such as your participant information sheet, consent form, interview 
questions and recruitment material with your application.  
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Checklist: 
 I have used layman’s terms to describe my research (applications are reviewed 
by lay members of the committee as well). 
 I have answered all the questions on the form, including those with several parts 
(refer to the guidance if you’re not sure how to answer a question or how much 
detail is required) 
 I have included any relevant supplementary materials such as  
 Recruitment material (posters, emails etc) 
 Sample participant information sheet 
 Sample consent form. Include different versions for different groups of 
participants eg for children and adults. 
 If I am not going to be using participant information sheets or consent forms I 
have explained why not and how informed consent will be otherwise obtained. 
 If you are a student have you discussed your application with your supervisor 
and are they satisfied that you have completed the form correctly? (This will 
speed up your application).  
 I have submitted a signed copy of my application. (If you are a student your 
supervisor also needs to sign the form).  
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MEEC 14-029 - Appendix 1 
 
Participant’s information sheets 
Research Project Title 
Effects of pomegranate and olive supplements on glycaemic response (blood 
glucose) in vivo. 
You are being invited to take part in a research project. Kindly read carefully all the 
information given as it is important that you understand why the study is going to be 
done and what it will involve. Before making any decision, if there is anything that is not 
clear, feel free to ask us and take time to decide whether to take part or not. Thank you 
for taking time to read this. 
What is the purpose of the project? 
Carbohydrate rich foods can be said to be high glycaemic index (GI) foods or low 
glycaemic index foods depending on the blood glucose resulting from consumption. High 
GI foods give rise to high blood glucose levels due to being absorbed rapidly whereas 
low GI foods give a lower blood glucose response due to being absorbed slowly. 
Different foods and beverages have different effects on blood glucose levels depending 
on whether they are high GI foods or low GI foods. Observational studies as well as 
research have shown that eating low GI foods rather than high GI foods may have long 
term health benefits. 
The research project will determine whether pomegranate and olive supplements will 
have an effect on blood glucose concentrations after a meal.  
Am I a suitable candidate for this study? 
Inclusion Criteria  
Measured on your first visit 
 
Fasting glucose (blood glucose level before breakfast) 3.9 - 5.9 mmol/L  
 
Self-assessed 
 
Apparently healthy  
Not diabetic 
Not on long term prescribed medication (except contraceptives) 
Not pregnant or lactating 
Not on special diet (for losing weight or fruit extracts supplements) 
Aged 18-75 
Do I have to take part? 
Taking part in this research study is entirely voluntary. You have the right to withdraw 
from it at any time without giving any reason. If you decide to take part, you will be 
given this information sheet to keep and you will be asked to sign a consent form two 
days before starting the study just to indicate that you have understood what it means to 
take part in this research. Even after signing the consent form, you can still withdraw at 
any time if you no longer feel comfortable. 
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What do I have to do? / What will happen to me if I take part? 
Firstly, you will be required to come for a screening to ensure that you meet the inclusion 
criteria. This will require you to fast overnight drinking only water from 9 pm the 
previous night and report to the school of Food Science and Nutrition before 10 am the 
following day. Then your fasting blood glucose will be measured using a standard 
glucometer. Afterwards you will be offered breakfast.  
If you qualify to take part in this study, you will then be asked to come for 3 visits with 
each visit not lasting more than 4 hours according to which days are convenient for you.  
You will be expected to arrive at the school of food science and nutrition in the morning 
before 10 am after an overnight fast of between 10-14 hours. You will be asked to have 
a meal of your choice the night before the study day but should consume the same meal 
on all the days prior to the visit and keep a record of what you eat. You will be asked to 
rest for 10 minutes during which you will be asked to report on what food you ate the 
previous evening prior to the fast. Body weight (fully clothed), height and blood pressure 
measurements will also be taken. Thereafter the fasting (time 0 sample) glucose blood 
sample will be collected from the fingertip using the finger prick device and immediately 
measured using the glucometer.  
You will then be asked to consume the supplements as 2 capsules with water and then 
eat white bread after 5 minutes with water within 10 minutes. Then glucose blood 
concentration will be measured using a glucometer after pricking your fingertip using a 
mild finger prick device at 15, 30, 45, 60, 90, 120, 150 and 180 minutes after starting to 
eat bread.  
All the procedures on the participants mentioned above will be carried out in an 
appropriate human study room at the school of food science and nutrition located in 
parkinsons building. 
What are the possible disadvantages and risks of taking part? 
There is very low risk to the participants as the method used is a World Health 
Organisation (WHO) approved and very common method. If you decide to discontinue 
your involvement in the study, this will not interfere in any way with the manner in which 
you will be treated. All data collected up to the point of withdrawal will only be used if 
the participant consents. If the participant does not want any of their data to be used after 
withdrawal, it will not be included. There are no additional risks involved as the 
procedures are according to standard guidelines. 
 
What are the possible benefits of taking part? 
You may not personally benefit from the study but the results may be beneficial for 
advancement of knowledge on nutrition/diet as it relates to human health. 
Will my taking part in this project be kept confidential? / What will happen to the results 
of the research project? 
 
Confidentiality will be maintained at all stages of the study as allocation of codes will be 
done from the beginning of the study. Identification will be coded using ID numbers that 
will be assigned on the day of study. All data collected will be treated as confidential and 
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stored securely in a locked filling cabinet according to current University regulations. 
The linkage between individual identity and ID number will be kept in written form only 
and stored in a locked filling cabinet in a restricted access area, thus it will not be possible 
to identify individual participants from the ID numbers. Data evaluation will only be 
performed using ID numbers. In accordance with the University guidelines on the 
password protected university server, anonymised data will be stored for at least 5 years. 
When any data needs to be published, the results will be reported in a manner without 
making reference to any individual. If you wish, we can inform you of the outcome of 
the total analysis although you will not be able to identify yourself in any results. 
Confidentiality and data protection 
Confidentiality of all participants’ information will be maintained.. 
What type of information will be sought from me and why is the collection of this 
information relevant for achieving the research project’s objectives? 
A questionnaire on suitability to participate will only ask you questions on your general 
health just to ensure that you are suitable for this research. 
Who is organising /funding the research? 
This research will be conducted at the School of Food Science and Nutrition under the 
supervision of Professor Gary Williamson, Food Biochemistry Group, University of 
Leeds, UK. 
Who do I contact for further information? 
 
Hilda Nyambe (Study Co-ordinator) 
School of Food Science and Nutrition 
Faculty of Mathematics and physical Sciences 
University of Leeds 
Email: fs07hs@leeds.ac.uk 
Mobile: 07415780195 
 
Thank you for taking the time to read this information sheet. 
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MEEC 14-029 - Appendix 2 
 
Participant Consent Form 
 
Research project title Effects of pomegranate and olive extracts on glycaemic response 
in vivo. 
Name of researcher Hilda Nyambe 
Initial the box if  you agree with the statement to the left 
 
1 I confirm that I have read and understand the Participant Information 
Sheet dated (TBC) explaining the above research project and I have 
had the opportunity to ask questions about the project. 
 
 
2 I understand that my participation is voluntary and that I am free to 
withdraw at any time without giving any reason and without there 
being any negative consequences.  In addition, should I not wish to 
answer any particular question or questions, I am free to decline.  In 
this case I can contact the study co-ordinator by email: 
fs07hs@leeds.ac.uk or mobile: 07415780195 
 
 
3 I understand that my responses will be kept strictly confidential.  I give 
permission for members of the research team to have access to my 
anonymised responses.  I understand that my name will not be linked with 
the research materials, and I will not be identified or identifiable in the report 
or reports that result from the research. 
 
 
4 I agree for the data collected from me to be used in future research. 
 
 
 
5 I agree to take part in the above research project and will inform the principal 
investigator should my contact details change. 
 
 
 
6 I agree to be re-contacted for future research projects related to this study.  
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Name of participant  Date  Signature 
     
     
     
Address of participant  Mobile phone 
number 
 Email address 
     
     
     
Lead Researcher  Date  Signature 
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MEEC 14-029 - Appendix 3 
Pre-Study Questionnaire 
 
D. Personal Information 
 
Full name: 
 
Age:      Gender: Male            Female 
 
Height:       Weight: 
 
      Contact phone no: 
 
Email ddress: 
 
E. Health History 
 
Q2.   Are you pregnant?  
     Yes     No 
Q3.  Are you breast feeding? 
 
   Yes      No 
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Q4.           Do you have any of the following diseases/conditions? 
 
 
Diabetes   
Yes 
  
No 
 
I don’t know 
 
 
Digestive disease 
(e.g. Crohn’s 
disease, celiac 
disease) 
  
Yes  
  
No  
 
I don’t know 
      
Food allergy  
 
If yes state to what 
  
Yes  
  
No 
 
I don’t know 
      
High blood 
pressure 
 Yes  No 
 
I don’t know  
    
 
 
   Q5.  Do you regularly take any dietary supplements? 
   Yes      No  
  Q6.  If yes to Q5 above, what supplements? 
                       -------------------------------------------------------------------------------------------- 
F. Lifestyle 
 
  Q7.  Are you currently taking any long term prescribed medication? 
   Yes     No 
 Q8.  Do you smoke? 
                Yes      No 
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 Q9.  Are you currently on a special diet (for losing weight or fruit extracts 
supplements)? 
 
Yes  
(specify) 
No 
 
Q10. Do you do any vigorous intensity sports, fitness or recreational activities 
that cause large increases in breathing or heart rate like running or basketball for at 
least 10 minutes continuously per day? 
 
Yes  
(specify)  
(frequency) 
No 
 
 
Q11. Do you do any moderate intensity sports, fitness or recreational 
activities that cause a small increase in breathing or heart rate such as Yoga, brisk 
walking, bicycling, swimming or golf for at 10 minutes continuously per day? 
 
Yes  
(specify) 
(frequency) 
No 
 
 
 
Q12.  Is there any more additional information you wish to give about your 
health and lifestyle? 
Yes  No 
 
Q13.       If yes to Q12, kindly write below 
  _____________________________________________________________________ 
  _____________________________________________________________________ 
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MEEC 14-029 - Appendix 4 
 
Blood glucose reading 
 
Equipment and Materials  
 
Glucometer with pricking device 
Disinfection swabs 
Gloves 
Spray bottle with 70% ethanol  
Plasters  
Cotton wool balls 
 
Protocol  
 
13. After the volunteer is seated in a chair, with gloves on, position the volunteer s 
hand with the palm-side up. 
14. To the selected finger, apply pressure to help the blood to flow. 
15. Clean the fingertip with a disinfection swab by starting in the middle and working 
outward to prevent contaminating the area. Allow the area to dry. 
16. Hold the finger and place a new sterile lancet on the centre of the fingertip and 
firmly press the lancet to puncture the fingertip. 
17. Wipe out the first drop of blood with a sterile pad or cotton ball which may contain 
excess tissue fluid. 
18. Place the strip and read the glucose concentration and record it according. 
19. Afterwards, place a cotton wool ball or pad over the puncture site and let the 
volunteer hold it for a few minutes to stop the bleeding. If need be, place a plaster 
afterwards. 
 
Waste disposal 
 
During both the screening and the actual human study, all waste will be disposed in 
disposable bench top clinical waste bins. At the end of each session, the waste bins will 
be sealed, placed in orange bags and finally disposed in the clinical waste bins found in 
the laboratories to be treated as the rest of the waste according to the university 
regulations on disposing clinical waste.  
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Responsibilities and emergency procedures 
 
Procedure  Person responsible  
 
Potential Hazards Existing controls Emergency procedures  
Finger prick with 
puncture device 
 
Investigator  Injury and infection  Appropriate human study room will be used. 
 
Use of disinfectant wipes to clean the fingertip area 
before pricking with the puncture device.  
 
Use of one finger per time to avoid pricking the same 
finger more than once per visit. 
Wash thoroughly the injured area with soap and 
warm water and disinfect injured area  
 
Avoid cross contamination and infection by keeping 
own injury covered with waterproof dressing. 
 
Seek immediate medical advice  
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MEEC 14-029 - Appendix 5 
Study design 
Advertisement              Volunteers asked to complete pre study questionnaire             Fasting glucose screening             Sign consent form              Three 
visits  
First visit                                       Second visit                                 Third visit     
 
                                       One week                 One week 
Volunteers will consume 
Either: 
Reference (bread, water and 2 x 500 mg placebo capsules) 
Dose 1 (bread, water, 500 mg placebo capsules and 500 mg pomegranate/olive capsules) 
Dose 2 (bread, water, 2 x 500 mg pomegranate/olive capsules) 
 
 
 
 
Blood glucose reading from finger prick using glucometer at 0, 15, 30, 45, 60, 90, 120, 150 and 180 minutes Data analysis 
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MEEC 14-029 - Appendix 6 
HUMAN STUDY VISITS DESIGN 
 1ST VISIT 2ND VISIT 3RD VISIT 
Volunteer  1 A B C 
Volunteer 2 B C A 
Volunteer 3 C A B 
 
 1ST VISIT 2ND VISIT 3RD VISIT 
Volunteer 4 B A C 
Volunteer 5 A C B 
Volunteer 6 C B A 
 
 1ST VISIT 2ND VISIT 3RD VISIT 
Volunteer 7 C A B 
Volunteer 8 B C A 
Volunteer 9 A B C 
 
 1ST VISIT 2ND VISIT 3RD VISIT 
Volunteer 10 A C B 
Volunteer 11 C B A 
Volunteer 12* B A C 
 
*Randomization will continue up to volunteer number 40 
A = Reference (bread, water and 2 x 500 mg placebo capsules) 
B = Dose 1 (bread, water, 500 mg placebo capsules and 500 mg pomegranate/olive capsules) 
C = Dose 2 (bread, water, 2 x 500 mg pomegranate/olive capsules) 
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MEEC 14-029 Appendix 7 - Recruitment Poster 
 
